PUBLIC_ID	D_PT_ic_day	D_PT_DIDPATIENTCOM	D_PT_deathdy	D_PT_lastdy	D_PT_PRIMARYREASON	D_PT_CAUSEOFDEATH	D_PT_disc_com	SE_SPECIFY2	dth_specify	D_PT_complete	D_PT_discont	D_PT_DISCREAS	D_PT_dthreas	dthord	D_PT_raceoth	D_PT_race	D_PT_ethnic	D_PT_gender	D_PT_DIDTHEPATIENT	D_PT_screen	D_PT_trtstdy	IMWG_Risk_Class	Prolif_Index	D_PT_lstalive	D_PT_sdeathdy	D_PT_age	D_PT_enr	D_PT_lvisit	D_PT_lvisitdy	D_PT_lvisitc	demog_height	demog_weight	D_PT_iss	DEMOG_HEIGHTUNITOFM	DEMOG_WEIGHTUNITOFM	D_PT_issstage_char	D_PT_issstage	CREATININE	ecog	sct_elig	D_PT_therclass	D_PT_therfstn	D_PT_therclassn	D_PT_maxline	ftrttrpl	sct_bresp	line1sct	sctline	prescttrt	presctst	prescten	fstsctdy	bmtx_type	sctflag	sct1stf	mainttrt	maintstdy	maintendy	maintday	maintflag	maint1stf	D_PT_pddy	D_PT_pdflag	D_PT_ttfpdw	D_PT_respdur	D_PT_mmstatus	D_PT_mmstatus1	D_PT_mmstatus2	D_PT_mmstatus3	D_PT_rapd	D_PT_dresp	earlydth	fhr	demog_vj_interval	demog_visitdy	DEMOG_PATIENTAGE	DEMOG_GENDER	DEMOG_AMERICANINDIA	DEMOG_ASIAN	DEMOG_BLACKORAFRICA	DEMOG_NATIVEHAWAIIA	DEMOG_WHITE	DEMOG_OTHER	DEMOG_SPECIFY	DEMOG_ETHNICITY	DEMOG_DAYOFVISIT	demog_visit	enr
MMRF_1014	-10	No		1186	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			1157		64	1	13	1157	Month 39	63	189	1	in	lb	Stage I	1	70.72	0	1	combined bortezomib/IMIDs/carfilzomib-based	3	5	1	0	0	1	1	Bortezomib/Dexamethasone	816	819	816	Stem cell, Autologous	1	1	Thalidomide	977	1157	180	1	1		0		377	1	1			2	1	1		Baseline	-10	64	Female					Checked			Not Hispanic or Latino	-10	0	1
MMRF_1017	-16	No	508	508	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			470		75	1	5	425	Month 15	68	201	1	in	lb			79.56	1	1	IMIDs-based	4	3	1	0		0							0									0		427	5	5			2	1	1		Baseline	-15	75	Male					Checked			Not Hispanic or Latino	-16	0	1
MMRF_1024	-27	Yes		2907						1	2					1	2	2	Yes	1	1		1.5159208435	2907		79	1	32	2907	Year 8	62	116	2	in	lb			123.76	1	2	combined bortezomib/IMIDs-based		1	2	1		0							0								353	1	50.428571429	1	3	3	1		2	2	1	1	Baseline	-27	79	Female					Checked			Not Hispanic or Latino	-27	0	1
MMRF_1038	-30	No	1753	1753	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.0486725808	1672		69	1	19	1672	Month 57	71	223	3	in	lb			97.24	1	1	IMIDs-based	4	3	1	0		0							0									0		1686	5	5			2	1			Baseline	-30	69	Male					Checked			Not Hispanic or Latino	-30	0	1
MMRF_1033	-29	Yes		2883						1	2					4	2	1	Yes	1	1	0	1.565462762	2883		64	1	32	2883	Year 8	69	159	1	in	lb			79.56	0	1	IMIDs-based	4	3	2	0		0							0								218	1	31.142857143	130	3	3	1		2	2	1	1	Baseline	-29	64	Male		Checked						Not Hispanic or Latino	-29	0	1
MMRF_1007	-17	No	327	327	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			248	327	78	1	4	326	Year 1	69	168	3	in	lb			176.8	1	2	combined bortezomib/IMIDs-based		1	1	1		0							0									0			5	5			2		1		Baseline	-17	78	Male	Checked				Checked			Not Hispanic or Latino	-17	0	1
MMRF_1052	-27	No	314	314	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			273		74	1	3	273	Month 9	71	223	2	in	lb			97.24	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		42	5	5			2	2	1		Baseline	-27	74	Male					Checked			Not Hispanic or Latino	-27	0	1
MMRF_1082	-14	No	830	830	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0		801	830	47	1	10	826	Month 30	70	252	2	in	lb	Stage II	2	159.12	1	1	combined bortezomib/IMIDs-based		1	3	1		0	2	Bortezomib/Lenalidomide/Dexamethasone	288	326	373	Stem cell, Autologous	1	0	Lenalidomide	500	582	82	1		255	1	36.428571429	204	5	3	2	5	2	2		1	Baseline	-14	47	Male			Checked					Not Hispanic or Latino	-14	0	1
MMRF_1094	-4	No	2728	2728	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			2544	2075	59	1	30	2712	Month 90	64	118	2	in	lb			88.4	0	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	95	144	Stem cell, Autologous	1	1							757	1	108.14285714	659	5	3	2	1	2	1		1	Baseline	-4	59	Female					Checked			Not Hispanic or Latino	-4	0	1
MMRF_1093	-23	No	2391	2391	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		2	2	2	Yes	1	1			2098	2252	66	1	26	2249	Month 78	64	183	1	in	lb			53.04	1	1	IMIDs-based	4	3	1	0		0							0									0		2359	5	5			2	1			Baseline	-9	66	Female			Checked					Not Hispanic or Latino	-9	0	1
MMRF_1129	-5	No	610	610	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			548	610	81	1	7	585	Month 21	70	204	1	in	lb			70.72	2	2	IMIDs-based	4	3	1	0		0							0									0		562	5	5			2	1	1		Baseline	1	81	Male					Checked			Not Hispanic or Latino	-5	0	1
MMRF_1130	-10	Yes		2894						1	2					1	2	1	Yes	1	1		1.9465438669	2894		82	1	32	2894	Year 8	71	168	2	in	lb			116.688	0	2	combined bortezomib/IMIDs-based	1	1	4	1		0							0								703	1	100.42857143	598	3	3	3	1	2	1	1	1	Baseline	-10	82	Male					Checked			Not Hispanic or Latino	-10	0	1
MMRF_1137	-5	No	1091	1091	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.3333445783	1003	1671	65	1	12	1087	Year 3	66	154	1	in	lb			70.72	0	1	IMIDs-based	4	3	4	0	0	1	1	Lenalidomide/Dexamethasone	1	195	225	Stem cell, Autologous	1	1	Lenalidomide	337	501	164	1	1	572	1	81.714285714	367	5	3	4	2	2	1		1	Baseline	-5	65	Male					Checked			Not Hispanic or Latino	-5	0	1
MMRF_1132	-1	No	238	238	Death	Other		COMPLICATION FROM SURGERY	Complication from surgery	2	1	1	2	2		1	2	2	Yes	1	1			168		70	1	2	168	Month 6	61	121	2	in	lb			53.04	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		147	5	5			2	2	1		Baseline	1	70	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1178	-41															1	2	1	Yes	1	1	2	1.8606331575	2712		60	1	30	2712	Month 90	71	196	3	in	lb			100.776	0	1	Bortezomib-based	3	2	3	0	1	1	1	Bortezomib/Melphalan/Dexamethasone	130	150	163	Stem cell, Autologous	1	1							1114	1	159.14285714	846	3	3	3	4	2	1	1		Baseline	-41	60	Male					Checked			Not Hispanic or Latino	-41	0	1
MMRF_1193	-6	No	1564	1564	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1466	1564	63	1	17	1555	Month 51	62	152	1	in	lb			68.068	1	1	Bortezomib-based	3	2	4	0		0							0								541	1	77.285714286	440	5	3	3	2	2	1		1	Baseline	-13	63	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1229	-24															1	2	1	Yes	1	1		2.5140619296	2724		68	1	30	2724	Month 90	74	210	3	in	lb			132.6	1	1	combined bortezomib/IMIDs-based	1	1	4	1		0	2	Carfilzomib	311	395	428	Stem cell, Autologous	1	0							143	1	20.428571429	1	3	1	3	3	2	2	1	1	Baseline	-25	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1256	-24															2	2	2	Yes	1	1			2703		55	1	30	2703	Month 90	59	224	1	in	lb			49.504	0	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		2198	1	1			2	1	1		Baseline	-16	55	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1277	0	No	150	150	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		6.8327725521	85		56	1	1	85	Month 3	64	264	3	in	lb			114.92	1	1	combined bortezomib/IMIDs-based		1	1	0		0							0									0		66	5	5			2	2	1		Baseline	1	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1285	-14	No	2018	2018	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.5737804831	1955	2018	75	1	24	2011	Year 6	66	178	1	in	lb			70.72	0	1	Bortezomib-based	2	2	3	1		0							0								789	1	112.71428571	735	5	3	1	5	2	1		1	Baseline	-27	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1359	-6	No	1170	1170	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	2	6.5983807758	1081	1170	54	1	13	1159	Month 39	62	213	3	in	lb			149.396	0	1	Bortezomib-based	3	2	3	0	0	1	1	Bortezomib/Dexamethasone	1	116	170	Stem cell, Autologous	1	1							624	1	89.142857143	562	5	3	3	5	2	1		1	Baseline	-6	54	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1395	-20															1	2	1	Yes	1	1	0	3.3079831148	2545		64	1	28	2466	Year 7	69	187	1	in	lb			94.588	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	126	191	Stem cell, Autologous	1	1								0		2479	1	1	1		2	1	1		Baseline	-32	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1401	-11	No	575	575	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	2.1281189529	528		82	1	6	528	Month 18	65	167	2	in	lb			88.4	2	2	combined bortezomib/IMIDs-based	1	1	3	1		0							0								427	1	61		5	4	3	5	2		1	1	Baseline	-11	82	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1410	-25	No		522	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1			508		51	1	6	508	Month 18	63	207	3	in	lb	Stage III	3	72.488	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Melphalan/RANDOMIZED MILS TRIAL, J1343 (NO MILS ARM)	175	187	177	Stem cell, Autologous	1	1	Lenalidomide	245	508	263	1	1	472	1	67.428571429	426	3	3			2	1	1	1	Baseline	-12	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1598	-24	No	45	45	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	3.1599197858		45	68	1	1	40	Month 3	161	66	3	cm	kg			769.08	0	1	IMIDs-based		3	1	0		0							0												5	5			2		1		Baseline	-6	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1670	-32	No	1902	1902	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	3.7742706656	1765	1286	93	1	22	1895	Month 66	74	238	1	in	lb			61.88	0	2	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	129	Stem cell, Autologous	1	1	Lenalidomide	278	477	199	1	1	446	1	63.714285714	366	5	3	2	4	2	1		1	Baseline	-24	93	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1695	-21	No		637	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	1	1.5201136726	637		61	1	8	637	Year 2	69	176	3	in	lb			380.12		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	198	198	198	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	199	214	15	1	1		0		618	1	1			2	1	1		Baseline	-21	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1838	-1	No	1005	1005	Death	Other		COGESTIVE HEART FAILURE	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	0		889	128	72	1	11	986	Month 33	71	287	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	78	155	224	Stem cell, Autologous	1	1	Lenalidomide	316	615	299	1	1	349	1	49.857142857	279	5	3	5		2	2		1	Baseline	-6	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1866	-40															2	2	1	Yes	1	1	1		2033		58	1	22	2033	Month 66	66	135	1	in	lb			110.5	0	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	1173	1183	1213	Stem cell, Autologous	1	1							1110	1	158.57142857	964	3	3	1		2	1	1		Baseline	38	58	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1950	-2														Patient Declined	6	3	1	Yes	1	1		4.1336565349	2131		75	1	24	2131	Year 6	68	184	3	in	lb			150.28	1	1	Bortezomib-based	2	2	2	1		0							0								950	1	135.71428571	858	3	3	1		2	1	1	1	Baseline	-6	75	Male						Checked	Patient Declined	Other		0	1
MMRF_1997	-13	No	2182	2182	Death	Disease progression				2	1	1	1			2	3	1	Yes	1	1	0	1.9473047156	2033	1475	86	1	24	2182	Year 6	67	127	1	in	lb			70.72	1	2	combined bortezomib/IMIDs-based	4	1	2	0		0							0								1186	1	169.42857143	897	5	3	5		2	1			Baseline	-4	86	Male			Checked					Other		0	1
MMRF_2214	-5	No	957	957	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	1.8390695694	758	957	75	1	9	758	Month 27	68	201	2	in	lb			114.92	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0								700	1	100	622	5	5			2	1		1	Baseline	-5	75	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2230	-4	No		380	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	1.8195342422	374		67	1	4	374	Year 1	61	172	1	in	lb			95.472	0	1	Bortezomib-based	2	2	1	1		0							0									0			4	4			2		1		Baseline	-13	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2258	-20	No	1299	1299	Death	Disease progression				2	1	1	1			1	1	2	Yes	1	1	1	1.7870257252	1225		74	1	14	1225	Month 42	62	151	3	in	lb			397.8	1	1	Bortezomib-based	3	2	1	0		0							0								331	1	47.285714286	1	5	5			2	2		1	Baseline	-11	74	Female					Checked			Hispanic or Latino		0	1
MMRF_2442	-27	No	1749	1749	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		1732		62	1	19	1732	Month 57	67	157	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	190	221	Stem cell, Autologous	1	1	Lenalidomide	406	1040	634	2	2	1457	1	208.14285714	1364	5	1	4	2	2	1			Baseline	-4	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2456	1															1	2	1	Yes	1	1	0	1.8551603735	1835		70	1	20	1835	Year 5	68	189	1	in	lb			88.4	0	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	2	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	153	472	511	Stem cell, Autologous	1	1	Lenalidomide	596	1788	1192	2	2	1793	1	256.14285714	1431	3	1	2		2	1	1		Baseline	-8	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2471	-10															1	2	1	Yes	1	1	1	3.2996656863	1809		71	1	20	1800	Year 5	69	146	3	in	kg			118.456	2	2	combined bortezomib/IMIDs-based	4	1	2	0		0							0								1073	1	153.28571429	990	3	3	1		2	1	1	1	Baseline	-5	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2475	-45															1	2	1	Yes	1	1	0	1.7677773504	1786		47	1	20	1786	Year 5	70	264	1	in	lb			97.24	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								491	1	70.142857143	432	3	1	1		2	1	1	1	Baseline	-34	47	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2546	-14	No	438	438	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1		425		81	1	5	425	Month 15	70	194	3	in	lb			106.08	0	2	combined bortezomib/IMIDs-based	4	1	1	0		0							0								282	1	40.285714286		5	5			2		1	1	Baseline	-20	81	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2579	-18															1	2	1	Yes	1	1	1	2.5447645143	1765		61	1	19	1765	Month 57	67	176	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	143	Stem cell, Allogenic	1	1								0		1687	1	1			2	1	1		Baseline	-6	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1021	-28	Yes		2984	Other		STUDY COMPLETION PER PROTOCOL			1	2	7				1	2	2	Yes	1	1	1	1.9076888137	2909		54	1	32	2909	Year 8	62	123	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	29	127	Stem cell, Autologous	1	1							623	1	89	565	3	3	3	1	2	1	1	1	Baseline	-28	54	Female					Checked			Not Hispanic or Latino	-28	0	1
MMRF_1030	-11	No	2859	2859	Death	Other		SUBDURAL HEMATOMA	Hematologic	2	1	1	2	4		1	2	2	Yes	1	1	0	1.6000829763	2740	2249	65	1	32	2858	Year 8	58	118	1	in	lb			55.692	1	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Cyclophosphamide/Dexamethasone	116	116	141	Stem cell, Autologous	1	1	Bortezomib/Thalidomide/Melphalan	280	283	3	1	1	1984	1	283.42857143	1905	5	1	3	4	2	1			Baseline	-10	65	Female					Checked			Not Hispanic or Latino	-11	0	1
MMRF_1032	-3	No	934	934	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		908	934	76	1	10	908	Month 30	67	223	2	in	lb			70.72	2	2	Bortezomib-based	2	2	2	1		0							0								908	1	129.71428571	862	5	1	5		2	1		1	Baseline	-2	76	Male					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1072	-6	Yes		2874						1	2					1	2	2	Yes	1	1			2874		63	1	32	2874	Year 8	63	121	1	in	lb			55.692	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Cyclophosphamide/Dexamethasone	60	60	117	Stem cell, Autologous	1	1								0		2800	1	1	1	4	2	1	1		Baseline	-6	63	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1079	-4	No	2207	2207	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	7.407985318	2138	2207	66	1	26	2194	Month 78	65	160	1	in	lb			102.544	1	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Cyclophosphamide/Dexamethasone	75	75	100	Stem cell, Autologous	1	1							1302	1	186	1228	5	3	3	4	2	1			Baseline	-6	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1098	-28	Yes		2799	Other		PATIENT COMPLETED THE STUDY			1	2	7				2	2	1	Yes	1	1	0	1.7528457166	2799		49	1	32	2799	Year 8	67	225	2	in	lb			83.096	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2787	1	1			2	1	1		Baseline	-28	49	Male			Checked					Not Hispanic or Latino	-28	0	1
MMRF_1099	-3	No	668	668	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1		3.9083178149	596	668	69	1	8	669	Year 2	67	185	2	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0									0		587	5	1	5		2	1	1		Baseline	-3	69	Female					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1139	-4	Yes		2937	Other		PATIENT COMPLETED STUDY			1	2	7				1	2	2	Yes	1	1			2937		57	1	32	2937	Year 8	65	196	1	in	lb			50.388	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	74	74	100	Stem cell, Autologous	1	1	Bortezomib/Melphalan	274	277	3	1	1		0		2864	1	1			2	1	1		Baseline	-4	57	Female					Checked			Not Hispanic or Latino	-4	0	1
MMRF_1159	-6															1	2	1	Yes	1	1		2.6918422581	2730		75	1	30	2730	Month 90	72	269	3	in	lb			115.804	1	1	Bortezomib-based	3	2	1	0	1	1	1	Cyclophosphamide/Dexamethasone	122	122	171	Stem cell, Autologous	1	1								0		2646	1	1			2	1	1		Baseline	-6	75	Male					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1177	-114	No	819	819	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1			705		83	1	8	705	Year 2	66	149	2	in	lb			114.92	1	2	Bortezomib-based	2	2	2	1		0							0								706	1	100.85714286	646	5	3	5		2	1		1	Baseline	-1	84	Male					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1208	1	No	1329	1329	Death	Other		RESPIRATORY FAILURE- PNEUMONIA, ACUTE RENAL FAILURE	Respiratory	2	1	1	2	7		4	2	2	Yes	1	1			1263		70	1	14	1263	Month 42	64	104	3	in	lb			212.16	1	1	Bortezomib-based	2	2	3	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	66	171	Stem cell, Autologous	1	1							682	1	97.428571429	613	5	3	1	5	2	1		1	Baseline	1	70	Female		Checked						Not Hispanic or Latino	1	0	1
MMRF_1194	-13	No	1760	1760	Death	Other		RESPIRATORY FAILURE/PNEUMONIA	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1			1630	1760	70	1	20	1760	Year 5	67	193	1	in	lb	Stage I	1	129.064	0	1	combined bortezomib/IMIDs-based	4	1	1	0	1	1	1	Cyclophosphamide/Dexamethasone	142	142	182	Stem cell, Autologous	1	1								0		1634	5	5			2	1			Baseline	-13	70	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1205	-13	No	976	976	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1			880	976	78	1	11	976	Month 33	65	171	3	in	lb			71.604	2	2	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	136	142	189	Stem cell, Autologous	1	1							552	1	78.857142857	380	5	3	5		2	1		1	Baseline	-13	78	Female			Checked					Not Hispanic or Latino	-13	0	1
MMRF_1211	-5															1	2	1	Yes	1	1		1.9261960368	2829		46	1	30	2724	Month 90	72	198	1	in	lb			188.292	1	1	Bortezomib-based	3	2	1	0	1	1	1	Cyclophosphamide/Dexamethasone	101	101	128	Stem cell, Autologous	1	1								0		2743	1	1			2	1	1		Baseline	-5	46	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1221	1	No	1181	1181	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1156		65	1	13	1156	Month 39	68	164	1	in	lb			61.88	2	2	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Cyclophosphamide/Dexamethasone	96	96	129	Stem cell, Autologous	1	1	Bortezomib/Melphalan/Dexamethasone	295	298	3	1	1	617	1	88.142857143	522	5	3	2	4	2	1		1	Baseline	1	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1230	1	No		679	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			617		68	1	7	617	Month 21	65	126	2	in	lb			72.488	1	1	combined bortezomib/IMIDs-based	6	1	1	0	0	1	1	Melphalan/Dexamethasone	168	170	170	Stem cell, Autologous	1	1							617	1	88.142857143	521	3	3			2	1	1	1	Baseline	1	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1257	-11	No	1666	1666	Death	Other		UNKNOWN CAUSE OF DEATH	Unknown	2	1	1	2	9		1	2	1	Yes	1	1		2.3414440456	1617		74	1	18	1617	Month 54	71	195	3	in	lb			100.776	1	1	Bortezomib-based	2	2	5	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	52	100	Stem cell, Autologous	1	1							898	1	128.28571429	820	5	3	3	3	2	1		1	Baseline	-11	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1274	-15															1	2	1	Yes	1	1	0	3.0123370612	2743		40	1	30	2743	Month 90	69	244	1	in	lb			80.444	1	1	Bortezomib-based	2	2	1	1	1	1	1	Cyclophosphamide/Dexamethasone	92	92	118	Stem cell, Autologous	1	1	Bortezomib/FLUDARABINE/Melphalan	288	292	4	1	1		0		2652	1	1			2	1	1		Baseline	-15	40	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1286	-18	No	2176	2176	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	1	4.6354567518	1941		74	1	22	1941	Month 66	69	184	1	in	lb			107.848	0	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Cyclophosphamide/Dexamethasone	74	74	100	Stem cell, Autologous	1	1							262	1	37.428571429	216	5	3	1	4	2	2		1	Baseline	-18	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1325	-7														Middle Eastern	6	2	2	Yes	1	1	1	1.3037073809	2545		58	1	28	2545	Year 7	65	296	3	in	lb			164.424	1	1	combined bortezomib/IMIDs-based	4	1	1	0	1	1	1	Cyclophosphamide/Dexamethasone	123	123	149	Stem cell, Autologous	1	1								0		2465	1	1			2	1	1		Baseline	-7	58	Female						Checked	Middle Eastern	Not Hispanic or Latino		0	1
MMRF_1394	-25															1	2	2	Yes	1	1			2555		61	1	28	2555	Year 7	64	145	2	in	lb			72.488	1	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Cyclophosphamide/Dexamethasone	87	87	113	Stem cell, Autologous	1	1							1366	1	195.14285714	1290	3	1	3	1	2	1	1		Baseline	1	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1408	-9															1	1	2	Yes	1	1	0	2.5594183766	2394		62	1	26	2394	Month 78	58	117	1	in	lb			54.808	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Cyclophosphamide/Dexamethasone	121	121	273	Stem cell, Autologous	1	1							1545	1	220.71428571	1468	3	3	2	1	2	1	1		Baseline	1	62	Female					Checked			Hispanic or Latino		0	1
MMRF_1413	-3															1	2	1	Yes	1	1	1	1.8964073578	2569		71	1	28	2569	Year 7	69	214	3	in	lb			154.7	1	1	Bortezomib-based	2	2	3	1	1	1	1	Cyclophosphamide/Dexamethasone	101	101	128	Stem cell, Autologous	1	1								0		2485	1	1	4	1	2	1	1		Baseline	1	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1418	-4															1	2	2	Yes	1	1			2551		61	1	28	2551	Year 7	64	181	2	in	lb			110.5	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	80	80	109	Stem cell, Autologous	1	1	Bortezomib/Melphalan	284	286	2	1	1	1157	1	165.28571429	1051	3	3	1		2	1	1		Baseline	-4	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1423	-14	No	2520	2520	Death	Other		PANCREATIC CANCER	Other	2	1	1	2	10		1	2	2	Yes	1	1	0	1.6401141524	2277	1682	63	1	28	2494	Year 7	63	204	2	in	lb			89.284	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	28	99	Stem cell, Autologous	1	1							65	1	9.2857142857	1	5	5			1	2		1	Baseline	-14	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1426	1															1	2	2	Yes	1	1		1.3879038678	2590		59	1	28	2590	Year 7	64	128	1	in	lb			68.952	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	122	122	148	Stem cell, Autologous	1	1							2387	1	341	2297	3	3			2	1	1		Baseline	1	59	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1433	-13	No	2158	2158	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	1.7551457078	2005		55	1	22	2005	Month 66	67	237	1	in	lb			94.588	1	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Cyclophosphamide/Dexamethasone	95	95	122	Stem cell, Autologous	1	1	Bortezomib/Melphalan	256	257	1	1	1	883	1	126.14285714	700	5	1	1	2	2	1		1	Baseline	1	55	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1434	-7															2	2	2	Yes	1	1	0	1.7050364343	2563		61	1	28	2563	Year 7	64	272	2	in	lb			53.04	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	88	88	114	Stem cell, Autologous	1	1							1625	1	232.14285714	1569	3	3	3		2	1	1		Baseline	11	61	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1452	1															1	2	1	Yes	1	1		1.6972937972	2536		58	1	28	2536	Year 7	65	166	2	in	lb			97.24	1	1	Bortezomib-based	2	2	2	1	0	1	1	Cyclophosphamide/Dexamethasone	107	107	134	Stem cell, Autologous	1	1							170	1	24.285714286	95	3	3	1		2	2	1	1	Baseline	1	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1461	-7	No	1033	1033	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	0	3.8745032064	1004		71	1	11	1004	Month 33	70	240	2	in	lb			105.196	0	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	56	108	Stem cell, Autologous	1	1							485	1	69.285714286	412	5	3	2	4	2	1		1	Baseline	-7	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1466	-3															1	2	2	Yes	1	1	1	2.3027800348	2552		70	1	28	2552	Year 7	64	208	3	in	lb			64.532	1	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Melphalan	114	116	117	Stem cell, Autologous	1	1							738	1	105.42857143	651	3	3	3	1	2	1	1	1	Baseline	-3	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1478	1															1	2	2	Yes	1	1		2.2754330225	2557		48	1	28	2557	Year 7	64	221	3	in	lb			109.616	1	1	combined bortezomib/IMIDs-based	6	1	1	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	91	94	119	Stem cell, Autologous	1	1	FLUDARABINE	305	308	3	1	1		0		2495	1	1			2	1	1		Baseline	1	48	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1485	-13	No	152	152	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	1.6065169533	82	152	80	1	2	152	Month 6	67	157	2	in	lb			104.312	1	2	IMIDs-based	4	3	1	0		0							0												5	5			2		1		Baseline	-13	80	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1497	-8	No	1176	1176	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		2	2	1	Yes	1	1	1	1.3695207053	573		61	1	6	573	Month 18	68	159	1	in	lb			80.444	0	1	combined bortezomib/IMIDs-based	4	1	1	0	0	1	1	Cyclophosphamide/Dexamethasone	172	182	209	Stem cell, Autologous	1	1								0		970	5	5			2	1			Baseline	-8	61	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1489	-16	No	390	390	Death	Other		GVHD-RELATED COMPLICATIONS POST TRANSPLANT	Complication post transplant	2	1	1	2	3		1	2	1	Yes	1	1	1	1.8382148875	358		72	1	4	358	Year 1	64	175	3	in	lb			93.704	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	107	358	Stem cell, Autologous	1	1								0		322	5	5			2	2	1		Baseline	-16	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1491	-5	No	404	404	Death	Other		SEPTIC SHOCK	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	2	5.0340229366	390	404	55	1	5	403	Month 15	62	186	2	in	lb			75.14	1	1	IMIDs-based	4	3	2	0	0	1	1	Cyclophosphamide/Dexamethasone	193	193	235	Stem cell, Autologous	1	1							390	1	55.714285714	299	5	1	5		2	2	1	1	Baseline	-5	55	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1494	-13															1	2	2	Yes	1	1		3.7138020343	2409		64	1	26	2409	Month 78	59	150	1	in	lb			73.372	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Cyclophosphamide/Dexamethasone	65	65	91	Stem cell, Autologous	1	1	Bortezomib/Melphalan	264	272	8	1	1		0		2328	1	1			2	1	1		Baseline	-13	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1500	-18															1	2	1	Yes	1	1			2486		60	1	28	2486	Year 7	68	179	1	in	lb			79.56	1	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Cyclophosphamide/Melphalan/Dexamethasone	102	122	123	Stem cell, Autologous	1	1	Bortezomib/Melphalan/Dexamethasone	260	263	3	1	1	904	1	129.14285714	826	3	3	3	1	2	1	1	1	Baseline	-18	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1523	0															1	2	1	Yes	1	1	0	1.9779490417	2457		59	1	26	2457	Month 78	75	182	2	in	lb			93.704	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	79	79	104	Stem cell, Autologous	1	1	Bortezomib/Melphalan	250	259	9	1	1		0		2270	1	1	1		2	1	1		Baseline	0	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1537	-12	No	2243	2243	Death	Other		SYMPTOMATIC HYPOTENSION	Other	2	1	1	2	10		1	2	1	Yes	1	1	1	1.3868895886	2143		62	1	24	2221	Year 6	70	273	3	in	lb			228.956	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2188	5	5			2	1			Baseline	-12	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1565	1	No		1210	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	2.3724738483	1281		39	1	14	1281	Month 42	60	117	1	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	129	129	163	Stem cell, Autologous	1	1							1130	1	161.42857143	1027	3	3	1		2	1	1		Baseline	1	39	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1573	1	No		1779	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	1.2426141645	1814		76	1	19	1814	Month 57	69	164	2	in	lb			87.516	1	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Melphalan	193	196	196	Stem cell, Autologous	1	1								0		1727	1	1			2	1	1		Baseline	1	75	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1583	-3															1	2	2	Yes	1	1	0	4.153447775	2417		49	1	26	2417	Month 78	61	177	1	in	lb			68.952		2	Bortezomib-based	2	2	1	1	0	1	1	Cyclophosphamide/Dexamethasone	67	67	120	Stem cell, Autologous	1	1	Bortezomib/Melphalan	259	262	3	1	1	2417	1	345.28571429	2327	3	3	4		2	1	1		Baseline	-3	49	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1625	0	No	347	347	Death	Other		MOST LIKELY SEPSIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	1	Yes	1	1	1	1.9359708092	261		51	1	3	261	Month 9	76	185	3	in	lb			194.48	2	2	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Lenalidomide/Cyclophosphamide/Doxorubicin	33	34	112	Stem cell, Autologous	1	1							237	1	33.857142857	70	5	3	5		2	2	1	1	Baseline	0	51	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1640	1															1	2	1	Yes	1	1	1	2.1138077293	2395		71	1	26	2395	Month 78	65	148	3	in	lb				1	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	34	137	Stem cell, Autologous	1	1								0		2289	1	1			2	1	1		Baseline	1	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1683	-34															1	2	1	Yes	1	1	2	2.5823530323	2196		71	1	24	2196	Year 6	70	200	2	in	lb			88.4	0	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	136	Stem cell, Autologous	1	1							1227	1	175.28571429	1164	3	1	2	3	2	1	1		Baseline	-34	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1714	-2															1	1	1	Yes	1	1	0	1.5217268462	2193		52	1	24	2193	Year 6	69	233	1	in	lb			98.124	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Cyclophosphamide/Dexamethasone	74	74	101	Stem cell, Autologous	1	1								0		2100	1	1			2	1	1		Baseline	-2	52	Male					Checked			Hispanic or Latino		0	1
MMRF_1731	1															1	2	2	Yes	1	1		2.6168099736	2162		50	1	24	2162	Year 6	66	45	2	in	kg			109.616	0	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	59	59	85	Stem cell, Autologous	1	1							728	1	104	651	3	3	1		2	1	1	1	Baseline	1	50	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1730	-22															1	2	1	Yes	1	1	0	1.7883831588	2170		50	1	24	2170	Year 6	73	207	1	in	lb			106.964	1	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Cyclophosphamide/Dexamethasone	92	92	118	Stem cell, Autologous	1	1							592	1	84.571428571	501	3	3	1	1	2	1	1	1	Baseline	-22	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1759	-5	No		1121	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	1.4149478598	747		76	1	8	747	Year 2	67	150	2	in	lb			121.108	1	2	Bortezomib-based	2	2	2	1		0							0								724	1	103.42857143	639	3	3	4		2	1	1	1	Baseline	-5	76	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1758	0	No	1685	1685	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	2	3.1719473554	1662		72	1	19	1662	Month 57	65	238	2	in	lb			144.092	1	1	Bortezomib-based	2	2	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	65	112	Stem cell, Autologous	1	1							1286	1	183.71428571	1181	5	3	5		2	1			Baseline	0	72	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1781	-26															1	2	2	Yes	1	1	0		2165		69	1	24	2165	Year 6	58	111	2	in	lb			75.14	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	60	107	Stem cell, Autologous	1	1	Bortezomib/Melphalan	295	298	3	1	1	1962	1	280.28571429	1884	3	3	1		2	1	1		Baseline	-26	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1787	-17															1	1	1	Yes	1	1	0	1.831850009	2147		70	1	24	2147	Year 6	67	221	2	in	lb			100.776	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	82	82	107	Stem cell, Autologous	1	1								0		2066	1	1			2	1	1		Baseline	-17	70	Male					Checked			Hispanic or Latino		0	1
MMRF_1802	-9															1	2	1	Yes	1	1	0	1.6077599192	2248		63	1	24	2248	Year 6	62	162	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	85	85	111	Stem cell, Autologous	1	1	Bortezomib/Melphalan	232	235	3	1	1		0		2167	1	1			2	1	1		Baseline	-9	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1801	-13	No		1086	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	3.7971058686	635		62	1	7	635	Month 21	70	184	1	in	lb			65.416	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	102	102	128	Stem cell, Autologous	1	1	Bortezomib/Melphalan	295	298	3	1	1		0		544	1	1			2	1	1		Baseline	-13	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1807	-46	No	946	946	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1		1.5908136505	858		78	1	10	858	Month 30	63	149	1	in	lb			65.416	1	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	82	123	Stem cell, Autologous	1	1								0		825	5	5			2	1			Baseline	-48	78	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1819	-34	No	628	628	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	0	2.1679503187	137		67	1	2	137	Month 6	65	153	2	in	lb			134.368	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	-34	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1850	-40															1	2	1	Yes	1	1	0	3.250280355	2088		55	1	22	2088	Month 66	74	233	1	in	lb			79.56	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	95	95	122	Stem cell, Autologous	1	1	Bortezomib/Melphalan	274	277	3	1	1		0		2045	1	1			2	1	1		Baseline	-40	55	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1860	-16															1	2	1	Yes	1	1	0	1.5586135179	2231		46	1	24	2231	Year 6	61	202	2	in	lb			111.384	2	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Doxorubicin	95	98	124	Stem cell, Autologous	1	1	Bortezomib/Melphalan	254	257	3	1	1		0		2142	1	1			2	1	1		Baseline	-16	46	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1865	0															1	2	2	Yes	1	1	0	1.3269950691	2204		56	1	24	2204	Year 6	64	116	1	in	lb			84.864	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Cyclophosphamide/Melphalan/Dexamethasone	167	167	168	Stem cell, Autologous	1	1	Bortezomib/FLUDARABINE/Melphalan							0		1581	1	1			2	1	1		Baseline	0	56	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1895	-11															1	2	1	Yes	1	1	0	4.4780364617	2114		50	1	24	2114	Year 6	71	173	1	in	lb			65.416	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	122	122	149	Stem cell, Autologous	1	1	Bortezomib/Melphalan	287	290	3	1	1		0		2038	1	1			2	1	1		Baseline	-11	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1936	1	No	640	640	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		25.033967404	637		62	1	7	637	Month 21	69	205	1	in	lb			60.112	1	1	combined bortezomib/IMIDs-based	1	1	5	1		0	2	Cyclophosphamide/Dexamethasone	270	270	295	Stem cell, Autologous	1	0							155	1	22.142857143	65	5	1	3	2	2	2	1	1	Baseline	1	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1941	-53															1	2	1	Yes	1	1		1.2217354342	2035		58	1	24	2035	Year 6	75	220	2	in	lb			68.068	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	130	130	192	Stem cell, Autologous	1	1								0		1907	1	1			2	1	1		Baseline	-58	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1947	-24															1	2	2	Yes	1	1		1.3668973665	2164		63	1	24	2164	Year 6	62	139	2	in	lb			59.228	0	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Cyclophosphamide/Dexamethasone	80	80	106	Stem cell, Autologous	1	1	Bortezomib/Melphalan	287	290	3	1	1	978	1	139.71428571	905	3	3	3	4	2	1	1	1	Baseline	-24	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1951	-3															1	1	2	Yes	1	1		2.2195704467	2006		77	1	22	2006	Month 66	65	160	3	in	lb			123.76	0	2	IMIDs-based	4	3	5	0		0							0								593	1	84.714285714	492	3	3	2	1	2	1	1	1	Baseline	-3	77	Female					Checked			Hispanic or Latino		0	1
MMRF_1967	-1															1	2	1	Yes	1	1	0	1.5511778017	2216		74	1	24	2216	Year 6	64	207	2	in	lb			99.892	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	167	2216	167	Stem cell, Autologous	1	1								0		1317	1	1			2	1	1		Baseline	-1	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1965	-1															1	2	2	Yes	1	1	1	5.1129158896	2196		60	1	24	2196	Year 6	60	122	3	in	lb			75.14	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	81	84	112	Stem cell, Autologous	1	1	Bortezomib/FLUDARABINE/Melphalan	261	265	4	1	1	831	1	118.71428571	771	3	3	1		2	1	1	1	Baseline	-1	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1981	-4															1	2	1	Yes	1	1	2	5.6051208871	2171		63	1	24	2171	Year 6	71	212	3	in	lb			234.26	1	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Cyclophosphamide/Dexamethasone	101	101	127	Stem cell, Autologous	1	1							988	1	141.14285714	911	3	3	3	1	2	1	1	1	Baseline	-4	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1988	-46															1	2	2	Yes	1	1	0	1.7738011869	2147		73	1	24	2147	Year 6	61	121	2	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	117	Stem cell, Autologous	1	1							1503	1	214.71428571	1489	3	3	1		2	1	1		Baseline	-46	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2059	1															1	2	1	Yes	1	1	1	3.7961585841	2016		57	1	22	2016	Month 66	71	204	3	in	lb			1069.64	2	2	combined bortezomib/IMIDs-based	6	1	2	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1	46	106	Stem cell, Autologous	1	1							798	1	114	716	3	3	1		2	1	1	1	Baseline	1	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2061	-5	No	938	938	Death	Other		RESPIRATORY INFECTION	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	0	1.4509827242	828	1011	74	1	10	938	Month 30	66	202	1	in	lb			83.98	1	1	combined bortezomib/IMIDs-based	6	1	1	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1	47	86	Stem cell, Autologous	1	1								0		853	5	5			2	1			Baseline	-5	74	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2076	-3															1	2	2	Yes	1	1	2	5.3762858398	1965		72	1	22	1965	Month 66	64	167	2	in	lb			60.112	0	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	42	125	Stem cell, Autologous	1	1							900	1	128.57142857	827	3	3	3	1	2	1	1	1	Baseline	-3	72	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2129	-6															1	2	2	Yes	1	1	0		2030		62	1	22	2030	Month 66	64	146	1	in	lb			73.372	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	151	151	176	Stem cell, Autologous	1	1								0		1863	1	1			2	1	1		Baseline	-6	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1755	-53	No		869	Patient is lost to follow-up					2	1	5				1	1	1	Yes	1	1	1	2.9811908233	256		78	1	3	256	Month 9	61	60	1	in	kg			93.704	1	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	206	Stem cell, Autologous	1	1								0		119	1	1			2	2	1		Baseline	-53	78	Male					Checked			Hispanic or Latino		0	1
MMRF_2152	-10	No		88	Patient is lost to follow-up					2	1	5				1	1	2	Yes	1	1	2		64		53	1	1	64	Month 3	60	127	3	in	lb			327.08	0	1	Bortezomib-based	2	2	1	1		0							0									0		1	1	1			2	2	1		Baseline	-10	53	Female					Checked			Hispanic or Latino		0	1
MMRF_2172	0	No	596	596	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1	2		554		72	1	6	554	Month 18	166	271	2	cm	lb			92.82	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	127	Stem cell, Autologous	1	1							359	1	51.285714286	260	5	1	5		2	2	1	1	Baseline	0	72	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2231	-19														Not Specified	6	1	2	Yes	1	1	0	3.1641108739	1929		74	1	22	1929	Month 66	59	152	1	in	lb			66.3	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Cyclophosphamide/Dexamethasone	130	130	233	Stem cell, Autologous	1	1							1222	1	174.57142857	1159	3	3	1		2	1	1		Baseline	-19	74	Female						Checked	Not Specified	Hispanic or Latino		0	1
MMRF_2267	-5															1	2	2	Yes	1	1	1	1.9585498137	1804		79	1	20	1804	Year 5	61	153	3	in	lb			81.328	1	2	combined bortezomib/IMIDs/carfilzomib-based	1	5	3	1	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	62	142	155	Stem cell, Autologous	1	1							1104	1	157.71428571	1001	3	3	1	1	2	1	1		Baseline	-5	79	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2291	-104	No		722	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0		72		75	1	2	72	Month 6	68	92	1	in	kg			80.444	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		9	1	1			2	2	1		Baseline	-104	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2310	-20	No	849	849	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	2	3.1775733911	822	849	67	1	10	849	Month 30	68	95	2	in	kg			99.008	0	1	combined bortezomib/IMIDs-based	6	1	4	0	0	1	1	Cyclophosphamide/Dexamethasone	95	95	120	Stem cell, Autologous	1	1							605	1	86.428571429	528	5	1	2	3	2	1		1	Baseline	-20	67	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2316	-2															1	2	1	Yes	1	1	1		1947		64	1	22	1947	Month 66	71	94	3	in	kg			655.044	1	1	Bortezomib-based	2	2	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	102	144	Stem cell, Autologous	1	1							1849	1	264.14285714	1779	3	1	1		2	1	1		Baseline	1	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2330	-10															1	2	1	Yes	1	1	2		2006		58	1	22	2006	Month 66	70	171	2	in	lb			91.052	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Cyclophosphamide/Dexamethasone	88	88	123	Stem cell, Autologous	1	1	Bortezomib/Melphalan	234	235	1	1	1	558	1	79.714285714	502	3	3	1	1	2	1	1	1	Baseline	-10	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2331	-23															1	2	2	Yes	1	1	2		1822		70	1	20	1822	Year 5	65	103	2	in	lb			58.344	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	64	123	Stem cell, Autologous	1	1							1417	1	202.42857143	1354	3	3	1		2	1	1		Baseline	-23	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2378	-17															1	2	1	Yes	1	1	0	2.4573822364	1803		66	1	20	1787	Year 5	172	93	1	cm	kg			67.184	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	44	86	Stem cell, Autologous	1	1								0		1723	1	1			2	1	1		Baseline	1	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2407	-9															1	1	1	Yes	1	1	0	1.6005866	1807		45	1	20	1807	Year 5	69	233	1	in	lb			74.256	0	1	combined bortezomib/IMIDs-based	6	1	2	0	0	1	1	Cyclophosphamide/Dexamethasone	64	64	90	Stem cell, Autologous	1	1	Bortezomib/Melphalan	207	210	3	1	1	1800	1	257.14285714	1719	3	1	2		2	1	1		Baseline	-9	45	Male					Checked			Hispanic or Latino		0	1
MMRF_2422	-34															2	2	1	Yes	1	1	0	1.6211989367	1593		62	1	18	1593	Month 54	70	184	1	in	lb			141.44	0	1	Bortezomib-based	3	2	1	0	0	1	1	Cyclophosphamide/Melphalan	237	254	255	Stem cell, Autologous	1	1								0		1512	1	1			2	1	1		Baseline	-34	62	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2437	-3															4	2	2	Yes	1	1	2	1.4541479127	1817		71	1	20	1817	Year 5	59	117	2	in	lb			91.936	0	1	combined bortezomib/IMIDs-based	6	1	2	0	1	1	1	Melphalan/Dexamethasone	106	106	107	Stem cell, Autologous	1	1							1470	1	210	1363	3	3	1		2	1	1		Baseline	-3	71	Female		Checked						Not Hispanic or Latino		0	1
MMRF_2489	1															1	2	1	Yes	1	1	0	2.380690877	1838		56	1	20	1838	Year 5	68	176	1	in	lb			84.864	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	73	73	99	Stem cell, Autologous	1	1	Bortezomib/Melphalan	273	276	3	1	1	1295	1	185	1204	3	3	1		2	1	1		Baseline	1	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2499	0															1	2	2	Yes	1	1	0	1.8431314766	1857		55	1	20	1857	Year 5	61	103	1	in	kg			72.488	0	1	combined bortezomib/IMIDs-based	11	1	2	0	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	59	115	140	Stem cell, Autologous	1	1							1550	1	221.42857143	1451	3	3	1		2	1	1		Baseline	0	55	Female	Checked				Checked			Not Hispanic or Latino		0	1
MMRF_2506	-16	No	1406	1406	Death	Other		METASTATIC ADENOCARCINOMA	Other	2	1	1	2	10		2	2	1	Yes	1	1	1	2.0180098138	1268	550	81	1	16	1405	Year 4	70	193	3	in	lb			152.048	0	2	IMIDs-based	4	3	1	0		0							0									0		1322	5	5			2	1			Baseline	-16	81	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2548	1	No	771	771	Death	Other		PROGRESSIVE PULMONARY FAILURE LIKELY METAPNEUMOVIRUS WITH ARDS.	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	0	2.6033886788	645		57	1	7	645	Month 21	66	71	1	in	kg			99.892	1	1	combined bortezomib/IMIDs-based	6	1	1	0	1	1	1	Cyclophosphamide/Dexamethasone	79	79	104	Stem cell, Autologous	1	1	Bortezomib/FLUDARABINE/Melphalan	247	251	4	1	1		0		674	5	5			2	1			Baseline	1	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2554	1	No	271	271	Death	Other		SEPTIC SHOCK	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	0	2.7704239251	200	271	65	1	3	271	Month 9	65	62	1	in	kg			82.212	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Cyclophosphamide/Dexamethasone	126	126	162	Stem cell, Autologous	1	1								0		170	5	5			2	2	1		Baseline	1	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2574	-2	No	475	475	Death	Other		MULTI-ORGAN FAILURE	Other	2	1	1	2	10		1	2	1	Yes	1	1	2	4.4020406778	354	475	74	1	5	446	Month 15	68	86	2	in	kg			94.588	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	54	90	Stem cell, Autologous	1	1							445	1	63.571428571	274	5	1	5		2	2	1	1	Baseline	-2	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2593	-2															1	2	1	Yes	1	1	0		1261		65	1	14	1261	Month 42	68	176	1	in	lb			129.948	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Cyclophosphamide/Dexamethasone	64	64	91	Stem cell, Autologous	1	1							1072	1	153.14285714	990	3	3	1		2	1	1	1	Baseline	-2	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2596	-19	No	139	139	Death	Other		FAILURE TO THRIVE AND UTI		2	1	1	1			1	2	2	Yes	1	1	0	2.1845041004	138		73	1	2	138	Month 6	60	92	1	in	kg			80.444	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	32	79	Stem cell, Autologous	1	1								0		56	5	5			2	2	1		Baseline	-19	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2605	-7	No	1337	1337	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	1.9581537037	1148		62	1	13	1148	Month 39	67	50	1	in	kg			76.908	1	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Cyclophosphamide/Dexamethasone	65	65	91	Stem cell, Autologous	1	1	Bortezomib/Melphalan/Dexamethasone	257	260	3	1	1	588	1	84	504	5	3	3	2	2	1		1	Baseline	-7	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2619	420															1	2	2	Yes	1	1			2120		69	1	18	2120	Month 54	67	108	2	in	kg			100.776	0	1	combined bortezomib/IMIDs/carfilzomib-based		5	1	0	0	1	1	Cyclophosphamide/Dexamethasone	510	510	537	Stem cell, Autologous	1	1	Daratumumab/Pomalidomide/Dexamethasone	1500	1662	162	1	1	1453	1	207.57142857	923	3	3			2	1	1		Baseline	420	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1222	-4	No	824	824	Death	Disease progression				2	1	1	1		Middle Eastern Indian	6	2	1	Yes	1	1			798	824	50	1	10	823	Month 30	172	72	2	cm	kg			127.296	0	1	Bortezomib-based	3	2	4	0		0	2	Carfilzomib/Pomalidomide/Dexamethasone	170	359	408	Stem cell, Autologous	1	0							158	1	22.571428571	96	5	3	3	2	2	2		1	Baseline	-4	50	Male						Checked	Middle Eastern Indian	Not Hispanic or Latino	-4	0	1
MMRF_1264	-7	No	2342	2342	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1			2150	1975	83	1	26	2341	Month 78	163	88		cm	kg			99.008	2	2	combined bortezomib/IMIDs-based	3	1	2	0		0							0								92	1	13.142857143	1	5	1	5		1	2		1	Baseline	-12	83	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1547	-5															1	2	1	Yes	1	1			2369		65	1	26	2369	Month 78	70	150	2	in	lb			63.648	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	148	194	Stem cell, Autologous	1	1	Bortezomib	642	865	223	1	1		0		2242	1	1			2	1	1		Baseline	-9	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1570	-34	No		980	Other		WITHDRAWN BY TREATING PHYSICIAN BECAUSE PATIENT WOULDN'T COME FOR VISITS.			2	1	7				2	2	2	Yes	1	1	0	1.4504763265	980		52	1	11	980	Month 33	69	152	1	in	lb			82.212	0	1	Bortezomib-based	2	2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	110	155	Stem cell, Autologous	1	1	Bortezomib	386	546	160	1	1	532	1	76	352	3	3	1		2	2	1	1	Baseline	1	52	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1586	1	No		416	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		2.6720178981	416		90	1	5	381	Month 15	62	125		in	lb			71.604	1	2	Bortezomib-based	3	2	1	0		0							0								343	1	49	239	3	3			2	2	1	1	Baseline	1	90	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2038	1															1	1	2	Yes	1	1	1	1.2942915703	2180		37	1	24	2172	Year 6	67	58	3	in	kg			1278.264	3	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Melphalan/Dexamethasone	158	168	169	Stem cell, Autologous	1	1	Lenalidomide/Thalidomide	275	538	263	1	1		0		2095	1	1			2	1	1		Baseline	-3	37	Female					Checked			Hispanic or Latino		0	1
MMRF_2168	-39															2	2	1	Yes	1	1	0	1.7457834648	1990		50	1	22	1990	Month 66	72	248	1	in	lb			99.008	0	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Bortezomib/Dexamethasone	309	322	309	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide/Dexamethasone	430	542	112	1	1		0		1738	1	1			2	1	1		Baseline	-39	50	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2215	-20															1	2	1	Yes	1	1	0	1.8685412797	1972		71	1	22	1930	Month 66	68	177	1	in	lb			79.56	0	1	combined bortezomib/IMIDs-based	3	1	1	0	0	1	1	Bortezomib/Dexamethasone	1	94	129	Stem cell, Autologous	1	1	Lenalidomide	242	1930	1688	2	2		0		1902	1	1			2	1	1		Baseline	-20	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1011	-9															1	2	1	Yes	1	1			1969		50	1	22	1969	Month 66	177	95	3	cm	kg			123.76	1	1	combined bortezomib/IMIDs-based	3	1	2	0	1	1	1	Melphalan/Dexamethasone	153	153	155	Stem cell, Autologous	1	1	Lenalidomide	253	925	672	2	2	1613	1	230.42857143	1541	3	3	1		2	1	1		Baseline	-9	50	Male					Checked			Not Hispanic or Latino	-9	0	1
MMRF_1034	-18	No		1661	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1			1661		55	1	19	1661	Month 57	63	183	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Lenalidomide/Dexamethasone	116	249	260	Stem cell, Autologous	1	1								0		1582	1	1			2	1	1		Baseline	-23	55	Female			Checked					Not Hispanic or Latino	-18	0	1
MMRF_1029	-4	No		1124	Other		PATIENT RELOCATED			2	1	7				1	2	1	Yes	1	1	0	1.7983422838	995		46	1	11	995	Month 33	72	279	1	in	lb			106.08	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		911	1	1			2	1	1		Baseline	-4	46	Male					Checked			Not Hispanic or Latino	-4	0	1
MMRF_1042	0															1	2	1	Yes	1	1			1980		72	1	22	2008	Month 66	172	72	3	cm	kg			362.44	2	2	Bortezomib-based	3	2	2	0		0							0								455	1	65	364	3	3	3		2	2	1	1	Baseline	-1	72	Male					Checked			Not Hispanic or Latino	0	0	1
MMRF_1039	-5	No		1794	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			1779		62	1	20	1779	Year 5	70	177	2	in	lb			97.24	0	1	combined bortezomib/IMIDs-based	3	1	2	0	0	1	1	Bortezomib/Dexamethasone	244	246	245	Stem cell, Autologous	1	1							995	1	142.14285714	910	3	3	1		2	1	1	1	Baseline	-5	62	Male					Checked			Not Hispanic or Latino	-5	0	1
MMRF_1055	-15	No	580	580	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		546	580	66	1	6	546	Month 18	71	156	2	in	lb			97.24	0	1	Bortezomib-based	3	2	2	0	0	1	1	Bortezomib/Dexamethasone	1	142	167	Stem cell, Autologous	1	1							244	1	34.857142857	96	5	3	5		2	2	1	1	Baseline	-15	66	Male					Checked			Not Hispanic or Latino	-15	0	1
MMRF_1124	-3	No	553	553	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			386		71	1	5	386	Month 15	154	61	2	cm	kg			282.88	1	1	Bortezomib-based	3	2	1	0		0							0								256	1	36.571428571	176	5	5			2	2	1	1	Baseline	-3	71	Female					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1166	-3	No	167	167	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1			92	167	67	1	2	157	Month 6	68	191	2	in	lb			150.28	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		62	5	5			2	2	1		Baseline	-30	67	Male					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1209	1	No	320	320	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			263	320	63	1	4	295	Year 1	72	202	2	in	lb			150.28	3	2	Bortezomib-based	2	2	1	1		0							0									0		117	5	5			2	2	1		Baseline	1	63	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1333	-3	No	267	267	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			155	267	67	1	3	264	Month 9	72	235	2	in	lb			79.56	1	1	Bortezomib-based	2	2	1	1		0							0									0		113	5	5			2	2	1		Baseline	-3	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1342	-12	No	778	778	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	3.4575789717	754	778	80	1	9	754	Month 27	70	154	3	in	lb			159.12	0	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		694	5	5			2	1			Baseline	-12	80	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1383	-20															1	2	1	Yes	1	1	0	1.6963720441	1527		73	1	17	1527	Month 51	66	72	1	in	kg			88.4	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	135	169	Stem cell, Autologous	1	1	Bortezomib	276	1009	733	2	2		0		1443	1	1			2	1	1		Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1550	-13															1	2	1	Yes	1	1	1	3.5389823947	1346		71	1	15	1346	Month 45	73	127	3	in	kg			97.24	0	1	combined bortezomib/IMIDs-based	2	1	2	1		0							0								706	1	100.85714286	621	3	3	3		2	1	1	1	Baseline	-5	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1568	-13															1	2	2	Yes	1	1	0		1356		66	1	15	1356	Month 45	63	56	2	in	kg			123.76	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	113	173	Stem cell, Autologous	1	1	Lenalidomide	285	441	156	1	1	1023	1	146.14285714	939	3	3	4		2	1	1	1	Baseline	1	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1721	-36	No		120	Patient is lost to follow-up					2	1	5				1	1	1	Yes	1	1	1	3.3227228656	120		57	1	2	120	Month 6	64	74	1	in	kg			106.08	0	1	Bortezomib-based	2	2	1	1		0							0									0		92	1	1			2	2	1		Baseline	-36	57	Male					Checked			Hispanic or Latino		0	1
MMRF_1834	-11															1	2	2	Yes	1	1	0		1117		64	1	13	1117	Month 39	63	163	2	in	lb			106.08	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	69	147	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	222	940	718	2	2		0		1011	1	1			2	1	1		Baseline	1	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1970	-26	No	259	259	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		254	259	69	1	3	254	Month 9	188	114	2	cm	kg			176.8	0	1	Bortezomib-based	3	2	1	0		0							0									0		175	5	5			2	2	1		Baseline	1	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2057	-6	No		319	Patient no longer consents to participate in the study					2	1	3				2	2	2	Yes	1	1	0	1.9392962531	246		90	1	3	246	Month 9	69	95	2	in	kg			106.08	1	2	IMIDs-based	4	3	1	0		0							0									0		162	1	1			2	2	1		Baseline	-6	90	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2454	0	No	74	74	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1				74	68	1	1	73	Month 3	65	76	3	in	kg			229.84	2	2	IMIDs-based	4	3	1	0		0							0												5	5			2		1		Baseline	0	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2480	-19	No	141	141	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		1.5031775494	92	141	63	1	2	120	Month 6	64	79		in	kg			176.8	1	1	IMIDs-based	4	3	1	0		0							0									0			5	5			2		1		Baseline	-19	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2560	-32															1	2	1	Yes	1	1		1.9338472949	865		63	1	10	865	Month 30	75	162		in	lb			123.76	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	865	137	Stem cell, Autologous	1	1								0		823	1	1			2	1	1		Baseline	-32	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1031	-1	No	1670	1670	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	7.0031746653	1581		62	1	18	1581	Month 54	155	83	1	cm	kg			81.328	0	1	combined bortezomib/IMIDs-based	1	1	3	1		0							0								1329	1	189.85714286	1226	5	3	1	5	2	1			Baseline	-1	62	Male					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1018	-11	No		1886	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1			1543		74	1	18	1543	Month 54	145	56	3	cm	kg			133.484	1	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		1325	1	1			2	1	1		Baseline	-8	74	Female					Checked			Not Hispanic or Latino	-8	0	1
MMRF_1041	1	No	1328	1328	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1			1226		66	1	14	1226	Month 42	157	137	3	cm	lb			295.256	1	1	combined bortezomib/IMIDs-based		1	3	0		0							0								351	1	50.142857143	267	5	3	3	5	2	2		1	Baseline	1	66	Female			Checked					Not Hispanic or Latino	1	0	1
MMRF_1016	1	No	692	692	Death	Other		TRAUMATIC BRAIN INJURY	Neurological	2	1	1	2	6		1	2	1	Yes	1	1	1		647		56	1	7	647	Month 21	178	233	1	cm	lb			86.632	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		590	5	5			2	1	1		Baseline	1	56	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1054	-8	Yes		2948	Other		COMPLETE THE STUDY			1	2	7				1	2	2	Yes	1	1	0		2948		58	1	32	2948	Year 8	152	129	2	cm	lb			61.88	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		2899	1	1			2	1	1		Baseline	-8	58	Female					Checked			Not Hispanic or Latino	-8	0	1
MMRF_1049	-4	Yes		2873						1	2					2	2	2	Yes	1	1	0		2873		68	1	32	2873	Year 8	160	167	2	cm	lb			81.328	0	1	Bortezomib-based	2	2	5	1		0	9	Cyclophosphamide/Dexamethasone	2144	2207	2207	Stem cell, Autologous	1	0	Elotuzumab/Pomalidomide/Dexamethasone	2395	2431	36	1		1079	1	154.14285714	901	3	1	3	2	2	1	1	1	Baseline	-4	68	Female			Checked					Not Hispanic or Latino	-4	0	1
MMRF_1064	-6	Yes		2901						1	2					1	2	1	Yes	1	1			2901		51	1	32	2901	Year 8	178	166	2	cm	lb			98.124	0	1	combined bortezomib/IMIDs-based	1	1	3	1		0	3	Carfilzomib/Dexamethasone	1543	1602	1617	Stem cell, Autologous	1	0	Elotuzumab/Lenalidomide/Dexamethasone	1769	2806	1037	2		1472	1	210.28571429	1395	3	3	4	3	2	1	1		Baseline	-6	51	Male					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1071	-28	No		2891	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			2733		42	1	30	2733	Month 90	158	73	2	cm	kg			109.616		2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								840	1	120	777	3	3	1		2	1	1	1	Baseline	-19	42	Male					Checked			Not Hispanic or Latino	-19	0	1
MMRF_1084	-23	No	1648	1648	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1			1599	1648	74	1	20	1647	Year 5	169	90	3	cm	kg	Stage III	3	95.472	1	1	combined bortezomib/IMIDs-based	1	1	5	1		0							0								624	1	89.142857143	532	5	3	1	2	2	1		1	Baseline	-23	74	Female					Checked			Not Hispanic or Latino	-23	0	1
MMRF_1100	-19	No			Other		PATIENT IS UNABLE TO COME TO CLINIC DUE TO COVID 19 PANDEMIC			2	1	7				1	2	2	Yes	1	1			2851		68	1	32	2851	Year 8	165	179	1	cm	lb			91.052		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	190	974	975	Stem cell, Autologous	1	1							859	1	122.71428571	787	3	1	3	1	2	1	1	1	Baseline	-19	68	Female					Checked			Not Hispanic or Latino	-19	0	1
MMRF_1101	-20	No		1282	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1			1261		77	1	14	1261	Month 42	164	61	2	cm	kg			108.732	0	2	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		1163	1	1			2	1	1		Baseline	-20	77	Male			Checked					Not Hispanic or Latino	-20	0	1
MMRF_1111	-1	Yes		2923	Other		COMPLETE THE STUDY			1	2	7				1	2	2	Yes	1	1			2923		45	1	32	2923	Year 8	167	120	3	cm	lb			155.584	0	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		2821	1	1			2	1	1		Baseline	-1	45	Female					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1127	-36	Yes		2878						1	2					1	2	2	Yes	1	1	0		2878		91	1	32	2878	Year 8	163	179	1	cm	lb			62.764	1	2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	82	265	Stem cell, Autologous	1	1							1958	1	279.71428571	1877	3	3	1		2	1	1		Baseline	-36	91	Female					Checked			Not Hispanic or Latino	-36	0	1
MMRF_1151	-6	No	250	250	Death	Other		CARDIAC EPISODE	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1			182	250	71	1	3	249	Month 9	178	203	3	cm	lb			191.828	1	1	Bortezomib-based	2	2	1	1		0							0									0		69	5	5			2	2	1		Baseline	1	71	Male					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1156	0	No		2950	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			2768		59	1	30	2768	Month 90	180	73	1	cm	kg			86.632	0	1	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	87	204	212	Stem cell, Autologous	1	1							1746	1	249.42857143	1663	3	1	1	2	2	1	1		Baseline	0	59	Male					Checked			Not Hispanic or Latino	-7	0	1
MMRF_1157	-13	Yes		2922	Other		COMPLETE THE STUDY			1	2	7				1	1	2	Yes	1	1			2739		69	1	30	2739	Month 90	156	64	1	cm	kg			67.184	0	1	combined bortezomib/IMIDs-based	2	1	5	1	1	1	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	240	240	240	Stem cell, Autologous	1	1	Lenalidomide	326	414	88	1	1	534	1	76.285714286	182	3	3	2	1	2	2	1	1	Baseline	-13	69	Female					Checked			Hispanic or Latino	-13	0	1
MMRF_1179	1	No	1955	1955	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1719	1955	80	1	22	1955	Month 66	170	67	2	cm	kg			121.108	0	2	combined bortezomib/IMIDs-based	1	1	5	1		0							0								710	1	101.42857143	562	5	3	1	2	2	1		1	Baseline	-2	80	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1212	-1	No		1919	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1		1.6010301788	1252		78	1	14	1252	Month 42	160	71	3	cm	kg			114.92	2	2	combined bortezomib/IMIDs-based	2	1	1	1		0							0								1252	1	178.85714286	1163	3	3			2	1	1		Baseline	-1	78	Female					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1223	4															1	2	1	Yes	1	1			2743		35	1	30	2743	Month 90	175	70	3	cm	kg			300.56	1	1	combined bortezomib/IMIDs-based		1	5	0	0	1	1	Lenalidomide	509	606	606	Stem cell, Autologous	1	1							579	1	82.714285714	492	3	3	3	1	2	1	1	1	Baseline	4	35	Male					Checked			Not Hispanic or Latino	4	0	1
MMRF_1224	-1	No	2356	2356	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	1	1	Yes	1	1		3.1902222895	2163		63	1	24	2163	Year 6	182	178	3	cm	lb			110.5		2	combined bortezomib/IMIDs-based	2	1	5	1	0	1	1	Lenalidomide/Dexamethasone	226	780	1056	Stem cell, Autologous	1	1							1519	1	217	1457	5	1	3	2	2	1			Baseline	-1	63	Male					Checked			Hispanic or Latino	-1	0	1
MMRF_1231	1	No	85	85	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		2	2	2	Yes	1	1	0	1.6441488923	78	85	77	1	1	78	Month 3	158	178	2	cm	lb			111.384	1	2	Bortezomib-based	2	2	1	1		0							0												5	5			2		1		Baseline	1	77	Female			Checked					Not Hispanic or Latino	1	0	1
MMRF_1232	-6	No	972	972	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		2	2	2	Yes	1	1			847	972	58	1	10	966	Month 30	164	76	3	cm	kg			185.64	1	1	combined bortezomib/IMIDs-based	3	1	4	0		0							0								627	1	89.571428571	540	5	3	2	4	2	1		1	Baseline	-6	58	Female			Checked					Not Hispanic or Latino	-6	0	1
MMRF_1244	-10	No		519	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1		1.6666246506	172		70	1	2	172	Month 6	156	58	2	cm	kg			133.484	1	1	Bortezomib-based	2	2	1	1		0							0									0		1	1	1			2	2	1		Baseline	-10	70	Female			Checked					Not Hispanic or Latino	-10	0	1
MMRF_1252	1	No	463	463	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			400	463	77	1	5	442	Month 15	163	58	2	cm	kg			59.228	1	2	combined bortezomib/IMIDs-based	2	1	2	1		0							0								283	1	40.428571429	183	5	3	5		2	2	1	1	Baseline	1	77	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1266	-13															1	2	2	Yes	1	1		1.4930891105	2644		74	1	30	2644	Month 90	156	61	1	cm	kg			63.648	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2567	1	1			2	1	1		Baseline	-13	74	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1267	0	No	1147	1147	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.3075188166	1080		39	1	12	1080	Year 3	186	148	2	cm	kg	Stage II	2	107.848	1	1	combined bortezomib/IMIDs-based	1	1	5	1		0	2	Carfilzomib/Lenalidomide/Dexamethasone	191	224	235	Stem cell, Autologous	1	0	Bortezomib/Lenalidomide/Dexamethasone	472	563	91	1		183	1	26.142857143	100	5	3	3	4	2	2		1	Baseline	0	39	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1275	-6	No	917	917	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			848	917	45	1	10	878	Month 30	184	229	1	cm	lb			122.876	0	1	combined bortezomib/IMIDs/carfilzomib-based		5	3	0	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1	391	401	Stem cell, Autologous	1	1							505	1	72.142857143	417	5	3	2	4	2	1		1	Baseline	-6	45	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1280	1															2	1	2	Yes	1	1			2753		58	1	30	2753	Month 90	163	87	2	cm	kg			59.228	1	1	combined bortezomib/IMIDs-based	2	1	5	1	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	37	349	340	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	350	350	0	1	1	331	1	47.285714286	193	3	3	2	2	2	2	1	1	Baseline	-7	58	Female			Checked					Hispanic or Latino		0	1
MMRF_1308	-10															2	2	1	Yes	1	1		3.5842553356	2546		53	1	28	2546	Year 7	191	228	1	cm	lb			104.312	0	1	combined bortezomib/IMIDs-based	2	1	4	1		0							0								271	1	38.714285714	170	3	3	2	1	2	2	1	1	Baseline	-10	53	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1307	-5															2	2	1	Yes	1	1		3.7339446995	2713		74	1	30	2713	Month 90	66	155	1	in	lb			83.096	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2621	1	1			2	1	1		Baseline	-5	74	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1314	-6															1	2	2	Yes	1	1		1.2244503299	2578		61	1	28	2578	Year 7	159	159	2	cm	lb			75.14	2	2	combined bortezomib/IMIDs-based	6	1	1	0		0							0									0		2512	1	1			2	1	1		Baseline	-6	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1311	-14															1	2	1	Yes	1	1		2.204917828	2531		57	1	28	2531	Year 7	69	288	2	in	lb			101.66	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	252	282	Stem cell, Autologous	1	1	Bortezomib/Melphalan	441	443	2	1	1		0		2433	1	1			2	1	1		Baseline	-14	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1324	-2	No		2622	Death	Other		COVID 19 INFECTION	Other	2	1	1	2	10		4	2	1	Yes	1	1	2	1.834345623	2540		61	1	28	2540	Year 7	64	67	2	in	kg			111.384	1	1	combined bortezomib/IMIDs-based	6	1	2	0		0	2	Carfilzomib/Cyclophosphamide/Dexamethasone	731	1310	775	Stem cell, Autologous	1	0	Lenalidomide	880	1446	566	2		612	1	87.428571429	538	3	3	3		2	1	1	1	Baseline	-2	61	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1345	-26															2	2	2	Yes	1	1			2538		60	1	28	2538	Year 7	66	157	1	in	lb			64.532	1	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	95	218	219	Stem cell, Autologous	1	1							911	1	130.14285714	839	3	1	3	1	2	1	1	1	Baseline	-6	60	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1352	-6															1	2	1	Yes	1	1	0	1.3924698632	2539		54	1	28	2539	Year 7	73	225	1	in	lb			99.892	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	219	233	267	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	374	1515	1141	2	2		0		2453	1	1			2	1	1		Baseline	-6	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1354	0															1	1	1	Yes	1	1	1	2.5577949032	2554		75	1	28	2554	Year 7	66	146	3	in	lb			114.92	1	1	combined bortezomib/IMIDs-based	6	1	2	0		0							0								389	1	55.571428571	287	3	3	1		2	2	1	1	Baseline	0	75	Male					Checked			Hispanic or Latino		0	1
MMRF_1089	-26	No		1511	Patient no longer consents to participate in the study					2	1	3				1	1	1	Yes	1	1	1	4.2581960787	1333		61	1	15	1333	Month 45	167	87	3	cm	kg			190.06	0	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		1185	1	1			2	1	1		Baseline	-26	61	Male					Checked			Hispanic or Latino		0	1
MMRF_1387	-3	No		328	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1					64	1	0	-3	Baseline	69	155	3	in	lb			108.732		2	Bortezomib-based	2	2	1	1		0							0												4	4			2		1		Baseline	-3	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1389	-17	No		946	Patient is lost to follow-up					2	1	5				1	1	2	Yes	1	1	0	5.5882695276	715		51	1	6	715	Month 18	164	74	1	cm	kg			57.46	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	78	183	Stem cell, Autologous	1	1								0		624	1	1			2	1	1		Baseline	-17	51	Female					Checked			Hispanic or Latino		0	1
MMRF_1391	-19	No		1681	Patient is lost to follow-up					2	1	5				4	2	2	Yes	1	1	2	2.2550359435	1031		65	1	13	1031	Month 39	170	53	2	cm	kg			66.3	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	148	162	Stem cell, Autologous	1	1	Lenalidomide	1026	1031	5	1	1		0		945	1	1			2	1	1		Baseline	-19	65	Female		Checked						Not Hispanic or Latino		0	1
MMRF_1446	-6															1	2	1	Yes	1	1	0	2.2487848678	2555		68	1	28	2555	Year 7	69	194	1	in	lb			88.4	0	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	2	1	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	346	346	346	Stem cell, Autologous	1	1							438	1	62.571428571	257	3	3	1		2	2	1	1	Baseline	1	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1450	-12	No	16	16	Death	Other		CARDIAC ARREST LIKELY DUE TO FAT EMBOLUS DURING L HIP OPERATION.	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	2	10.217224512		16	69	1	1	16	Month 3	65	219	2	in	lb			46.852		2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	-12	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1455	-13															1	2	1	Yes	1	1		1.5567330901	2568		54	1	28	2568	Year 7	172	83	1	cm	kg			126.412	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	140	147	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	247	2568	2321	2	2		0		2514	1	1			2	1	1		Baseline	-13	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1454	-27	No		1471	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	1.8706876369	1471		53	1	16	1471	Year 4	65	177	2	in	lb			71.604	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	159	161	Stem cell, Autologous	1	1	Bortezomib	337	524	187	1	1		0		1338	1	1			2	1	1		Baseline	-27	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1474	-6															1	2	1	Yes	1	1		1.9744539127	2549		27	1	28	2549	Year 7	68	89	2	in	kg			89.284	0	1	combined bortezomib/IMIDs-based	3	1	3	0		0							0								1173	1	167.57142857	1089	3	3	2	1	2	1	1		Baseline	-6	27	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1479	1															1	2	1	Yes	1	1			2553		67	1	28	2553	Year 7	173	92	1	cm	kg			79.56	2	2	combined bortezomib/IMIDs-based	1	1	3	1		0							0								1240	1	177.14285714	1186	3	1	2	3	2	1	1		Baseline	-2	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1502	-3	No	1620	1620	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	2.0698128216	1527	1620	58	1	18	1620	Month 54	61	117	3	in	lb			99.008	3	2	Bortezomib-based	2	2	4	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	47	219	Stem cell, Autologous	1	1	Bortezomib	368	764	396	2	2	792	1	113.14285714	700	5	3	1	2	2	1		1	Baseline	-3	58	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1510	0															4	2	1	Yes	1	1	1	2.3979784163	2383		58	1	26	2383	Month 78	65	91	3	in	kg			150.28		2	combined bortezomib/IMIDs-based	1	1	4	1		0	2	Carfilzomib/Cyclophosphamide/Dexamethasone	1470	1671	1745	Stem cell, Autologous	1	0							1472	1	210.28571429	1389	3	1	1	1	2	1	1		Baseline	0	58	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1513	-19	No	2043	2044	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.1066400209	1948	1491	59	1	24	2043	Year 6	70	91	2	in	kg			89.284	0	1	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	889	906	Stem cell, Autologous	1	1							889	1	127	810	5	3	3	2	2	1		1	Baseline	-19	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1516	-10	No	1176	1176	Death	Other		NOT DOCUMENTED	Other	2	1	1	2	10		1	2	1	Yes	1	1	0	1.629900133	1032	1176	83	1	14	1175	Month 42	71	143	1	in	lb			108.732	1	2	IMIDs-based		3	1	0		0							0									0		1083	5	5			2	1			Baseline	-17	83	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1622	-14															1	2	1	Yes	1	1			2385		61	1	26	2385	Month 78	72	179		in	lb			103.428	0	1	combined bortezomib/IMIDs-based	6	1	1	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	307	637	307	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	638	638	0	1	1		0		2267	1	1			2	1	1		Baseline	-3	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1628	-22															1	2	2	Yes	1	1	1		2378		63	1	26	2378	Month 78	162	53	1	cm	kg			83.98	1	1	combined IMIDs/carfilzomib-based	4	4	4	0		0	2	Carfilzomib	1028	1061	1159	Stem cell, Autologous	1	0							1505	1	215	1403	3	1	3	2	2	1	1		Baseline	-22	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1634	-2	No	16	16	Death	Other		MYOCARDIAL INFARCTION	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	2	2.6046492535		16	36	1	1	13	Month 3	68	156	2	in	lb			115.804	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	-3	36	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1637	-10															1	2	2	Yes	1	1		4.9307152984	2384		64	1	26	2384	Month 78	68	222		in	lb			91.052	0	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	207	596	207	Stem cell, Autologous	1	1							719	1	102.71428571	534	3	1	2	4	2	1	1	1	Baseline	-10	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1643	-19	No		1733	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	1.8657475828	1590		62	1	18	1590	Month 54	182	85	1	cm	kg			77.792	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1485	1	1			2	1	1		Baseline	-19	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1648	-17	No		177	Patient is lost to follow-up					2	1	5				4	2	1	Yes	1	1	0	2.7488130523	58		63	1	1	58	Month 3	63	153	1	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0			4	4			2		1		Baseline	-17	63	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1665	1	No		1765	Other		DID NOT RECONSENT TO CONTINUE TO BE FOLLOWED			2	1	7				1	2	2	Yes	1	1	1	2.1630616215	1774		64	1	20	1774	Year 5	65	131	1	in	lb			95.472	0	1	combined bortezomib/IMIDs/carfilzomib-based	6	5	2	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	309	309	310	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Prednisone	432	932	500	2	2		0		1480	1	1	1		2	1	1		Baseline	-6	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1677	-26	No		2017	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	2.0446913003	2017		50	1	22	2017	Month 66	176	98	2	cm	kg			94.588	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	301	313	301	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide	314	574	260	1	1		0		1886	1	1			2	1	1		Baseline	-26	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1686	-14															1	2	2	Yes	1	1	0	1.6461076377	2273		37	1	26	2367	Month 78	65	143	1	in	lb			68.068	1	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	173	214	225	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide	275	380	105	1	1		0		2107	1	1			2	1	1		Baseline	-17	37	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1710	-7	No		1163	Other		PT RELOCATED TO MA AND IS RECEIVING CARE AT MA FACILITY			2	1	7				1	2	2	Yes	1	1	1	3.062286759	796		48	1	9	796	Month 27	64	181	1	in	lb			76.024	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		699	1	1			2	1	1		Baseline	-7	48	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1698	-4	No		1166	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1	1	1.1021814623	870		59	1	10	870	Month 30	69	166	3	in	lb			126.412	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	60	129	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	204	270	66	1	1		0		601	1	1			2	1	1		Baseline	0	59	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1746	1	No		1751	Patient no longer consents to participate in the study					2	1	3				2	2	2	Yes	1	1	0		1751		51	1	20	1751	Year 5	162	79	1	cm	kg			74.256	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	161	1125	161	Stem cell, Autologous	1	1								0		1614	1	1			2	1	1		Baseline	1	51	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1744	1	No		2379	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1		2.2868277681	2197		68	1	24	2197	Year 6	160	96		cm	kg			226.304	0	1	combined bortezomib/IMIDs-based	2	1	5	1		0	4	Carfilzomib/Melphalan	1550	1551	1553	Stem cell, Autologous	1	0							846	1	120.85714286	344	3	3	2	2	2	2	1	1	Baseline	1	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1768	-14	No		732	Patient is lost to follow-up					2	1	5				1	1	2	Yes	1	1	0	3.2521259484	478		64	1	6	478	Month 18	160	80	1	cm	kg			72.488	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	148	148	149	Stem cell, Autologous	1	1								0		402	1	1			2	1	1		Baseline	-14	64	Female					Checked			Hispanic or Latino		0	1
MMRF_1808	-13	No	729	729	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		1.5100171641	694		56	1	8	694	Year 2	170	107		cm	kg			80.444	0	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1	1	1	1	Bortezomib/Carfilzomib/Cyclophosphamide/Melphalan/Dexamethasone	174	174	175	Stem cell, Autologous	1	1	Lenalidomide/Prednisone	267	366	99	1	1		0		288	5	5			2	2			Baseline	-13	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1830	-3															1	2	2	Yes	1	1	1	1.5032905517	2180		69	1	24	2180	Year 6	152	79	3	cm	kg			120.224	0	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		2089	1	1			2	1	1		Baseline	1	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1859	0	No		2001	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	2.7192293887	1808		63	1	20	1808	Year 5	175	93	1	cm	kg			101.66	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1710	1	1			2	1	1		Baseline	-8	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1871	-1															1	2	2	Yes	1	1	0	1.6747886231	2051		69	1	22	2051	Month 66	156	61	2	cm	kg			67.184	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	167	2051	167	Stem cell, Autologous	1	1								0		1959	1	1			2	1	1		Baseline	-1	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1921	-9															1	2	1	Yes	1	1	0	1.6131482478	2182		61	1	24	2182	Year 6	177	85	1	cm	kg			85.748	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	222	720	222	Stem cell, Autologous	1	1	Ixazomib	724	1307	583	2	2	1266	1	180.85714286	1172	3	3	1		2	1	1		Baseline	-9	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1963	1	No		305	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	1	2.174407006	305		64	1	4	305	Year 1	181	77	3	cm	kg			114.036	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		236	1	1			2	2	1		Baseline	-5	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1992	1															1	2	2	Yes	1	1	1	4.5595101764	2206		53	1	24	2206	Year 6	177	74	3	cm	kg			389.844	3	2	combined bortezomib/IMIDs-based	6	1	5	0	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1	113	167	Stem cell, Autologous	1	1							450	1	64.285714286	361	3	3	3	4	2	2	1	1	Baseline	1	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1998	-12	No	292	292	Death	Other		UNCLEAR ETIOLOGY	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	0	1.7937779853	164		63	1	2	164	Month 6	183	233	2	cm	lb			138.788	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		129	5	5			2	2	1		Baseline	-12	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2000	1															1	2	1	Yes	1	1	0	1.5683365472	2202		49	1	24	2202	Year 6	170	78	1	cm	kg			82.212	1	1	combined bortezomib/IMIDs-based	6	1	1	0	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1	93	126	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	287	1177	890	2	2		0		2096	1	1			2	1	1		Baseline	1	49	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2002	-5	No		80	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	1.7366618305	106		71	1	2	106	Month 6	177	73	2	cm	kg			106.08	0	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		27	1	1			2	2	1		Baseline	-18	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2018	-11															1	2	1	Yes	1	1	0	2.942883657	2066		71	1	24	2066	Year 6	171	68	2	cm	kg			109.616	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1		0							0									0		1987	1	1			2	1	1		Baseline	-11	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2081	-4															1	2	2	Yes	1	1	0	1.7753362322	2006		69	1	22	2006	Month 66	150	58	1	cm	kg			65.416	0	1	combined bortezomib/IMIDs/carfilzomib-based	8	5	2	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	100	180	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	373	735	362	1	1	1699	1	242.71428571	1601	3	3	4		2	1	1		Baseline	-4	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2082	-27															1	2	2	Yes	1	1	0	1.5983644126	1981		67	1	22	1978	Month 66	168	61	1	cm	kg			60.996	1	1	combined bortezomib/IMIDs-based	1	1	3	1		0	2	Bortezomib/Lenalidomide/Dexamethasone	437	498	510	Stem cell, Autologous	1	0							926	1	132.28571429	870	3	1	3	1	2	1	1	1	Baseline	-27	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2107	-2	No		1844	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	2.8075936763	1844		63	1	20	1844	Year 5	174	168	1	cm	lb			48.62	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1760	1	1			2	1	1		Baseline	-2	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2144	-38															1	2	1	Yes	1	1	0		1920		71	1	22	1920	Month 66	167	74	1	cm	kg			94.588	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		1864	1	1			2	1	1		Baseline	-38	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2176	-26															2	2	2	Yes	1	1	2		1848		44	1	20	1848	Year 5	161	56	2	cm	kg			96.356	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1809	1	1			2	1	1		Baseline	-26	44	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2180	-20	No		1895	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	1.5240058917	1697		60	1	19	1697	Month 57	154	93	2	cm	kg			46.852	0	2	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1		0							0								757	1	108.14285714	405	3	3			2	1	1	1	Baseline	-20	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2199	0															1	2	2	Yes	1	1	0	2.17359512	1835		77	1	20	1835	Year 5	154	63	1	cm	kg			61.88	0	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1709	1	1			2	1	1		Baseline	0	77	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2207	-17															1	2	1	Yes	1	1	0		1898		57	1	22	1898	Month 66	73	99	1	in	kg			123.76	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	122	173	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	323	801	478	2	2		0		1817	1	1			2	1	1		Baseline	-17	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2240	1	No	1624	1624	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	1.6007925319	1568		67	1	17	1568	Month 51	168	77	3	cm	kg			190.944	1	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	4	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	203	672	735	Stem cell, Autologous	1	1							832	1	118.85714286	577	5	3	1	2	2	1		1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2289	-6															1	2	1	Yes	1	1	0		2020		52	1	22	2020	Month 66	180	102	1	cm	kg			108.732	1	1	combined bortezomib/IMIDs-based	1	1	3	1		0	2	Bortezomib/Cyclophosphamide/Dexamethasone	359	431	443	Stem cell, Autologous	1	0	Ixazomib	550	1033	483	2		351	1	50.142857143	270	3	3	1	3	2	2	1	1	Baseline	-6	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2341	-6	No		86	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1		4.1111755332	86		53	1	1	86	Month 3	171	85	2	cm	kg			104.312	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0			4	4			2		1		Baseline	-6	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2344	-1															2	2	1	Yes	1	1	0		1973		66	1	22	1973	Month 66	193	120	1	cm	kg			105.196	0	1	combined bortezomib/IMIDs-based	6	1	3	0		0	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	573	596	573	Stem cell, Autologous	1	0							279	1	39.857142857	64	3	1	1	1	2	2	1	1	Baseline	-8	66	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2353	-16															1	2	1	Yes	1	1	0	1.899648685	1975		56	1	22	1975	Month 66	72	105	1	in	kg			102.544	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Lenalidomide/Cyclophosphamide/Dexamethasone	289	394	444	Stem cell, Autologous	1	1							1419	1	202.71428571	1342	3	3			2	1	1		Baseline	-32	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2366	-3	No		824	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1		1.7563794683	907		75	1	10	907	Month 30	64	91	1	in	kg			36.244		2	Bortezomib-based	2	2	4	1		0							0								80	1	11.428571429		3	4	1	2	1		1	1	Baseline	-19	75	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2373	-12	No	542	542	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	3.1149553425	529		67	1	6	529	Month 18	66	63	1	in	kg			100.776	0	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	146	175	Stem cell, Autologous	1	1							170	1	24.285714286	92	5	3	2	5	2	2	1	1	Baseline	-12	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2404	1	No	331	331	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1	6.3056330658	245	331	50	1	4	329	Year 1	70	123	3	in	kg			130.832	1	1	Bortezomib-based	2	2	2	1	1	1	1	Cyclophosphamide/Dexamethasone	104	202	104	Stem cell, Autologous	1	1							245	1	35	165	5	1	5		2	2	1	1	Baseline	1	50	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2410	-9	No		746	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	1		85		60	1	1	85	Month 3	175	80	1	cm	kg			73.372	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		18	1	1			2	2	1		Baseline	-9	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2445	-66															1	2	2	Yes	1	1	0	2.8832074886	1774		64	1	20	1774	Year 5	63	259	1	in	lb			107.848		2	combined bortezomib/IMIDs-based	3	1	4	0		0							0								737	1	105.28571429	699	3	1	2	3	2	1	1	1	Baseline	-66	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2457	-40	No	1156	1156	Death	Other		PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	1	2.2065575573	1107	1156	52	1	14	1155	Month 42	190	105	3	cm	kg			99.008	0	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	40	331	369	Stem cell, Autologous	1	1							324	1	46.285714286	246	5	3	1	2	2	2		1	Baseline	-34	52	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2469	-3															1	2	1	Yes	1	1	1	4.0659452938	1817		53	1	20	1817	Year 5	186	228	3	cm	lb			99.008	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Elotuzumab/Melphalan	396	708	397	Stem cell, Autologous	1	1	Lenalidomide	736	1817	1081	2	2		0		1466	1	1			2	1	1		Baseline	-3	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2472	-1															1	2	2	Yes	1	1	1		1815		62	1	20	1815	Year 5	160	73	1	cm	kg			56.576	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		1724	1	1			2	1	1		Baseline	-4	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2498	-15															1	2	1	Yes	1	1	0	1.4601784866	1823		43	1	20	1823	Year 5	170	100	1	cm	kg			84.864	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	111	174	Stem cell, Autologous	1	1	Bortezomib/Dexamethasone	288	288	0	1	1	1358	1	194	1304	3	1	1		2	1	1		Baseline	-7	43	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2538	-10	No		1418	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	2	3.2556303481	1343		68	1	15	1343	Month 45	189	224	2	cm	lb			75.14	2	2	combined bortezomib/IMIDs-based	1	1	3	1		0							0								970	1	138.57142857	889	3	3	1	2	2	1	1	1	Baseline	-10	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2550	-17	No		520	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1		2.2324685791	249		62	1	4	249	Year 1	160	86	3	cm	kg			79.56	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		148	1	1			2	2	1		Baseline	-17	62	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2564	-13															2	2	2	Yes	1	1		4.1700026803	1822		55	1	20	1822	Year 5	163	76	1	cm	kg			63.648	0	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	119	414	120	Stem cell, Autologous	1	1								0		1761	1	1	4	1	2	1	1		Baseline	-9	55	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2577	-18															1	2	1	Yes	1	1	0		1836		51	1	20	1836	Year 5	69	281	2	in	lb			91.936	1	1	combined bortezomib/IMIDs-based	2	1	3	1	1	1	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	780	792	780	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide	793	953	160	1	1	1661	1	237.28571429	1582	3	1	2	4	2	1	1		Baseline	-18	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2614	1															1	2	1	Yes	1	1	0	1.8542363691	1648		58	1	18	1648	Month 54	173	169	1	cm	lb			66.3		2	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Melphalan/Prednisone	181	181	184	Stem cell, Autologous	1	1	Lenalidomide/Prednisone	300	1252	952	2	2		0		1592	1	1	1	1	2	1	1		Baseline	1	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1037	-13	No		116	Other		PT. ENTERED HOSPICE			2	1	7				1	2	2	Yes	1	1	0	1.8841885519	96		81	1	1	96	Month 3	152	102	1	cm	lb	Stage III	3	70.72	1	2	IMIDs-based	4	3	1	0		0							0									0			4	4			2		1		Baseline	-13	81	Female					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1088	-23	No		438	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			341		69	1	4	341	Year 1	157	215	3	cm	lb			132.6		2	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		183	1	1			2	2	1		Baseline	-30	69	Female					Checked			Not Hispanic or Latino	-16	0	1
MMRF_1102	-25	No	46	46	Death	Other		RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1					61	1	0	-25	Baseline	188	81	3	cm	kg			477.36	1	1	IMIDs-based		3	1	0		0							0												5	5			2		1		Baseline	-25	61	Male					Checked			Not Hispanic or Latino	-25	0	1
MMRF_1128	-30	Yes		2807	Other		COMPLETED			1	2	7				1	2	2	Yes	1	1		3.7530087495	2883		48	1	32	2811	Year 8	179	78	2	cm	kg	Stage II	2	70.72	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Thalidomide	118	147	214	Stem cell, Autologous	1	1	Lenalidomide	313	1118	805	2	2		0		2822	1	1			2	1	1		Baseline	-30	48	Female					Checked			Not Hispanic or Latino	-30	0	1
MMRF_1475	-21	No		43	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		2.266597476			70	1	0	-21	Baseline	156	129	2	cm	lb			70.72	1	1	IMIDs-based	11	3	1	0		0							0												4	4			2		1		Baseline	-21	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1735	-17															1	2	1	Yes	1	1	0	1.7055891416	2207		64	1	24	2202	Year 6	190	110	2	cm	kg			88.4	0	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	106	Stem cell, Autologous	1	1	Lenalidomide	176	507	331	1	1	507	1	72.428571429	332	3	3	3	1	2	2	1	1	Baseline	1	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1061	-6	No		2153	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			1997		70	1	22	1997	Month 66	62	153	2	in	lb			220.116		2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	120	Stem cell, Autologous	1	1							1382	1	197.42857143	1284	3	3	1		2	1	1		Baseline	1	70	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1068	-11	No	564	564	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	0	2.5100647538	552	564	58	1	6	552	Month 18	66	212	1	in	lb			67.184	0	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	78	127	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	239	407	168	1	1	521	1	74.428571429		5	4	5		2		1	1	Baseline	-6	58	Female			Checked					Not Hispanic or Latino	-2	0	1
MMRF_1065	-39	No	2858	2858	Death					2	1	1				1	2	2	Yes	1	1			2717	2075	67	1	32	2857	Year 8	66	119	1	in	lb			55.692		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	126	214	127	Stem cell, Autologous	1	1								0		2809	5	5			2	1			Baseline	-31	67	Female					Checked			Not Hispanic or Latino	-31	0	1
MMRF_1368	-13	Yes		2861	Other		REACHED 8 YEAR MARK, END OF STUDY			1	2	7				1	2	1	Yes	1	1			2861		67	1	32	2861	Year 8	71	186	1	in	lb			94.588	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	282	194	Stem cell, Autologous	1	1	Lenalidomide	299	2861	2562	2	2		0		2770	1	1			2	1	1		Baseline	11	67	Male					Checked			Not Hispanic or Latino	11	0	1
MMRF_1180	-6	No	914	914	Death	Other		RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	2	Yes	1	1	1	1.5237899024	798	914	63	1	11	913	Month 33	62	118	3	in	lb			211.276	0	1	Bortezomib-based	2	2	1	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	195	539	196	Stem cell, Autologous	1	1								0		824	5	5			2	1			Baseline	-6	63	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1188	-27	No	1777	1777	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	2	2.9750906122	1724	1777	76	1	20	1777	Year 5	69	172	3	in	lb			123.76	2	2	Bortezomib-based		2	2	1		0							0								1240	1	177.14285714	1078	5	3	5		2	1			Baseline	-27	76	Male			Checked					Not Hispanic or Latino	-26	0	1
MMRF_1213	-13	No	1694	1694	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1			1671		72	1	19	1671	Month 57	67	255	3	in	lb			109.616	1	1	combined bortezomib/IMIDs-based	11	1	3	0		0							0								441	1	63		5	2	2	5	2			1	Baseline	-13	72	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1268	-13	No	111	111	Death	Other		AMYLOIDOSIS OF THE LUNGS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1			86	111	89	1	2	110	Month 6	71	195	3	in	lb			112.268	1	2	Bortezomib-based		2	1	1		0							0									0		23	5	5			2	2	1		Baseline	-13	89	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1331	-3	No		324	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	1	1.4537248076	324		68	1	4	324	Year 1	75	190	3	in	lb			242.216		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0								284	1	40.571428571		2	2			2		1	1	Baseline	-3	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1487	-11															2	2	2	Yes	1	1			2475		65	1	26	2476	Month 78	66	166	2	in	lb			197.132	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	186	970	186	Stem cell, Autologous	1	1								0		1570	1	1			2	1	1		Baseline	51	65	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1541	-21	No	1788	1788	Death	Other		SEPSIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1	1.7720888782	1752		57	1	20	1738	Year 5	69	235	3	in	lb			129.064	2	2	combined IMIDs/carfilzomib-based	8	4	5	1		0							0								323	1	46.142857143	183	5	3	1	2	2	2		1	Baseline	-44	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1603	1															1	2	1	Yes	1	1	1	2.0247859185	2363		70	1	24	2167	Year 6	66	134	3	in	lb			230.724	2	2	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		2105	1	1	1		2	1	1		Baseline	1	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1664	-6	No	2169	2169	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	2	4.7057172803	2019		63	1	22	2019	Month 66	69	212	2	in	lb			165.308	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	176	940	177	Stem cell, Autologous	1	1	Lenalidomide	941	2019	1078	2	2	1529	1	218.42857143	1429	5	5			2	1			Baseline	15	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1719	1	No		1144	Other		PATIENT IS RECEIVING CARE AT ANOTHER FACILITY			2	1	7				1	2	1	Yes	1	1	1	4.0659075447	1066		65	1	12	1066	Year 3	76	170	3	in	lb			226.304		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		988	1	1			2	1	1		Baseline	1	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1815	-7	No	373	373	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		2	2	2	Yes	1	1	2	4.0123238144	363		81	1	4	363	Year 1	59	127	3	in	lb			90.168	2	2	IMIDs-based	4	3	1	0		0							0												5	5			2		1		Baseline	-7	81	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1880	-21	No		1036	Other		PATIENT RELOCATED TO ANOTHER STATE			2	1	7				1	2	2	Yes	1	1	0	1.7151400059	922		66	1	11	922	Month 33	65	186	2	in	lb			95.472		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	142	190	Stem cell, Autologous	1	1								0		825	1	1			2	1	1		Baseline	1	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1949	-7															1	2	1	Yes	1	1		4.7140105239	2206		63	1	24	2206	Year 6	67	174	2	in	lb			87.516	1	1	combined IMIDs/carfilzomib-based	8	4	3	1	0	1	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	184	184	184	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	185	2206	2021	2	2	707	1	101	624	3	3	3	4	2	1	1	1	Baseline	-5	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2216	1	No	406	385	Other		PATIENT ADMITTED TO HOSPICE CARE DUE TO PROGRESSION			2	1	7				1	2	1	Yes	1	1	1	2.0846456072	365	406	84	1	5	385	Month 15	64	138	3	in	lb			125.528		2	IMIDs-based	4	3	1	0		0							0								265	1	37.857142857		5	5			2		1	1	Baseline	1	84	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2429	-21															1	2	1	Yes	1	1	2	1.7175394812	1779		69	1	20	1779	Year 5	71	207	2	in	lb			76.024	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	1779	147	Stem cell, Autologous	1	1								0		1534	1	1			2	1	1		Baseline	-6	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2539	-14															1	2	2	Yes	1	1	0	1.7833482404	1837		51	1	20	1837	Year 5	64	174	2	in	lb			57.46	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	1837	117	Stem cell, Autologous	1	1								0		1754	1	1			2	1	1		Baseline	-14	51	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2562	-10	No	1209	1209	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.1872352648	1156		66	1	13	1156	Month 39	64	190	2	in	lb			69.836	2	2	combined bortezomib/IMIDs-based	1	1	4	1		0							0								199	1	28.428571429	120	5	1	3	3	2	2		1	Baseline	-10	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1020	-14	No	2150	2150	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1826	2150	60	1	26	2150	Month 78	175	88	1	cm	kg			88.4	0	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	91	135	Stem cell, Allogenic	1	1							714	1	102	623	5	3	3	2	2	1		1	Baseline	-14	60	Male					Checked			Not Hispanic or Latino	-14	0	1
MMRF_1045	-30	No		641	Inter-current illness that interferes with study assessments					2	1	4				2	2	2	Yes	1	1			609		81	1	7	609	Month 21	152	64		cm	kg			167.96	0	2	IMIDs-based	4	3	1	0		0							0								609	1	87	536	3	3			2	1	1	1	Baseline	-30	81	Female			Checked					Not Hispanic or Latino	-20	0	1
MMRF_1044	-13	Yes		2912						1	2					1	2	2	Yes	1	1			2912		81	1	32	2912	Year 8	150	58	1	cm	kg			88.4	1	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2835	1	1			2	1	1		Baseline	-13	81	Female					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1046	0	Yes		2940						1	2					1	2	2	Yes	1	1			2940		58	1	32	2940	Year 8	173	70	2	cm	kg			70.72	2	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	137	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	218	306	88	1	1		0		2849	1	1			2	1	1		Baseline	4	58	Female					Checked			Not Hispanic or Latino	4	0	1
MMRF_1059	-1	Yes		2912						1	2					4	2	1	Yes	1	1			2912		46	1	32	2912	Year 8	152	60	2	cm	kg			44.2		2	combined bortezomib/IMIDs-based	3	1	3	0	0	1	1	Lenalidomide	177	933	207	Stem cell, Autologous	1	1	Lenalidomide/Melphalan	934	935	1	1	1	1532	1	218.85714286	1451	3	3	4	1	2	1	1		Baseline	0	46	Male		Checked						Not Hispanic or Latino	-2	0	1
MMRF_1074	-6	No	465	465	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			386	465	69	1	5	417	Month 15	155	67	2	cm	kg			79.56	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	98	129	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	204	319	115	1	1	303	1	43.285714286	219	5	3	5		2	2	1	1	Baseline	-6	69	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1150	-21	No		601	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			406		59	1	5	406	Month 15	170	93	3	cm	kg			141.44	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		184	1	1			2	2	1		Baseline	-21	59	Male					Checked			Not Hispanic or Latino	-21	0	1
MMRF_1181	-2	No	39	39	Death	Other		ACUTE ON CHRONIC SYSTOLIC HEART FAILURE	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1				39	63	1	1	39	Month 3	180	91	3	cm	kg			132.6		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	-2	63	Male					Checked			Not Hispanic or Latino	-2	0	1
MMRF_1242	-4	No	610	610	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1		4.6619531754	554		61	1	6	554	Month 18	63	103	2	in	lb			35.36	1	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	141	190	235	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	386	540	154	1	1	554	1	79.142857143	470	5	5			2	1	1	1	Baseline	8	61	Female			Checked					Not Hispanic or Latino	-4	0	1
MMRF_1258	-22	No	268	268	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1			146		83	1	2	146	Month 6	173	82	3	cm	kg			167.96	2	2	IMIDs-based	4	3	1	0		0							0									0		214	5	5			2	2	1		Baseline	-22	83	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1281	-4	No	153	153	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1		2.1797594798	76		37	1	1	76	Month 3	161	80	3	cm	kg			185.64	2	2	Bortezomib-based	2	2	1	1		0							0									0		81	5	5			2	2	1		Baseline	-4	37	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1318	-10															1	2	1	Yes	1	1	2	2.0592585576	2542		85	1	28	2542	Year 7	165	60	3	cm	kg			79.56	1	2	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		2458	1	1			2	1	1		Baseline	-6	85	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1355	-23															2	2	1	Yes	1	1		1.5145814916	2602		74	1	28	2602	Year 7	185	79	1	cm	kg			88.4	1	1	IMIDs-based		3	1	1		0							0									0		2518	1	1			2	1	1		Baseline	-13	74	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1358	-32	No		548	Patient no longer consents to participate in the study					2	1	3				2	2	2	Yes	1	1	0	1.2212870448	523		74	1	6	523	Month 18	163	94	2	cm	lb			88.4	2	2	combined bortezomib/IMIDs-based	4	1	1	0		0							0								394	1	56.285714286	246	3	3			2	2	1	1	Baseline	-31	74	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1361	0	No	207	207	Death	Other		SEPTIC SHOCK	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	2	1.7265819187	194	207	67	1	3	207	Month 9	170	74	3	cm	kg			424.32		2	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1		0							0									0		50	5	5			2	2	1		Baseline	0	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1392	1	No	769	769	Death	Other		CARDIOPULMONARY ARREST	Cardiovascular	2	1	1	2	1	More Than One Race	6	1	1	Yes	1	1	0	1.8530809161	714	769	41	1	9	766	Month 27	191	105	1	cm	kg			167.96	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	463	507	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	595	769	174	1	1		0		686	5	5			2	1			Baseline	-5	41	Male						Checked	More Than One Race	Hispanic or Latino		0	1
MMRF_1393	-7															1	2	2	Yes	1	1	0	1.565811171	2575		58	1	28	2575	Year 7	166	82	2	cm	kg			44.2	1	2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	133	1209	134	Stem cell, Autologous	1	1	Lenalidomide	1210	2575	1365	2	2	2148	1	306.85714286	2064	3	3			2	1	1		Baseline	1	58	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1420	-4	No		1401	Other		PATIENT IS REHAB FACILITATED			2	1	7				2	2	1	Yes	1	1			1241		59	1	13	1135	Month 39	193	87	3	cm	kg			539.24	0	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1		0							0									0		1157	1	1			2	1	1		Baseline	-4	59	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1520	-17															2	2	2	Yes	1	1		2.2469222568	2324		62	1	26	2324	Month 78	67	201	1	in	lb			79.56	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	106	150	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	225	607	382	2	2		0		2240	1	1			2	1	1		Baseline	-18	62	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1540	-52	No	527	527	Death	Other		FLU COMPLICATIONS, COPD EXACERBATION	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	2	Yes	1	1	0	2.8104187012	420	527	58	1	6	511	Month 18	157	42	2	cm	kg			53.04		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0								57	1	8.1428571429	1	5	5			1	2	1	1	Baseline	-41	58	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1576	-1	No	41	41	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	1			41	68	1	1	20	Month 3	149	58	3	cm	kg			176.8	2	2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	-1	68	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1621	-11															1	1	1	Yes	1	1	1	1.5750175605	2304		60	1	26	2304	Month 78	170	112	1	cm	kg			79.56	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	139	2304	140	Stem cell, Autologous	1	1								0		2276	1	1			2	1	1		Baseline	-60	60	Male					Checked			Hispanic or Latino		0	1
MMRF_1630	-4															1	2	1	Yes	1	1	2	1.9958845948	2373		59	1	26	2373	Month 78	185	83	2	cm	kg			70.72	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	173	867	174	Stem cell, Autologous	1	1	Lenalidomide	868	2373	1505	2	2		0		2290	1	1			2	1	1		Baseline	0	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1652	-12															2	2	2	Yes	1	1	2	1.9968810003	2379		74	1	26	2379	Month 78	163	80	2	cm	kg			88.4	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	100	142	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	246	2379	2133	2	2		0		2316	1	1			2	1	1		Baseline	-20	74	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1690	-17															1	2	2	Yes	1	1	0	2.291417179	2213		57	1	24	2213	Year 6	160	70	1	cm	kg			44.2	1	2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	107	141	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	226	653	427	2	2	2213	1	316.14285714	2128	3	3			2	1	1		Baseline	-17	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1749	0															1	1	1	Yes	1	1			2205		52	1	24	2205	Year 6	67	176	2	in	lb			114.92	1	1	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	106	147	Stem cell, Autologous	1	1	Carfilzomib/Dexamethasone	231	258	27	1	1		0		2121	1	1			2	1	1		Baseline	1	52	Male					Checked			Hispanic or Latino		0	1
MMRF_1773	-18															2	2	1	Yes	1	1	0	2.083388742	2164		44	1	24	2164	Year 6	71	101	1	in	kg			132.6	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	118	216	119	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	217	218	1	1	1		0		2080	1	1			2	1	1		Baseline	1	44	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1797	-20	No	677	677	Death	Other		POLYMORPHIC VENTRICULAR TACHYCARDIA	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	0	2.2147799406	617	677	64	1	8	677	Year 2	66	222	1	in	lb			79.56	1	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	227	567	228	Stem cell, Autologous	1	1								0		621	5	5			2	1	1		Baseline	-20	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1822	-6	No	1978	1978	Death					2	1	1				2	2	1	Yes	1	1	2	3.4626435127	1814	1373	43	1	22	1978	Month 66	71	236	3	in	lb			132.6	1	1	combined bortezomib/IMIDs/carfilzomib-based	8	5	5	1		0							0								710	1	101.42857143	631	5	3	3	2	2	1		1	Baseline	-6	43	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2005	-46															1	2	2	Yes	1	1	0	2.5877315468	2130		53	1	24	2130	Year 6	166	103	1	cm	kg			61.88	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib	113	113	151	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	239	2130	1891	2	2		0		2074	1	1			2	1	1		Baseline	-46	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2021	-21															2	2	1	Yes	1	1			2156		66	1	24	2156	Year 6	180	103	1	cm	kg			123.76	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	105	146	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	224	687	463	2	2		0		2073	1	1			2	1	1		Baseline	-21	66	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2056	-14															1	2	2	Yes	1	1	0	2.2752515851	2017		50	1	22	2017	Month 66	168	62	1	cm	kg			61.88	1	1	combined IMIDs/carfilzomib-based	8	4	2	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	143	1247	144	Stem cell, Autologous	1	1	Lenalidomide	1248	1687	439	2	2		0		1933	1	1	1		2	1	1		Baseline	-4	50	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2091	-26															2	2	2	Yes	1	1	2	2.1480880049	2002		49	1	22	2002	Month 66	168	109	2	cm	kg			97.24	1	1	combined IMIDs/carfilzomib-based	8	4	4	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	143	1080	144	Stem cell, Autologous	1	1							1149	1	164.14285714	1065	3	1	3	4	2	1	1		Baseline	-20	49	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2098	-22	No	352	352	Death	Other		CARDIAC ARREST	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	1	1.4804805335	237	352	79	1	4	352	Year 1	168	132	3	cm	kg			167.96	0	2	IMIDs-based	4	3	1	0		0							0									0		271	5	5			2	2	1		Baseline	-22	79	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2122	-6															1	2	2	Yes	1	1	2	1.4904926846	2015		67	1	22	2015	Month 66	166	178	2	cm	kg			61.88	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								349	1	49.857142857	246	3	3	1		2	2	1	1	Baseline	-6	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2238	3															1	2	1	Yes	1	1	2	1.4639812431	1967		52	1	22	1967	Month 66	198	100	3	cm	kg			194.48	0	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	27	118	143	Stem cell, Autologous	1	1	Lenalidomide	230	1722	1492	2	2	1703	1	243.28571429	1593	3	3	4		2	1	1		Baseline	6	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2570	-17															1	2	2	Yes	1	1	0	1.562512602	1836		61	1	20	1836	Year 5	161	52	1	cm	kg			53.04	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	107	148	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	225	625	400	2	2		0		1752	1	1			2	1	1		Baseline	1	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1085	-13	No	1470	1470	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1388		60	1	16	1388	Year 4	173	98	2	cm	kg			132.6	1	1	combined bortezomib/IMIDs-based	1	1	4	1		0	2	Carfilzomib/Pomalidomide/Dexamethasone	449	841	871	Stem cell, Autologous	1	0							435	1	62.142857143	330	5	3	3	2	2	2		1	Baseline	-13	60	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1233	1															2	2	1	Yes	1	1			2738		58	1	30	2723	Month 90	202	120	3	cm	kg			503.88	1	1	combined bortezomib/IMIDs-based	2	1	3	1		0							0								540	1	77.142857143	449	3	3	3	4	2	1	1	1	Baseline	1	58	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1327	-4	No		154	Noncompliance with study procedures					2	1	2				1	2	2	Yes	1	1	1				71	1	0	-4	Baseline	163	68	3	cm	kg			106.08	1	1	Bortezomib-based	2	2	1	1		0							0												4	4			2		1		Baseline	-4	71	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1700	-5	No	569	569	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1	2.4011056168	530	569	75	1	7	560	Month 21	173	90	3	cm	kg			156.468	1	1	combined bortezomib/IMIDs-based	1	1	3	1		0							0								279	1	39.857142857	191	5	3	2	5	2	2	1	1	Baseline	1	75	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1739	1															2	2	2	Yes	1	1	1	2.099178697	2190		45	1	24	2190	Year 6	170	44	3	cm	kg			88.4	1	1	combined bortezomib/IMIDs-based	2	1	3	1	1	1	1	Lenalidomide	254	733	289	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	734	1100	366	2	2	1086	1	155.14285714	806	3	3	2	1	2	1	1	1	Baseline	1	45	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1774	-8	No	2062	2062	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1		1974	1313	65	1	22	1974	Month 66	190	108	1	cm	kg			75.14	1	1	combined bortezomib/IMIDs-based	1	1	5	1		0	2	Bortezomib/Dexamethasone	1014	1435	1015	Stem cell, Autologous	1	0							979	1	139.85714286	911	5	3	3	1	2	1		1	Baseline	-8	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1814	-12	No	1025	1025	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1	3.8775617308	986	1025	75	1	12	1025	Year 3	180	68	3	cm	kg			150.28	1	1	Bortezomib-based	2	2	1	1		0							0								776	1	110.85714286	692	5	5			2	1		1	Baseline	-5	75	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1823	-7	No	1353	1353	Death	Disease progression				2	1	1	1		Not Specified	6	2	1	Yes	1	1	2	1.7265692711	1252	1353	51	1	15	1353	Month 45	172	81	2	cm	kg			62.764	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	141	198	Stem cell, Autologous	1	1	Lenalidomide	293	743	450	2	2	715	1	102.14285714	631	5	1	2	5	2	1		1	Baseline	1	51	Male						Checked	Not Specified	Not Hispanic or Latino		0	1
MMRF_1832	-8	No	1190	1190	Death	Other		CARDIAC EVENT	Cardiovascular	2	1	1	2	1		2	2	1	Yes	1	1	1	2.035928401	1160	1190	71	1	14	1190	Month 42	186	137	3	cm	kg			356.252	1	1	Bortezomib-based	3	2	1	0		0							0									0		1102	5	5			2	1			Baseline	-8	71	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1841	-12															1	2	2	Yes	1	1	2		2170		61	1	24	2170	Year 6	160	81	2	cm	kg			56.576	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	162	179	Stem cell, Autologous	1	1	Lenalidomide	288	438	150	1	1		0		2086	1	1			2	1	1		Baseline	-12	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2080	-10															1	2	2	Yes	1	1	1	1.5986351376	1981		48	1	22	1981	Month 66	159	61	3	cm	kg			72.488	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	212	108	Stem cell, Autologous	1	1	Lenalidomide	213	1981	1768	2	2		0		1912	1	1			2	1	1		Baseline	-10	48	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2104	-18															1	2	1	Yes	1	1			1988		62	1	22	1985	Month 66	184	91	1	cm	kg			83.096	0	1	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								1976	1	282.28571429	1891	3	3			2	1	1		Baseline	-18	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2190	-4															1	2	2	Yes	1	1	0		1886		54	1	22	1886	Month 66	166	80	1	cm	kg			56.576	2	2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	1295	108	Stem cell, Autologous	1	1							1262	1	180.28571429	1186	3	3	1		2	1	1		Baseline	-6	54	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2250	-11															1	2	2	Yes	1	1	2	3.0353645678	1975		71	1	22	1975	Month 66	148	59	2	cm	kg			85.748	0	1	combined bortezomib/IMIDs-based	1	1	3	1		0	3	Carfilzomib/Dexamethasone	1291	1362	1439	Stem cell, Autologous	1	0	Bortezomib	1545	1765	220	1		1057	1	151	994	3	3	4	1	2	1	1	1	Baseline	-31	71	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2333	-13															1	2	2	Yes	1	1			1974		80	1	22	1839	Month 66	164	63		cm	kg			81.328	0	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1855	1	1			2	1	1		Baseline	-14	80	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2511	-57															1	2	1	Yes	1	1			1810		63	1	20	1789	Year 5	175	77		cm	kg			141.44	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	308	393	Stem cell, Autologous	1	1	Lenalidomide	484	1566	1082	2	2	1579	1	225.57142857	1314	3	3	1		2	1	1		Baseline	-9	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1056	-6	No	2387	2387	Death	Other		BREAST CANCER	Other	2	1	1	2	10		1	2	2	Yes	1	1			2321		68	1	26	2321	Month 78	165	77	3	cm	kg			74.256		2	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	69	108	Stem cell, Autologous	1	1	Lenalidomide	215	445	230	1	1	635	1	90.714285714	578	5	1	3	2	2	1		1	Baseline	-5	68	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1048	1	Yes		2917						1	2					1	2	2	Yes	1	1	1	2.3288471603	2917		53	1	32	2917	Year 8	161	67	1	cm	kg			60.112		2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	81	81	84	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	192	953	761	2	2	1770	1	252.85714286	1742	3	3	1		2	1	1		Baseline	1	53	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1057	1	No	2470	2470	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1			2376		50	1	26	2376	Month 78	157	105	2	cm	kg			121.992		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	103	134	Stem cell, Allogenic	1	1	Lenalidomide	233	954	721	2	2		0		2403	5	5			2	1			Baseline	1	50	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1060	1	Yes		2872						1	2					1	2	2	Yes	1	1			2872		51	1	32	2872	Year 8	161	63	3	cm	kg			244.868		2	combined bortezomib/IMIDs-based		1	2	0	1	1	1	Bortezomib/Cyclophosphamide/Vincristine/Dexamethasone	54	138	164	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	285	716	431	2	2	1990	1	284.28571429	1937	3	1	2		2	1	1		Baseline	1	51	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1070	-2	No		906	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1			796		56	1	9	796	Month 27	172	92	2	cm	kg			93.704		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	93	95	Stem cell, Autologous	1	1	Bortezomib	208	796	588	2	2		0		729	1	1			2	1	1		Baseline	1	56	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1086	-9	Yes		2885						1	2					1	2	2	Yes	1	1	1		2885		66	1	32	2885	Year 8	157	59	1	cm	kg			50.388		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	142	176	Stem cell, Autologous	1	1	Lenalidomide	257	358	101	1	1	1879	1	268.42857143	1773	3	3	3	1	2	1	1		Baseline	-9	66	Female					Checked			Not Hispanic or Latino	-9	0	1
MMRF_1097	-13	No		1813	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			1759		73	1	20	1759	Year 5	157	71	3	cm	kg			195.364		2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								1187	1	169.57142857	1107	3	3	1		2	1	1		Baseline	-13	73	Female					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1110	-9	No	2365	2365	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			2304		69	1	26	2304	Month 78	157	71	3	cm	kg			114.036		2	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	71	96	Stem cell, Autologous	1	1	Lenalidomide	204	876	672	2	2	1219	1	174.14285714	1169	5	3	3	2	2	1			Baseline	-41	69	Male					Checked			Not Hispanic or Latino	-9	0	1
MMRF_1119	-3	Yes		2944						1	2					1	2	1	Yes	1	1			2944		65	1	32	2944	Year 8	174	87	1	cm	kg			87.516		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	70	109	Stem cell, Autologous	1	1	Lenalidomide	207	2944	2737	2	2		0		2902	1	1			2	1	1		Baseline	-3	65	Male					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1138	-2	No		819	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1			819		66	1	9	811	Month 27	179	99	1	cm	kg			95.472		2	combined bortezomib/IMIDs-based		1	1	1	1	1	1	Bortezomib/Thalidomide/Dexamethasone	1	60	117	Stem cell, Autologous	1	1	Lenalidomide	258	811	553	2	2		0		211	1	1			2	2	1		Baseline	-2	66	Male			Checked					Not Hispanic or Latino	-2	0	1
MMRF_1141	1	No	175	175	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			91	175	67	1	2	175	Month 6	173	75	1	cm	kg			60.996		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		85	5	5			2	2	1		Baseline	1	67	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1142	-20	No		799	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1			799		66	1	9	799	Month 27	173	89	3	cm	kg			97.24		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Melphalan/Dexamethasone	103	105	106	Stem cell, Autologous	1	1	Lenalidomide	216	948	732	2	2		0		730	1	1			2	1	1		Baseline	-20	66	Male					Checked			Not Hispanic or Latino	-20	0	1
MMRF_1143	-13	Yes		2908						1	2					1	2	1	Yes	1	1			2908		71	1	32	2908	Year 8	168	76	2	cm	kg			79.56		2	IMIDs-based	4	3	4	0		0	2	Bortezomib/Lenalidomide/Dexamethasone	997	1090	1100	Stem cell, Autologous	1	0							656	1	93.714285714	568	3	3	1	3	2	1	1	1	Baseline	-13	71	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1155	-11	Yes		2895						1	2					2	2	1	Yes	1	1			2895		63	1	32	2895	Year 8	171	89	2	cm	kg			136.136	1	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	596	105	Stem cell, Autologous	1	1							718	1	102.57142857	635	3	3	3	2	2	1	1	1	Baseline	-11	63	Male			Checked					Not Hispanic or Latino	-11	0	1
MMRF_1160	1	No	69	69	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1				69	65	1	1	69	Month 3	172	81	3	cm	kg			266.084		2	Bortezomib-based	10	2	1	0		0							0												5	5			2		1		Baseline	1	65	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1173	1															1	2	1	Yes	1	1			2692		69	1	30	2692	Month 90	185	94	2	cm	kg			68.952		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	126	133	Stem cell, Autologous	1	1	Lenalidomide	248	2692	2444	2	2		0		2507	1	1			2	1	1		Baseline	1	69	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1195	-3	No		707	Patient no longer consents to participate in the study					2	1	3				2	2	2	Yes	1	1			676		60	1	7	676	Month 21	174	92	1	cm	kg			97.24		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	109	676	109	Stem cell, Autologous	1	1								0		589	1	1			2	1	1		Baseline	-3	60	Female			Checked					Not Hispanic or Latino	-3	0	1
MMRF_1219	1															1	2	2	Yes	1	1			2721		70	1	30	2721	Month 90	162	55	3	cm	kg			114.92		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	95	127	Stem cell, Autologous	1	1							278	1	39.714285714	211	3	1	3	1	2	2	1	1	Baseline	1	70	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1225	-14															1	2	1	Yes	1	1			2703		57	1	30	2703	Month 90	171	92	2	cm	kg			84.864		2	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	344	158	Stem cell, Autologous	1	1	Lenalidomide	345	394	49	1	1	1373	1	196.14285714	1300	3	1	2	2	2	1	1		Baseline	-14	57	Male					Checked			Not Hispanic or Latino	-14	0	1
MMRF_1226	1	No		1830	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1			1798		46	1	20	1798	Year 5	165	61	2	cm	kg			56.576		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	68	99	Stem cell, Autologous	1	1	Bortezomib	218	735	517	2	2	1377	1	196.71428571	1300	3	3			2	1	1		Baseline	1	46	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1234	1	No		707	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			410		48	1	4	410	Year 1	73	291	1	in	lb			83.98		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	83	203	83	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	204	206	2	1	1		0		312	1	1			2	2	1		Baseline	1	48	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1269	-16	No	1590	1590	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.6891706591	1566		52	1	18	1566	Month 54	182	109	1	cm	kg			114.92		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	103	138	Stem cell, Autologous	1	1	Lenalidomide	236	1462	1226	2	2	1462	1	208.85714286	1420	5	3	2	5	2	1			Baseline	-16	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1270	1	No	45	45	Death	Other		HEART ATTACK, CARDIOVASCULAR SHOCK	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	0	3.2139697916		45	65	1	1	45	Month 3	156	81	2	cm	kg			68.952		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	1	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1289	-6	No		477	Other		PATIETTNT WENT ON HOSPICE			2	1	7				1	2	1	Yes	1	1		5.7812970155	487		53	1	6	487	Month 18	180	73	3	cm	kg			105.196		2	combined bortezomib/IMIDs/carfilzomib-based	1	5	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	49	91	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	219	295	76	1	1	393	1	56.142857143	348	3	1	2	4	2	2	1	1	Baseline	-6	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1356	1	No	1704	1704	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	2.6953360978	1690		70	1	19	1690	Month 57	171	96	1	cm	kg			79.56		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Lenalidomide	261	464	552	Stem cell, Autologous	1	1							464	1	66.285714286		5	2	3	5	2			1	Baseline	-27	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1373	1	No		424	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		3.3627300569	424		62	1	4	424	Year 1	157	81	2	cm	kg			56.576		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	71	127	Stem cell, Autologous	1	1	Lenalidomide	227	424	197	1	1		0		367	1	1			2	1	1		Baseline	1	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1390	-2	No	238	238	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			78		75	1	1	78	Month 3	171	82	2	cm	kg			97.24		2	Bortezomib-based	3	2	1	0		0							0									0		161	5	5			2	2	1		Baseline	-2	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1441	-14	No		479	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1			203		67	1	2	203	Month 6	59	146	2	in	lb			70.72		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		119	1	1			2	2	1		Baseline	-14	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1445	-2	No		485	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	1	2.4010335284	184		77	1	2	184	Month 6	60	136	3	in	lb			100.776		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		92	1	1			2	2	1		Baseline	-2	77	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1496	-1	No	494	494	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		8.1018881487	461		39	1	5	461	Month 15	66	90	3	in	kg			127.296		2	combined bortezomib/IMIDs-based	3	1	2	0	1	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	121	121	124	Stem cell, Autologous	1	1	Lenalidomide	226	288	62	1	1	340	1	48.571428571	252	5	3	5		2	2	1	1	Baseline	-1	39	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1511	-10															1	2	1	Yes	1	1	0	1.382797537	2367		77	1	26	2367	Month 78	165	73	2	cm	kg			82.212		2	combined bortezomib/IMIDs/carfilzomib-based	1	5	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	63	78	Stem cell, Autologous	1	1	Bortezomib	192	776	584	2	2	1215	1	173.57142857	1106	3	1	2	3	2	1	1		Baseline	-10	77	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1584	7	No		49	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1					44	1	0	7	Baseline	168	65	2	cm	kg			69.836		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												4	4			2		1		Baseline	7	43	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1624	-8	No	2070	2070	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.5216785645	2044		70	1	22	2044	Month 66	181	98	2	cm	kg			87.516		2	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	142	184	Stem cell, Autologous	1	1	Lenalidomide	292	1440	1148	2	2	1440	1	205.71428571	1379	5	3	3	1	2	1			Baseline	-8	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1667	-22															1	2	2	Yes	1	1	0		2333		57	1	26	2333	Month 78	164	65	1	cm	kg			74.256	2	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	107	149	Stem cell, Autologous	1	1	Lenalidomide	259	536	277	1	1		0		2266	1	1			2	1	1		Baseline	-28	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1668	1	No	308	308	Death	Other		INTRACRANIAL HEMORRHAGE	Hematologic	2	1	1	2	4		1	2	1	Yes	1	1	1	9.1219597988	273		63	1	3	273	Month 9	174	100	1	cm	kg			302.328		2	Bortezomib-based	2	2	3	1		0	3	Carfilzomib/Pomalidomide/Dexamethasone	209	251	251	Stem cell, Autologous	1	0							142	1	20.285714286	66	5	1	2	5	2	2	1	1	Baseline	1	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1760	-6	No		2075	Other		HOSPICE			2	1	7				2	2	1	Yes	1	1	1		2031		78	1	22	2031	Month 66	178	68	1	cm	kg			75.14	1	2	IMIDs-based	4	3	4	0		0							0								197	1	28.142857143		3	2	3	2	2		1	1	Baseline	-6	78	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1783	-32	No	718	718	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.3858536976	674		57	1	8	674	Year 2	196	153	2	cm	kg			87.516	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0	2	Carfilzomib/Cyclophosphamide/Dexamethasone	380	481	495	Stem cell, Autologous	1	0	Pomalidomide	632	718	86	1		380	1	54.285714286	316	5	1	5		2	2		1	Baseline	-32	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1784	-40															1	2	1	Yes	1	1			2151		60	1	24	2151	Year 6	166	100		cm	kg			88.4		2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	77	123	Stem cell, Autologous	1	1	Lenalidomide	204	1688	1484	2	2	1688	1	241.14285714	1618	3	3	3	4	2	1	1		Baseline	-40	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1839	-13	No		1815	Other		PATIENT DID NOT RECONSENT TO FOLLOW-UP BEYOND 5 YEARS			2	1	7				1	2	2	Yes	1	1	2	4.2556754666	1815		66	1	22	1957	Month 66	165	90	3	cm	kg			131.716		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	102	116	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	240	1123	883	2	2		0		1908	1	1			2	1	1		Baseline	-13	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1851	5	No	31	31	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	8.8737073726		31	63	1	1	12	Month 3	167	50	3	cm	kg			52.156		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	5	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1876	0	No	600	600	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	3.4671677781	505		70	1	6	505	Month 18	153	58	3	cm	kg			68.068	1	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	85	149	Stem cell, Autologous	1	1	Lenalidomide	239	490	251	1	1	445	1	63.571428571	389	5	3	5		2	1	1	1	Baseline	0	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1889	-33	No	836	836	Death	Other		SEPTIC SHOCK DUE TO HEALTHCARE ASSOCIATED PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	2	Yes	1	1	1	3.4476754878	836		62	1	10	836	Month 30	155	96	3	cm	kg			138.788		2	combined IMIDs/carfilzomib-based	8	4	4	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	106	142	Stem cell, Autologous	1	1	Lenalidomide	266	421	155	1	1	407	1	58.142857143	344	5	3	2	3	2	2		1	Baseline	-26	62	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1891	-42															1	2	1	Yes	1	1	0	1.7271191109	2143		65	1	24	2143	Year 6	182	110	2	cm	kg			75.14	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	103	106	Stem cell, Autologous	1	1	Lenalidomide	204	599	395	2	2	634	1	90.571428571	592	3	3	1		2	1	1	1	Baseline	-42	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1893	-6	No		1844	Other		PATIENT DID NOT RECONSENT FOR FU BEYOND 5 YEARS			2	1	7				1	2	1	Yes	1	1	0	2.8581447656	1844		38	1	20	1844	Year 5	170	89	1	cm	kg			78.676	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	73	120	Stem cell, Autologous	1	1	Lenalidomide	232	802	570	2	2		0		1788	1	1			2	1	1		Baseline	-6	38	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1900	-12	No	1282	1282	Death	Other		HEART FAILURE	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	1	2.5925941004	1188		77	1	14	1188	Month 42	185	125	3	cm	kg			122.876	1	2	combined bortezomib/IMIDs-based	1	1	3	1		0							0								407	1	58.142857143	120	5	1	3	5	2	2		1	Baseline	-43	77	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1911	-12															1	2	1	Yes	1	1	0	2.8005748289	2169		53	1	24	2103	Year 6	169	97	1	cm	kg			92.82	0	1	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	317	119	Stem cell, Autologous	1	1	Lenalidomide	360	2103	1743	2	2		0		2100	1	1			2	1	1		Baseline	-12	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1953	-6	No		1178	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			940		63	1	11	940	Month 33	170	93	1	cm	kg			87.516		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	65	127	Stem cell, Autologous	1	1	Lenalidomide	248	940	692	2	2		0		876	1	1			2	1	1		Baseline	-6	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1955	1	No	483	483	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1		438		65	1	5	427	Month 15	153	97	3	cm	kg			331.5	1	1	Bortezomib-based	3	2	1	0		0							0								415	1	59.285714286	331	5	5			2	2	1	1	Baseline	1	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1974	0	No	892	892	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1		3.8318067904	877		60	1	10	877	Month 30	176	90	3	cm	kg			669.188		2	combined bortezomib/IMIDs/carfilzomib-based	2	5	4	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	96	106	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	188	363	175	1	1	384	1	54.857142857	264	5	1	3	3	2	2		1	Baseline	0	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1982	-52	No		1752	Other		PATIENT DID NOT SIGN RECONSENT FOR FOLLOW-UP BEYOND 5 YEARS			2	1	7				2	2	2	Yes	1	1	0	1.6004841682	1752		52	1	20	1752	Year 5	63	165	1	in	lb			61.88	2	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	91	172	Stem cell, Autologous	1	1								0		1636	1	1			2	1	1		Baseline	-65	52	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1986	3															2	2	1	Yes	1	1	0		2218		69	1	24	2218	Year 6	72	160	2	in	lb			268.736	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2024	1	1			2	1	1		Baseline	13	69	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1999	0	No		1305	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0		1305		53	1	14	1305	Month 42	159	50	2	cm	kg			55.692		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	56	121	Stem cell, Autologous	1	1								0		1250	1	1			2	1	1		Baseline	-1	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2014	-27	No	2094	2094	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	1		2007	1170	61	1	24	2042	Year 6	73	278	3	in	lb			97.24		2	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	93	109	Stem cell, Autologous	1	1	Lenalidomide	212	457	245	1	1	1010	1	144.28571429	918	5	3	3	5	2	1		1	Baseline	-27	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2043	-3															1	2	1	Yes	1	1	2	1.4694801148	2114		70	1	24	2114	Year 6	64	178	3	in	lb			111.384		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	105	Stem cell, Autologous	1	1	Lenalidomide	202	254	52	1	1		0		2034	1	1			2	1	1		Baseline	-3	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2063	-28	No	46	46	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1				67	1	0	-28	Baseline	71	331	3	in	lb			106.08		2	Bortezomib-based		2	1	0		0							0												5	5			2		1		Baseline	-28	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2101	-14															1	2	2	Yes	1	1	1		1995		54	1	22	1995	Month 66	61	133	3	in	lb			65.416	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	89	112	Stem cell, Autologous	1	1	Lenalidomide	224	1995	1771	2	2		0		1907	1	1			2	1	1		Baseline	-14	54	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2124	1															1	2	2	Yes	1	1	2		2016		55	1	22	2016	Month 66	62	145	3	in	lb			271.388	2	2	combined bortezomib/IMIDs/carfilzomib-based		5	3	0	1	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	1	159	167	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	280	679	399	2	2	1218	1	174	1116	3	3	3	4	2	1	1		Baseline	1	55	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2198	-2															1	2	1	Yes	1	1	1		2003		55	1	22	2003	Month 66	71	246	3	in	lb			132.6	0	1	combined bortezomib/IMIDs-based	1	1	5	1		0	2	Carfilzomib/Dexamethasone	141	225	252	Stem cell, Autologous	1	0	Bortezomib	365	742	377	2		138	1	19.714285714	57	3	3	3	2	2	2	1	1	Baseline	1	55	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2226	-4	No		91	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0				67	1	0	-4	Baseline	71	226	2	in	lb			118.456	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0												4	4			2		1		Baseline	-4	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2270	0															1	2	1	Yes	1	1	0		2031		56	1	22	2031	Month 66	69	232	2	in	lb			132.6	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	99	113	Stem cell, Autologous	1	1	Lenalidomide	226	1991	1765	2	2	1614	1	230.57142857	1544	3	3			2	1	1		Baseline	0	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2271	-16	No		1770	Other		PATIENT DID NOT RECONSENT FOR FOLLOW-UP BEYOND 5 YEARS			2	1	7				1	2	2	Yes	1	1	0	1.8366191987	1770		88	1	20	1770	Year 5	62	132	1	in	lb			49.504	2	2	Bortezomib-based	3	2	1	0		0							0								1552	1	221.71428571	1035	3	3			2	1	1		Baseline	-21	88	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2272	1	No	41	41	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	5.9180274177			57	1	-1	1	Screening	68	194	3	in	lb			302.328	1	1	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	-2	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2449	1	No		1838	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	2	2.3480945316	1838		56	1	20	1838	Year 5	63	148	3	in	lb			398.684	1	1	combined bortezomib/IMIDs-based	2	1	1	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	74	116	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	215	1838	1623	2	2		0		1767	1	1			2	1	1		Baseline	1	56	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2446	-1	No		1814	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0		1814		50	1	20	1814	Year 5	60	183	2	in	lb			70.72	2	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	93	120	Stem cell, Autologous	1	1	Bortezomib	232	259	27	1	1		0		1718	1	1			2	1	1		Baseline	-1	50	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2514	-3	No		666	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	2.098588589	651		63	1	7	651	Month 21	66	157	1	in	lb			53.04	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Dexamethasone	287	389	420	Stem cell, Autologous	1	1	Lenalidomide	555	651	96	1	1		0		596	1	1			2	1	1		Baseline	-3	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2531	1	No	546	546	Death	Other		ACUTE RESPIRATORY FAILURE WITH HYPOXIA	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1	2	6.9359373989	505		70	1	6	505	Month 18	72	280	3	in	lb			134.368	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	121	Stem cell, Autologous	1	1	Lenalidomide	239	413	174	1	1	449	1	64.142857143	365	5	1	2	5	2	2	1	1	Baseline	1	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2541	-21	No	1079	1079	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1	0	6.2727057044	1073		57	1	12	1073	Year 3	59	113	2	in	lb			47.736		2	combined bortezomib/IMIDs/carfilzomib-based	2	5	5	1	1	1	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	106	158	163	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide/Dexamethasone	273	385	112	1	1	560	1	80	407	5	3	3	2	2	1		1	Baseline	-21	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2592	-2															1	2	2	Yes	1	1	1		1787		59	1	20	1787	Year 5	60	164	3	in	lb			338.572	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	125	168	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide/Dexamethasone	282	394	112	1	1		0		1613	1	1			2	1	1		Baseline	-2	59	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2611	-7															1	2	2	Yes	1	1		8.9069066497	1767		66	1	20	1767	Year 5	64	173	2	in	lb			71.604	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	136	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide/Dexamethasone	246	358	112	1	1	1481	1	211.57142857	1390	3	3	1		2	1	1		Baseline	-7	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2621	-1	No	201	201	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	12.555804521	189		52	1	2	189	Month 6	64	168	3	in	lb			121.992	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		159	5	5			2	2	1		Baseline	-1	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1013	-11	No	2226	2226	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			2167		66	1	24	2167	Year 6	158	59	3	cm	kg			186.524	1	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	96	135	Stem cell, Autologous	1	1	Lenalidomide	212	1865	1653	2	2	1333	1	190.42857143	1227	5	3	2	2	2	1			Baseline	-12	66	Female					Checked			Not Hispanic or Latino	-11	0	1
MMRF_1073	-8															1	2	2	Yes	1	1	0	1.4713472229	2694		62	1	32	2954	Year 8	154	52	1	cm	kg			56.576	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	92	139	Stem cell, Autologous	1	1	Lenalidomide	265	2954	2689	2	2		0		2859	1	1			2	1	1		Baseline	-8	62	Female					Checked			Not Hispanic or Latino	-8	0	1
MMRF_1076	-30	No	1168	1168	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1150		68	1	13	1150	Month 39	159	61	2	cm	kg			76.024	1	1	combined bortezomib/IMIDs-based	1	1	3	1		0							0								416	1	59.428571429	342	5	3	2	5	2	2		1	Baseline	-30	68	Female					Checked			Not Hispanic or Latino	-30	0	1
MMRF_1095	-19															2	2	1	Yes	1	1			2732		69	1	30	2732	Month 90	173	125	1	cm	kg			121.108		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Lenalidomide/Dexamethasone	113	142	288	Stem cell, Autologous	1	1	Lenalidomide	449	899	450	2	2		0		2674	1	1			2	1	1		Baseline	-19	69	Male			Checked					Not Hispanic or Latino	-19	0	1
MMRF_1092	-41															2	2	1	Yes	1	1	0	2.4452015132	2716		69	1	30	2716	Month 90	183	97	2	cm	kg			107.848		2	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Lenalidomide/Dexamethasone	191	1539	1551	Stem cell, Autologous	1	1							1436	1	205.14285714	1341	3	3	1		2	1	1		Baseline	-41	69	Male			Checked					Not Hispanic or Latino	-41	0	1
MMRF_1115	-9															1	2	1	Yes	1	1			2897		65	1	32	2897	Year 8	172	80	1	cm	kg			75.14	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	119	Stem cell, Autologous	1	1								0		2814	1	1			2	1	1		Baseline	-9	65	Male					Checked			Not Hispanic or Latino	-9	0	1
MMRF_1134	-13															1	2	1	Yes	1	1			2888		59	1	32	2888	Year 8	166	79	1	cm	kg			60.996	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	56	134	Stem cell, Autologous	1	1	Lenalidomide	531	2888	2357	2	2		0		2833	1	1			2	1	1		Baseline	-13	59	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1153	-11															1	2	2	Yes	1	1		2.2473469622	2892		59	1	32	2892	Year 8	166	79	1	cm	kg			60.996	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	102	185	Stem cell, Autologous	1	1	Lenalidomide	339	875	536	2	2	1240	1	177.14285714	1149	3	3	4	1	2	1	1		Baseline	-34	59	Female					Checked			Not Hispanic or Latino	-34	0	1
MMRF_1168	-5															1	2	2	Yes	1	1			2844		57	1	30	2844	Month 90	155	75	2	cm	kg			91.052	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2764	1	1			2	1	1		Baseline	-6	57	Female					Checked			Not Hispanic or Latino	-5	0	1
MMRF_1171	-22															1	2	2	Yes	1	1	0	1.8801696537	2540		36	1	28	2540	Year 7	164	86	2	cm	kg			70.72	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	89	155	Stem cell, Autologous	1	1	Lenalidomide	278	2540	2262	2	2		0		2452	1	1			2	1	1		Baseline	-22	36	Female					Checked			Not Hispanic or Latino	-22	0	1
MMRF_1185	-6															1	2	1	Yes	1	1	1	1.7382033183	2847		67	1	30	2847	Month 90	170	79	3	cm	kg			335.036	2	2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	117	Stem cell, Autologous	1	1	Lenalidomide	256	1211	955	2	2		0		2784	1	1			2	1	1		Baseline	-9	67	Male					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1196	-44	No	795	795	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1			765	795	62	1	9	765	Month 27	185	87	2	cm	kg	Stage I	1	43.316	3	2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	259	329	Stem cell, Autologous	1	1							71	1	10.142857143	1	5	1	3	5	1	2		1	Baseline	-44	62	Female			Checked					Not Hispanic or Latino	-44	0	1
MMRF_1235	-7	No	2571	2544	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.3218794551	2544	1899	56	1	28	2544	Year 7	174	87	2	cm	kg			56.576		2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	72	106	Stem cell, Autologous	1	1	Lenalidomide	254	2303	2049	2	2		0		2500	5	1	5		2	1			Baseline	-7	56	Male					Checked			Not Hispanic or Latino	-7	0	1
MMRF_1251	-7															1	2	1	Yes	1	1	2	4.20445813	2739		43	1	30	2739	Month 90	190	91	2	cm	kg			226.304	1	1	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	112	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	183	213	30	1	1	869	1	124.14285714	764	3	3	3	4	2	1	1	1	Baseline	-7	43	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1290	-3															1	2	2	Yes	1	1		4.0267869312	2727		55	1	30	2727	Month 90	170	74	3	cm	kg			98.124	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	86	131	Stem cell, Autologous	1	1	Lenalidomide	206	2727	2521	2	2		0		2639	1	1			2	1	1		Baseline	-3	55	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1284	-2															1	2	1	Yes	1	1	0	1.5090702509	2739		59	1	30	2739	Month 90	173	77	2	cm	kg			87.516	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	71	74	108	Stem cell, Autologous	1	1							82	1	11.714285714		1	2	1		1		1	1	Baseline	-2	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1304	-5															1	2	1	Yes	1	1		1.9639653121	2557		72	1	28	2501	Year 7	179	85	3	cm	kg			118.456	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	78	122	Stem cell, Autologous	1	1	Lenalidomide	288	2501	2213	2	2		0		2465	1	1			2	1	1		Baseline	-5	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1323	-15															1	2	2	Yes	1	1	0	3.8651522726	2540		73	1	28	2540	Year 7	164	93	2	cm	kg			87.516		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	77	117	Stem cell, Autologous	1	1	Lenalidomide	230	2540	2310	2	2		0		2388	1	1			2	1	1		Baseline	-16	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1328	-8	No	1500	1500	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	9.8541266046	1497		46	1	17	1487	Month 51	165	97	1	cm	kg			108.732	1	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Lenalidomide	216	544	595	Stem cell, Autologous	1	1							553	1	79	478	5	3	1	3	2	1		1	Baseline	-7	46	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1374	-21	No	354	354	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1		3.1018633026	340	354	71	1	5	354	Month 15	179	99	2	cm	kg			147.628	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	23	59	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	144	340	196	1	1	340	1	48.571428571	288	5	5			2	2	1	1	Baseline	-21	71	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1415	-3	No	469	469	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		12.32932996	460		50	1	5	460	Month 15	188	115	3	cm	kg			146.744	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	84	117	Stem cell, Autologous	1	1	Lenalidomide	220	309	89	1	1	368	1	52.571428571	313	5	3	5		2	2	1	1	Baseline	-3	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1430	0	No	1574	1574	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1			1533		66	1	17	1533	Month 51	180	96	3	cm	kg			638.248		2	combined bortezomib/IMIDs-based	3	1	3	0	1	1	1	Bortezomib/Thalidomide/Dexamethasone	42	119	194	Stem cell, Autologous	1	1	Lenalidomide	316	665	349	1	1	875	1	125	785	5	3	2	5	2	1		1	Baseline	11	66	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1447	-2															1	2	1	Yes	1	1	0	4.6580973352	2569		71	1	28	2569	Year 7	175	76	2	cm	kg			107.848	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	125	Stem cell, Autologous	1	1	Lenalidomide	259	2569	2310	2	2	2363	1	337.57142857	2281	3	3			2	1	1		Baseline	-2	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1506	-5															1	2	2	Yes	1	1	1	2.6122266232	2373		54	1	26	2373	Month 78	163	63	3	cm	kg			66.3	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	77	106	Stem cell, Autologous	1	1								0		2310	1	1			2	1	1		Baseline	1	54	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1522	-5															2	2	2	Yes	1	1	0	1.6867837007	2342		42	1	26	2342	Month 78	174	63	2	cm	kg			125.528		2	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	114	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	205	1291	1086	2	2	1297	1	185.28571429	1239	3	3	2	1	2	1	1		Baseline	-6	42	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1534	-19															1	2	1	Yes	1	1	0	4.5149709879	2149		64	1	24	2149	Year 6	181	81	1	cm	kg			143.208		2	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Lenalidomide/Melphalan/Dexamethasone	161	161	163	Stem cell, Autologous	1	1	Lenalidomide	238	1101	863	2	2	157	1	22.428571429	107	3	3	2	3	2	2	1	1	Baseline	-35	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1539	-9															1	2	2	Yes	1	1	0	11.500494586	1998		57	1	22	1998	Month 66	152	55	2	cm	kg			103.428	1	1	combined bortezomib/IMIDs-based	3	1	4	0	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	45	175	230	Stem cell, Autologous	1	1	Lenalidomide	327	604	277	1	1	851	1	121.57142857	779	3	3	4	2	2	1	1	1	Baseline	-9	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1543	-23															2	2	2	Yes	1	1	0	2.0089968039	2189		63	1	24	2189	Year 6	160	68	1	cm	kg			58.344		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	109	144	Stem cell, Autologous	1	1							2000	1	285.71428571	1909	3	3			2	1	1		Baseline	-23	63	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1546	-6															2	2	1	Yes	1	1	0	5.3929266137	2356		67	1	26	2356	Month 78	171	100	2	cm	kg			132.6		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0								717	1	102.42857143	661	3	3			2	1	1	1	Baseline	-6	67	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1572	-10															1	2	1	Yes	1	1	2	1.9216201284	2395		68	1	26	2395	Month 78	179	92	2	cm	kg			84.864	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	124	150	Stem cell, Autologous	1	1	Lenalidomide	268	270	2	1	1		0		2325	1	1			2	1	1		Baseline	-12	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1595	-13	No	796	796	Death	Other		SECONDARY MALIGNANCY	Secondary Malignancy	2	1	1	2	8		1	2	1	Yes	1	1	2	11.564205649	776	796	73	1	9	792	Month 27	177	65	3	cm	kg			101.66	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0								581	1	83	469	5	5			2	1		1	Baseline	-13	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1602	1														Unkown	6	3	1	Yes	1	1	0		2337		66	1	26	2337	Month 78	177	90	1	cm	kg			71.604		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	83	116	Stem cell, Autologous	1	1	Lenalidomide	265	2337	2072	2	2		0		2232	1	1			2	1	1		Baseline	1	66	Male						Checked	Unkown	Other		0	1
MMRF_1656	-17	No	523	523	Death	Other		CARDIA ARREST, SEPSIS	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	1	2.5506361059	433	523	70	1	6	505	Month 18	165	70	3	cm	kg			121.108	1	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	79	133	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	229	260	31	1	1	427	1	61	350	5	3	2	5	2	2	1	1	Baseline	-17	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1674	-12														Unknown	6	3	2	Yes	1	1	2		2367		70	1	26	2367	Month 78	165	58	2	cm	kg			63.648	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	104	140	Stem cell, Autologous	1	1	Bortezomib	235	912	677	2	2		0		2283	1	1			2	1	1		Baseline	1	69	Female						Checked	Unknown	Other		0	1
MMRF_1694	-24														Unknown	6	3	1	Yes	1	1	2	2.2013995499	2139		66	1	24	2139	Year 6	185	106	2	cm	kg			102.544	0	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	123	170	Stem cell, Autologous	1	1	Lenalidomide	394	935	541	2	2	917	1	131	848	3	3	3	1	2	1	1	1	Baseline	-24	66	Male						Checked	Unknown	Other		0	1
MMRF_1711	-2	No	2021	2021	Death	Other		ACUTE SUBDURAL HEMORRHAGE	Other	2	1	1	2	10		1	3	1	Yes	1	1			1998		64	1	22	1998	Month 66	189	85	2	cm	kg			118.456		2	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	82	124	Stem cell, Autologous	1	1	Lenalidomide	240	1017	777	2	2	1009	1	144.14285714	943	5	3	2	2	2	1		1	Baseline	-2	64	Male					Checked			Other		0	1
MMRF_1713	-3															2	2	2	Yes	1	1	1	3.190531107	2037		60	1	22	2037	Month 66	161	43	3	cm	kg			90.168		2	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	126	171	Stem cell, Autologous	1	1	Lenalidomide	281	448	167	1	1	1106	1	158	1043	3	1	2		2	1	1		Baseline	-3	60	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1722	-3															1	2	1	Yes	1	1		3.0692897963	2198		71	1	24	2198	Year 6	174	97		cm	kg			117.572		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	71	141	Stem cell, Autologous	1	1	Lenalidomide	408	2198	1790	2	2		0		2135	1	1			2	1	1		Baseline	-3	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1736	-30															1	2	1	Yes	1	1	0	6.0436785402	2136		79	1	24	2136	Year 6	168	75	2	cm	kg			126.412	0	2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								502	1	71.714285714	462	3	3	1		2	1	1	1	Baseline	-30	79	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1817	-23	No	1709	1709	Death	Disease progression				2	1	1	1		Unknown	6	3	1	Yes	1	1	0	3.1808909559	1607		68	1	18	1607	Month 54	180	85	1	cm	kg			83.98		2	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	93	170	Stem cell, Autologous	1	1	Lenalidomide	401	1251	850	2	2	1250	1	178.57142857	1187	5	3	1	2	2	1			Baseline	-16	68	Male						Checked	Unknown	Other		0	1
MMRF_1837	-14														Unknown	6	3	2	Yes	1	1	2	2.4376966467	2163		60	1	24	2163	Year 6	157	75	2	cm	kg			55.692	3	2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	76	125	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	216	692	476	2	2	1236	1	176.57142857	1159	3	3	1		2	1	1		Baseline	-14	60	Female						Checked	Unknown	Other		0	1
MMRF_1854	-12														Unknown	6	2	2	Yes	1	1	0	3.9644821256	2031		52	1	22	2031	Month 66	163	86	2	cm	kg			80.444		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	119	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	211	1282	1071	2	2		0		1954	1	1			2	1	1		Baseline	-13	52	Female						Checked	Unknown	Not Hispanic or Latino		0	1
MMRF_1906	-4	No	911	911	Death	Other		WEST NILE ENCEPHALITIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1	3.072441157	876	911	77	1	11	910	Month 33	168	75	3	cm	kg			145.86	0	2	combined bortezomib/IMIDs-based	2	1	3	1		0							0								344	1	49.142857143	261	5	1	2	5	2	2		1	Baseline	-4	77	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1940	-5															1	2	1	Yes	1	1	0		2150		59	1	24	2150	Year 6	178	87	1	cm	kg			82.212	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	161	Stem cell, Autologous	1	1	Bortezomib	291	1480	1189	2	2		0		2060	1	1			2	1	1		Baseline	-5	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1957	-14															1	2	1	Yes	1	1	0		2206		75	1	24	2206	Year 6	175	75	2	cm	kg			83.096	0	1	IMIDs-based	4	3	2	0	1	1	1	Lenalidomide/Dexamethasone	1	144	196	Stem cell, Autologous	1	1	Lenalidomide	324	1077	753	2	2	978	1	139.71428571	896	3	3	1		2	1	1	1	Baseline	-14	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2001	-54															1	2	1	Yes	1	1	0	1.8114134046	2116		57	1	24	2116	Year 6	183	107	2	cm	kg			107.848	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	103	170	Stem cell, Autologous	1	1	Lenalidomide	404	549	145	1	1	725	1	103.57142857	686	3	3	2		2	1	1	1	Baseline	-82	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2090	-12	No		1701	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1	2		1324		52	1	15	1324	Month 45	168	81	2	cm	kg			100.776		2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	95	140	Stem cell, Autologous	1	1	Lenalidomide	263	1324	1061	2	2		0		1289	1	1			2	1	1		Baseline	-27	52	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2111	-8														Unknown	6	3	2	Yes	1	1	0	2.6267201162	1968		60	1	22	1968	Month 66	167	80	2	cm	kg			76.024		2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	93	154	Stem cell, Autologous	1	1	Lenalidomide	327	1564	1237	2	2		0		1906	1	1	4		2	1	1		Baseline	-22	60	Female						Checked	Unknown	Other		0	1
MMRF_2128	-19	No	1877	1877	Death	Other		ACUTE RESPIRATORY FAILURE; SHOCK; SEPSIS, TROPONEMIA	Other	2	1	1	2	10		1	2	2	Yes	1	1	0		1834		66	1	20	1831	Year 5	169	76	1	cm	kg			64.532	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	106	162	Stem cell, Autologous	1	1	Lenalidomide	323	343	20	1	1	1409	1	201.28571429	1295	5	5			2	1			Baseline	-19	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2137	-26															1	2	1	Yes	1	1	0		1628		68	1	18	1628	Month 54	170	64	1	cm	kg			71.604	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	107	157	Stem cell, Autologous	1	1	Lenalidomide	467	1628	1161	2	2		0		1639	1	1			2	1	1		Baseline	-37	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2140	87															2	2	2	Yes	1	1	0		2137		65	1	22	2137	Month 66	166	90	2	cm	kg			62.764	0	1	combined bortezomib/IMIDs-based	11	1	1	0	1	1	1	Lenalidomide	201	2137	226	Stem cell, Autologous	1	1								0		1952	1	1			2	1	1		Baseline	87	65	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2211	1															1	2	1	Yes	1	1	1	8.2022122462	1997		45	1	22	1997	Month 66	193	110	3	cm	kg			209.508		2	combined bortezomib/IMIDs-based	3	1	4	0	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	43	74	121	Stem cell, Autologous	1	1	Lenalidomide	249	1054	805	2	2	1037	1	148.14285714	951	3	3	4	4	2	1	1	1	Baseline	-3	45	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2209	-13	No		137	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0		137		70	1	2	137	Month 6	177	76	1	cm	kg			75.14	1	1	combined bortezomib/IMIDs/carfilzomib-based		5	1	0	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	1	125	175	Stem cell, Autologous	1	1								0		53	1	1			2	2	1		Baseline	-13	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2239	-69															2	2	2	Yes	1	1			1726		73	1	19	1726	Month 57	165	63	2	cm	kg			117.572		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	127	Stem cell, Autologous	1	1	Lenalidomide	236	1726	1490	2	2		0		1681	1	1			2	1	1		Baseline	-51	73	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2284	-27	No	1487	1487	Death	Other		SEPSIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	0		1443		67	1	16	1443	Year 4	163	89	2	cm	kg			82.212		2	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	94	133	Stem cell, Autologous	1	1	Lenalidomide	239	771	532	2	2	1317	1	188.14285714	1254	5	1	2	4	2	1			Baseline	-27	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2397	-27															1	2	1	Yes	1	1	2		1800		50	1	20	1800	Year 5	180	76	2	cm	kg			90.168	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	53	165	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	183	218	35	1	1		0		1737	1	1			2	1	1		Baseline	-27	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2383	-12														Unknown	6	3	1	Yes	1	1	0		1629		64	1	18	1619	Month 54	175	84	2	cm	kg			85.748		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	127	Stem cell, Autologous	1	1	Lenalidomide	235	1619	1384	2	2		0		1542	1	1			2	1	1		Baseline	-12	64	Male						Checked	Unknown	Other		0	1
MMRF_2388	-5															1	2	2	Yes	1	1	0		1830		74	1	20	1830	Year 5	169	63	2	cm	kg			93.704	0	1	combined bortezomib/IMIDs-based	1	1	4	1		0							0								616	1	88	532	3	3	3	3	2	1	1	1	Baseline	1	74	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2411	-20														Unknown	6	3	1	Yes	1	1	1		1803		56	1	20	1803	Year 5	178	81	3	cm	kg			116.688	0	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	130	Stem cell, Autologous	1	1	Lenalidomide	246	914	668	2	2	897	1	128.14285714	834	3	3	2	3	2	1	1	1	Baseline	-20	56	Male						Checked	Unknown	Other		0	1
MMRF_2459	-9														Unknown	6	3	2	Yes	1	1	0	1.5249976779	1716		66	1	19	1716	Month 57	172	106	2	cm	lb			73.372	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	82	136	Stem cell, Autologous	1	1	Lenalidomide	224	1716	1492	2	2		0		1624	1	1			2	1	1		Baseline	-9	66	Female						Checked	Unknown	Other		0	1
MMRF_2516	-15															2	2	1	Yes	1	1	0	2.3787575276	1799		67	1	20	1799	Year 5	170	78	1	cm	kg			92.82		2	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	77	121	Stem cell, Autologous	1	1	Lenalidomide	245	259	14	1	1	1513	1	216.14285714	1436	3	3	1		2	1	1		Baseline	-20	67	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2532	-1															1	2	1	Yes	1	1	0	3.8660173042	1821		73	1	20	1821	Year 5	174	78	1	cm	kg			115.804	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	81	135	Stem cell, Autologous	1	1	Lenalidomide	239	605	366	2	2		0		1723	1	1			2	1	1		Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2559	1															1	3	1	Yes	1	1		1.3523923609	1814		51	1	20	1810	Year 5	191	92		cm	kg			81.328	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	133	Stem cell, Autologous	1	1	Lenalidomide	275	1810	1535	2	2		0		1734	1	1			2	1	1		Baseline	1	51	Male					Checked			Other		0	1
MMRF_1121	-31															4	2	2	Yes	1	1			2732		42	1	30	2732	Month 90	66	120	2	in	lb			48.62	0	2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	74	131	Stem cell, Autologous	1	1	Lenalidomide	345	464	119	1	1		0		2641	1	1			2	1	1		Baseline	1	42	Female		Checked						Not Hispanic or Latino	1	0	1
MMRF_1149	-11	No	862	862	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1			844	862	53	1	11	861	Month 33	70	170	2	in	lb			83.98	2	2	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	85	186	Stem cell, Autologous	1	1							140	1	20	56	5	3	3	3	2	2		1	Baseline	-3	53	Male					Checked			Hispanic or Latino	-3	0	1
MMRF_1080	-10	No		764	Other		SITE CLOSED TO CLINICAL RESEARCH. BASELINE LABS DO NOT SUPPORT ELIGIBILITY			2	1	7				1	2	1	Yes	1	1			617		66	1	7	617	Month 21	69	200	2	in	lb			87.516	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	144	159	Stem cell, Autologous	1	1	Lenalidomide	295	617	322	1	1		0		554	1	1			2	1	1		Baseline	1	66	Male					Checked			Not Hispanic or Latino	1	0	1
MMRF_1198	-19	No		595	Other		SITE CLOSED TO CLINICAL RESEARCH.			2	1	7			Not Specified	6	1	1	Yes	1	1			525		76	1	6	434	Month 18	68	174	3	in	lb			141.44		2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		448	1	1			2	1	1		Baseline	-19	76	Male						Checked	Not Specified	Hispanic or Latino		0	1
MMRF_1255	-15	No		543	Other		SITE CLOSED TO CLINICAL RESEARCH.			2	1	7				1	2	1	Yes	1	1			447		50	1	5	447	Month 15	69	221	2	in	lb			73.372	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		360	1	1			2	2	1		Baseline	-15	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1339	-23	No	186	186	Death	Other		SEVERE ENCEPHALOPATHY SECONDARY TO CEREBROVASCULAR ACCIDENT	Neurological	2	1	1	2	6		2	2	1	Yes	1	1	1		138	186	79	1	3	186	Month 9	70	173	3	in	lb			141.44		2	Bortezomib-based	3	2	1	0		0							0								138	1	19.714285714		5	5			2		1	1	Baseline	-23	79	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1236	-41															1	2	2	Yes	1	1			2706		67	1	30	2672	Month 90	68	130	1	in	lb			53.04	0	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	190	203	Stem cell, Autologous	1	1	Pomalidomide	313	1027	714	2	2	1397	1	199.57142857	1275	3	3	1	3	2	1	1		Baseline	-50	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1918	-76															1	2	2	Yes	1	1	0	3.7419794195	2080		56	1	24	2080	Year 6	66	180	1	in	lb			106.08	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	100	273	288	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide	456	631	175	1	1		0		2018	1	1			2	1	1		Baseline	-80	56	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2329	-17	No	1845	1845	Death	Other		RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1	1	1.5278300761	1807		72	1	20	1807	Year 5	70	194	3	in	lb			114.92	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								1158	1	165.42857143	1079	5	3	5		2	1			Baseline	-6	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1067	-7	Yes		2906						1	2					1	2	1	Yes	1	1			2906		72	1	32	2906	Year 8	165	72	1	cm	kg			91.052		2	combined bortezomib/IMIDs-based	2	1	3	1	1	1	1	Cyclophosphamide/Melphalan/Dexamethasone	148	161	162	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	348	421	73	1	1	1285	1	183.57142857	1195	3	3	3	1	2	1	1		Baseline	-1	72	Male					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1131	-3	No		445	Noncompliance with study procedures					2	1	2				1	2	2	Yes	1	1			444		41	1	5	415	Month 15	161	62	2	cm	kg			73.372		2	combined bortezomib/IMIDs-based		1	2	0		0							0								206	1	29.428571429	121	3	3	2		2	2	1	1	Baseline	-3	41	Female					Checked			Not Hispanic or Latino	-3	0	1
MMRF_1245	-46	No		408	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			309		69	1	4	294	Year 1	156	67	2	cm	kg			82.212		2	Bortezomib-based	3	2	1	0		0							0									0		244	1	1			2	2	1		Baseline	-46	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1412	-19															1	2	1	Yes	1	1			2519		68	1	28	2519	Year 7	175	92	1	cm	kg			96.356	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Melphalan	134	147	148	Stem cell, Autologous	1	1	Lenalidomide	294	2519	2225	2	2		0		2438	1	1			2	1	1		Baseline	-19	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1680	-13	No	1530	1530	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2		1418	1530	55	1	17	1522	Month 51	184	122	3	cm	kg			136.136	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Cyclophosphamide/Melphalan	133	145	146	Stem cell, Autologous	1	1	Cyclophosphamide/ETOPOSIDE (VERSED)/Dexamethasone/Doxorubicin	1376	1422	46	1	1		0		1415	5	5			2	1			Baseline	-9	55	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2119	-11	No	934	934	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	3.6906819524	891	934	60	1	11	933	Month 33	151	82	3	cm	kg			119.34	1	1	combined bortezomib/IMIDs-based	1	1	3	1		0							0								526	1	75.142857143	464	5	3	2	5	2	1		1	Baseline	-11	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2213	-1															1	2	2	Yes	1	1	1	2.5944124581	2016		63	1	22	2016	Month 66	155	44	3	cm	kg			180.336	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	99	153	Stem cell, Autologous	1	1	Lenalidomide	312	355	43	1	1		0		1908	1	1	1		2	1	1		Baseline	-1	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2476	-5	No		552	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	1	4.9064388107	525		83	1	6	525	Month 18	175	80	3	cm	kg			121.992	1	2	IMIDs-based	4	3	1	0		0							0									0		434	1	1			2	1	1		Baseline	-5	83	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2549	1	No	1119	1119	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	3.208460249	1101	1119	64	1	13	1119	Month 39	170	121	3	cm	kg			149.396	2	2	Bortezomib-based	3	2	4	0		0							0								1101	1	157.28571429	1013	5	1	4	1	2	1			Baseline	7	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1309	-57	No		1799	Inter-current illness that interferes with study assessments					2	1	4				1	2	2	Yes	1	1	0	1.3875168579	1799		83	1	20	1799	Year 5	62	221	2	in	lb			118.456	0	2	combined bortezomib/IMIDs-based	11	1	2	0		0							0								517	1	73.857142857	274	3	3	2		2	2	1	1	Baseline	-21	83	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1431	-27	No	1245	1245	Death	Other		PANCREATIC CANCER	Other	2	1	1	2	10		1	2	1	Yes	1	1	0		1153		75	1	13	1153	Month 39	72	188	2	in	lb			76.024	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		1192	5	5			2	1			Baseline	-9	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2308	-45	No		1370	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0		1370		74	1	15	1370	Month 45	61	105	1	in	lb			53.04	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0								830	1	118.57142857		2	2			2		1	1	Baseline	-27	74	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1077	-21	No	1944	1944	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		2.3067036712	1792		67	1	20	1791	Year 5	175	110	2	cm	kg				0	2	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	206	1903	267	Stem cell, Autologous	1	1							1426	1	203.71428571	1273	5	5			2	1			Baseline	-21	67	Male					Checked			Not Hispanic or Latino	-21	0	1
MMRF_1078	-13															1	2	1	Yes	1	1			2941		45	1	32	2941	Year 8	179	103	1	cm	kg			76.024	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	77	177	Stem cell, Autologous	1	1								0		2878	1	1	4		2	1	1		Baseline	-13	45	Male					Checked			Not Hispanic or Latino	-13	0	1
MMRF_1105	-6	Yes		2979						1	2					1	2	2	Yes	1	1			2962		57	1	32	2851	Year 8	162	63	1	cm	kg			66.3	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0								309	1	44.142857143	267	3	3			2	2	1	1	Baseline	-6	57	Female					Checked			Not Hispanic or Latino	-6	0	1
MMRF_1136	-7	No	401	401	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			369		70	1	4	351	Year 1	173	86	2	cm	kg			107.848	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Cyclophosphamide/Dexamethasone	96	131	208	Stem cell, Autologous	1	1	Carfilzomib	309	309	0	1	1	365	1	52.142857143	281	5	3	5		2	2	1	1	Baseline	-7	70	Male					Checked			Not Hispanic or Latino	-7	0	1
MMRF_1148	0	No	270	270	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	1.6616219604	209	270	71	1	3	269	Month 9	151	57	2	cm	kg			76.908		2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								196	1	28		5	2	5		2		1	1	Baseline	0	71	Female					Checked			Not Hispanic or Latino	0	0	1
MMRF_1189	-11	No	1789	1789	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1717		65	1	19	1717	Month 57	164	96	1	cm	kg			67.184	1	1	Bortezomib-based	3	2	3	0	0	1	1	Bortezomib/Dexamethasone	1	11	228	Stem cell, Autologous	1	1							697	1	99.571428571	619	5	1	3	2	2	1		1	Baseline	-11	65	Female					Checked			Not Hispanic or Latino	-11	0	1
MMRF_1214	-5															1	2	1	Yes	1	1			2763		69	1	30	2763	Month 90	164	67	3	cm	kg			409.292		2	combined bortezomib/IMIDs-based		1	1	0		0							0									0		1954	1	1			2	1	1		Baseline	-5	69	Male					Checked			Not Hispanic or Latino	-8	0	1
MMRF_1335	-37	No	1317	1317	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		4.615014554	1243	1317	44	1	15	1317	Month 45	178	91	3	cm	kg			241.332	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	352	463	Stem cell, Autologous	1	1							343	1	49		5	2	5		2			1	Baseline	-6	44	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1402	-27															1	1	2	Yes	1	1			2474		64	1	28	2474	Year 7	163	62	1	cm	kg			76.908	0	1	combined bortezomib/IMIDs-based	4	1	1	0	1	1	1	Lenalidomide/Dexamethasone	244	247	313	Stem cell, Autologous	1	1	Lenalidomide	558	1152	594	2	2		0		2221	1	1			2	1	1		Baseline	1	64	Female					Checked			Hispanic or Latino		0	1
MMRF_1560	-18															1	2	1	Yes	1	1	2	2.1609925211	2388		57	1	26	2388	Month 78	193	106	3	cm	kg			106.08	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	2	1	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	44	114	274	Stem cell, Autologous	1	1								0		2153	1	1	1		2	1	1		Baseline	-23	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1579	-4	No	1887	1887	Death	Other		UNKNOWN; PATIENT RECORDS FROM OTHER SITE NOT SHARED WITH OUR SITE	Unknown	2	1	1	2	9		1	2	2	Yes	1	1	1	4.0314139171	1834	1456	68	1	22	1887	Month 66	160	91	3	cm	kg			105.196		2	IMIDs-based	4	3	2	0		0							0								1726	1	246.57142857	1439	5	1	1	5	2	1			Baseline	17	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1613	-20	No	1340	1340	Death	Other		DISEASE PROGRESSION		2	1	1	1			1	2	1	Yes	1	1	2	2.810335214	1254		74	1	14	1254	Month 42	192	90	2	cm	kg	Stage II	2	114.036	0	1	combined bortezomib/IMIDs-based	3	1	3	0		0							0								604	1	86.285714286	500	5	3	2	3	2	1		1	Baseline	-20	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1761	0															1	2	1	Yes	1	1	1		2198		66	1	24	2198	Year 6	177	104	3	cm	kg			328.848		2	combined bortezomib/IMIDs-based	10	1	2	0		0							0									0		1844	1	1	1		2	1	1		Baseline	0	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1890	-13	No	134	134	Death	Other		RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	2	Yes	1	1	2	16.597142843	76	134	47	1	2	105	Month 6	170	73	2	cm	kg			79.56	1	1	Bortezomib-based	10	2	2	0		0							0									0		56	5	1	5		2	2	1		Baseline	-13	47	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2183	-7	No	603	434	Other		PATIENT  IS NOW HOME BOUND.			2	1	7				1	2	2	Yes	1	1			260	603	79	1	4	344	Year 1	165	58		cm	kg			100.776	2	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0								261	1	37.285714286	150	5	5			2	2	1	1	Baseline	-7	79	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2246	-32															1	2	2	Yes	1	1	1		1983		65	1	22	1983	Month 66	164	85	3	cm	kg			84.864		2	IMIDs-based	4	3	1	0		0							0									0		1911	1	1			2	1	1		Baseline	-32	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2477	0	No	485	485	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	2		365		61	1	4	365	Year 1	158	77	3	cm	kg			112.268	3	2	combined bortezomib/IMIDs-based	3	1	2	0		0							0								365	1	52.142857143	281	5	3	5		2	2	1	1	Baseline	0	61	Female	Checked				Checked			Not Hispanic or Latino		0	1
MMRF_1163	-3	No		332	Patient no longer consents to participate in the study					2	1	3				2	3	1	Yes	1	1			262		79	1	3	262	Month 9	69	186	3	in	lb			118.456	1	2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								136	1	19.428571429	71	3	3	2		2	2	1	1	Baseline	-3	79	Male			Checked					Other	-3	0	1
MMRF_1182	-28														Unknown/Declined	6	3	1	Yes	1	1			2703		39	1	30	2703	Month 90	64	82	1	in	kg			70.72	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	234	133	Stem cell, Autologous	1	1	Lenalidomide	264	644	380	2	2		0		2636	1	1			2	1	1		Baseline	-28	39	Male						Checked	Unknown/Declined	Other	-28	0	1
MMRF_1186	-23	No	1850	1850	Death	Other		PARKINSON'S DISEASE COMPLICATIONS	Neurological	2	1	1	2	6		1	2	1	Yes	1	1			1649	1850	68	1	22	1850	Month 66	167	75	1	cm	kg			79.56	0	1	IMIDs-based	4	3	2	0		0							0								1228	1	175.42857143	1176	5	3	5		2	1			Baseline	-23	68	Male					Checked			Not Hispanic or Latino	-12	0	1
MMRF_1201	-6															1	2	2	Yes	1	1		1.5251425034	2799		67	1	30	2799	Month 90	165	55	2	cm	kg			70.72	1	1	combined bortezomib/IMIDs-based	1	1	5	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	196	197	Stem cell, Autologous	1	1	Lenalidomide	436	789	353	1	1	628	1	89.714285714	558	3	3	2	1	2	1	1	1	Baseline	-2	67	Female					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1202	-22	No	921	921	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.3148350523	921	921	59	1	11	921	Month 33	173	117	2	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	4	1	3	0	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	152	227	314	Stem cell, Autologous	1	1							708	1	101.14285714	592	5	1	1	5	2	1		1	Baseline	-13	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1210	-2														Unknown/Declined	6	3	1	Yes	1	1	0	3.1151959542	2799		67	1	30	2799	Month 90	165	112	1	cm	kg	Stage II	2	96.356	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0	2	Carfilzomib/Lenalidomide/Dexamethasone	1503	2799	1681	Stem cell, Autologous	1	0							1405	1	200.71428571	1281	3	3	1		2	1	1		Baseline	8	67	Male						Checked	Unknown/Declined	Other		0	1
MMRF_1293	-66															4	2	1	Yes	1	1	0	1.6699371904	2645		59	1	30	2645	Month 90	174	82	2	cm	kg			82.212	0	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	432	260	Stem cell, Autologous	1	1							886	1	126.57142857	830	3	3	2	3	2	1	1	1	Baseline	-66	59	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1320	-2															1	2	1	Yes	1	1		12.702404875	2560		63	1	28	2560	Year 7	180	79	2	cm	kg			54.808	4	2	combined bortezomib/IMIDs-based	2	1	4	1		0							0								367	1	52.428571429	240	3	3	3	1	2	2	1	1	Baseline	1	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1300	-45														Unknown/Declined	6	2	2	Yes	1	1		2.8207639949	2569		62	1	28	2559	Year 7	157	114		cm	lb			44.2	0	2	combined bortezomib/IMIDs-based		1	5	1		0							0								440	1	62.857142857	359	3	3	3	2	2	2	1	1	Baseline	-10	62	Female						Checked	Unknown/Declined	Not Hispanic or Latino		0	1
MMRF_1338	1	No		848	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	2.5868372384	825		31	1	9	825	Month 27	180	97	1	cm	kg			151.164	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0								845	1	120.71428571	736	3	3			2	1	1	1	Baseline	13	31	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1375	0															1	2	1	Yes	1	1			2499		61	1	28	2499	Year 7	172	75	1	cm	kg			60.996	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	181	181	Stem cell, Autologous	1	1	Lenalidomide	360	1218	858	2	2		0		2465	1	1			2	1	1		Baseline	0	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1490	-1														Unknown/Declined	6	2	2	Yes	1	1		1.8573195153	2467		67	1	26	2467	Month 78	151	82	1	cm	kg			62.764	0	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								470	1	67.142857143	330	3	3	1		2	2	1	1	Baseline	-8	67	Female						Checked	Unknown/Declined	Not Hispanic or Latino		0	1
MMRF_1518	-12	No	240	240	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			207		63	1	2	190	Month 6	159	109	2	cm	kg			45.968	1	2	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	155	158	157	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	159	240	81	1	1	50	1	7.1428571429		5	2	5		1		1	1	Baseline	-12	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1772	-1															4	2	1	Yes	1	1			2173		48	1	24	2173	Year 6	180	180		cm	lb			98.124	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	2	1	1	1	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	73	1157	210	Stem cell, Autologous	1	1							1241	1	177.28571429	982	3	3	1		2	1	1		Baseline	-13	48	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1952	-7															2	2	2	Yes	1	1		1.468357034	2231		65	1	24	2231	Year 6	174	66	2	cm	kg			63.648	0	1	combined bortezomib/IMIDs-based	2	1	2	1		0							0								1545	1	220.71428571	1398	3	3	1		2	1	1		Baseline	-3	65	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1983	-10															2	2	1	Yes	1	1			2060		57	1	22	2060	Month 66	177	72	1	cm	kg			84.864	0	1	IMIDs-based	4	3	2	0		0							0								1209	1	172.71428571	1068	3	3	1		2	1	1		Baseline	1	57	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1991	-4															1	2	1	Yes	1	1	0	2.0495475858	2192		58	1	24	2192	Year 6	178	87	1	cm	kg			80.444	0	1	combined bortezomib/IMIDs-based	1	1	3	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	20	121	Stem cell, Autologous	1	1	Bortezomib/Dexamethasone	260	507	247	1	1	507	1	72.428571429	366	3	3	3	1	2	1	1	1	Baseline	0	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2097	-14														Unknown/Declined	6	3	1	Yes	1	1	0		1987		56	1	22	1987	Month 66	71	173	1	in	lb			74.256		2	combined bortezomib/IMIDs-based	2	1	1	1	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	1360	1360	1360	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	1361	1373	12	1	1	1346	1	192.28571429	1284	3	3			2	1	1		Baseline	-14	56	Male						Checked	Unknown/Declined	Other		0	1
MMRF_2367	-3														Unknown/Declined	6	3	1	Yes	1	1	0	2.4474323436	1836		70	1	20	1836	Year 5	182	92	1	cm	kg			95.472	0	1	Bortezomib-based	2	2	2	1		0							0								1094	1	156.28571429	982	3	3	1		2	1	1		Baseline	-6	70	Male						Checked	Unknown/Declined	Other		0	1
MMRF_2412	0														Unknown/Declined	6	3	2	Yes	1	1	1	1.9948070992	1919		65	1	20	1919	Year 5	158	50	3	cm	kg			247.52	1	1	Bortezomib-based	2	2	2	1		0							0								161	1	23	64	3	3	3		2	2	1	1	Baseline	0	65	Female						Checked	Unknown/Declined	Other		0	1
MMRF_2433	0															1	2	1	Yes	1	1	0	2.4686707165	1834		53	1	20	1834	Year 5	172	74	2	cm	kg			110.5	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	167	215	248	Stem cell, Autologous	1	1	Lenalidomide	342	1834	1492	2	2		0		1753	1	1			2	1	1		Baseline	-6	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2458	-13														Unknown/Declined	6	3	2	Yes	1	1	0	3.4127328151	1898		61	1	20	1898	Year 5	164	71	2	cm	kg			98.124		2	combined bortezomib/IMIDs/carfilzomib-based	1	5	2	1		0							0								1891	1	270.14285714	1808	3	3	4		2	1	1		Baseline	-13	61	Female						Checked	Unknown/Declined	Other		0	1
MMRF_1112	1	No		2388	Patient no longer consents to participate in the study					2	1	3				1	1	1	Yes	1	1			2354		59	1	26	2354	Month 78	164	127	2	cm	lb			70.72	3	2	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	190	346	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	489	2354	1865	2	2	1186	1	169.42857143	1097	3	3	2	4	2	1	1		Baseline	1	59	Male					Checked			Hispanic or Latino	1	0	1
MMRF_1152	-2	Yes		2951	Other		COMPLETED STUDY			1	2	7				1	2	1	Yes	1	1			2867		67	1	32	2867	Year 8	71	216	3	in	lb			203.32	2	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0								1503	1	214.71428571	1423	3	3			2	1	1		Baseline	-2	67	Male					Checked			Not Hispanic or Latino	-2	0	1
MMRF_1283	-28	No		131	Other		PATIENT HAS MOVED OUT OF STATE AND IS NO LONGER CONTACTABLE			2	1	7				1	2	2	Yes	1	1	2		48		65	1	1	48	Month 3	65	145	2	in	lb			79.56	0	1	IMIDs-based	4	3	1	0		0							0												4	4			2		1		Baseline	-28	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1360	-14	No		1607	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	1.591812742	1607		64	1	19	1607	Month 57	67	184	2	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	399	207	Stem cell, Autologous	1	1								0		1455	1	1			2	1	1		Baseline	-14	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1484	-29	No		1180	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	2.3974335935	1040		72	1	12	1050	Year 3	73	236	2	in	lb			291.72	0	1	Bortezomib-based	3	2	1	0		0							0									0		802	1	1			2	1	1		Baseline	-29	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1601	-2	No		38	Other		PATIENT DECIDED SHE WAS NOT RETURNING TO THE CLINIC - NO LONGER WANTS TX			2	1	7				1	2	2	Yes	1	1	1				84	1	0	-2	Baseline	61	108	3	in	lb			194.48	2	2	Bortezomib-based	3	2	1	0		0							0												4	4			2		1		Baseline	-2	84	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1641	-2	No	529	529	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	4.1613168682	435		70	1	5	435	Month 15	67	129	3	in	lb			70.72	3	2	Bortezomib-based	2	2	3	1		0							0								90	1	12.857142857		5	5		5	1		1	1	Baseline	-2	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2083	-19	No	870	870	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	2.3427355705	797		66	1	9	797	Month 27	67	231	1	in	lb			70.72	1	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	5	1		0							0									0		261	5	5		4	2	2			Baseline	-23	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2400	-1	No		684	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0	5.7980693091	620		68	1	7	620	Month 21	72	214	2	in	lb			63.648	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		83	1	1			2	2	1		Baseline	-1	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2473	-9	No		624	Patient no longer consents to participate in the study					2	1	3				1	1	2	Yes	1	1	0	2.1088347133	534		74	1	6	534	Month 18	62	173	1	in	lb			88.4	1	1	IMIDs-based	4	3	1	0		0							0								343	1	49		2	2			2		1	1	Baseline	-9	74	Female					Checked			Hispanic or Latino		0	1
MMRF_1310	-8															1	2	1	Yes	1	1		2.9622775021	2487		80	1	28	2487	Year 7	69	177	2	in	lb			116.688	0	2	combined bortezomib/IMIDs-based	6	1	1	0		0							0								1765	1	252.14285714	1681	3	3			2	1	1		Baseline	-4	80	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1407	-16															1	1	1	Yes	1	1		2.0731427055	2441		71	1	28	2441	Year 7	66	157	1	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	277	121	Stem cell, Autologous	1	1	Lenalidomide	278	1021	743	2	2		0		2352	1	1			2	1	1		Baseline	-12	71	Male					Checked			Hispanic or Latino		0	1
MMRF_1424	-16	No	2144	2144	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	2	9.2800904445	1976		40	1	22	1976	Month 66	66	224	3	in	lb			91.052	1	1	combined bortezomib/IMIDs-based	1	1	5	1	1	1	1	Bortezomib/Dexamethasone	150	192	250	Stem cell, Autologous	1	1	Lenalidomide	361	926	565	2	2	1325	1	189.28571429	1241	5	3	1	2	2	1			Baseline	-6	40	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1556	-5	No		1877	Other		REMOVED PT FROM STUDY PER THE TREATING MD DUE TO POOR PERFORMANCE STATUS			2	1	7				1	2	1	Yes	1	1		1.3455863022	1853		71	1	20	1853	Year 5	67	165		in	lb			199.784	2	2	Bortezomib-based	2	2	2	1		0							0								1197	1	171	1014	3	3	4		2	1	1		Baseline	-5	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1617	-7															1	2	1	Yes	1	1	0	4.5292221315	2386		47	1	26	2386	Month 78	71	258	1	in	lb			103.428	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	108	149	Stem cell, Autologous	1	1	Lenalidomide	251	2386	2135	2	2		0		2300	1	1			2	1	1		Baseline	2	47	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1723	-49															1	2	2	Yes	1	1	1		2123		69	1	24	2123	Year 6	62	178	1	in	lb			79.56	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2011	1	1			2	1	1		Baseline	-77	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1984	-21	No		1806	Patient no longer consents to participate in the study					2	1	3				4	2	1	Yes	1	1			1806		59	1	20	1806	Year 5	63	140	1	in	lb			84.864	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1723	1	1			2	1	1		Baseline	-10	59	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1107	-14	No	118	118	Death	Other		CARDIAC ARREST, HEART FAILURE, AORTIC STENOSIS, AORTIC ABDOMINAL ANEURYSM	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1			50	118	82	1	2	118	Month 6	67	172	3	in	lb			119.34	1	2	Bortezomib-based	3	2	1	0		0							0									0		69	5	5			2	2	1		Baseline	-14	82	Male					Checked			Not Hispanic or Latino	-14	0	1
MMRF_1227	-19	No	1325	1325	Death	Other		HEART ATTACK	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1			1353	1325	73	1	15	1353	Month 45	71	174	1	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0			5	5			2				Baseline	-11	73	Male					Checked			Not Hispanic or Latino	-11	0	1
MMRF_1271	1	No		2284	Other		SITE NO LONGER WANTED TO PARTICIPATE			2	1	7				1	2	2	Yes	1	1			1989		79	1	22	1989	Month 66	64	197	3	in	lb			212.16	1	2	combined bortezomib/IMIDs-based		1	1	0		0							0									0		1728	1	1			2	1	1		Baseline	1	79	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1440	-13	No		2102	Other		SITE NO LONGER WANTED TO PARTICIPATE IN STUDY			2	1	7				2	2	2	Yes	1	1			1786		71	1	20	1786	Year 5	64	147	1	in	lb			106.08	0	1	combined bortezomib/IMIDs-based		1	2	0		0							0								408	1	58.285714286	323	3	3	1		2	2	1	1	Baseline	1	71	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1687	-20	No	211	211	Death	Other		FAILURE TO THRIVE		2	1	1	1			1	2	1	Yes	1	1	0		153	211	77	1	3	210	Month 9	65	138	1	in	lb			132.6	0	2	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		141	5	5			2	2	1		Baseline	-36	77	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1929	-14	No		1741	Other		SITE NO LONGER WANTED TO PARTICIPATE IN THE STUDY			2	1	7				1	2	2	Yes	1	1	0		1635		62	1	18	1635	Month 54	150	54	2	cm	kg			114.92		2	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	85	113	Stem cell, Autologous	1	1	Lenalidomide	238	1635	1397	2	2	1329	1	189.85714286	1245	3	1	1		2	1	1		Baseline	-1	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2132	-74	No	195	195	Death	Other		DECLINING HEALTH / NOT SPECIFIEC IF RELATED TO DISEASE UNDER STUDY	Other	2	1	1	2	10		2	2	1	Yes	1	1	0		106	195	87	1	3	194	Month 9	71	191	2	in	lb			114.92	0	2	Bortezomib-based	3	2	1	0		0							0									0		174	5	5			2	2	1		Baseline	-74	87	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2455	-17	No	264	264	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	11.942511425	163	264	63	1	3	255	Month 9	69	182	2	in	lb			132.6	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0								257	1	36.714285714	193	5	5			2	2	1	1	Baseline	-17	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1388	-11	No	2079	2079	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	3.0156134594	1954		81	1	22	1954	Month 66	61	131	3	in	lb			274.04	0	2	Bortezomib-based	10	2	1	0		0							0								1429	1	204.14285714		5	5			2				Baseline	3	81	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2598	1	No	1690	1690	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	2.0518565286	1642		82	1	18	1642	Month 54	63	141	3	in	lb			132.6	1	2	IMIDs-based	4	3	1	0		0							0									0			5	5			2				Baseline	1	82	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1170	-59	No		219	Other		PATIENT WENT FOR TREATMENT TO ANOTHER MEDICAL CENTER			2	1	7				1	1	1	Yes	1	1			310		60	1	4	310	Year 1	70	242	2	in	lb			60.996	0	1	Bortezomib-based	3	2	1	0		0							0									0		224	1	1			2	2	1		Baseline	-52	60	Male					Checked			Hispanic or Latino	-52	0	1
MMRF_1346	-30	No		494	Other		PATIENT WENT TO SEE ANOTHER HEMATOLOGY			2	1	7				1	1	1	Yes	1	1		1.2861554788	427		63	1	5	427	Month 15	59	109	2	in	lb			177.684	0	1	Bortezomib-based	10	2	1	0		0							0									0		281	1	1			2	2	1		Baseline	-30	63	Male					Checked			Hispanic or Latino		0	1
MMRF_1439	-25	No		409	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1	0	3.1751821415	253		49	1	3	253	Month 9	64	203	1	in	lb			65.416	0	1	Bortezomib-based	10	2	1	0		0							0									0		175	1	1			2	2	1		Baseline	-18	49	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1108	-2	No	1616	1616	Death	Other		HEALTH CARE ASSCOCIATED PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	1	1.821507653	1518	1616	85	1	18	1615	Month 54	62	134	3	in	lb				1	2	combined bortezomib/IMIDs-based	4	1	3	0		0							0								1433	1	204.71428571	1344	5	1	1	5	2	1			Baseline	1	85	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1113	1	No	1477	1477	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1			1270	1606	64	1	15	1477	Month 45	66	144	1	in	lb			159.12	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	2	1	1	1	1	Thalidomide	175	440	225	Stem cell, Autologous	1	1	Bortezomib/Thalidomide	441	604	163	1	1	905	1	129.28571429	85	5	3	5		2	2		1	Baseline	8	64	Male					Checked			Hispanic or Latino	8	0	1
MMRF_1164	1	No	372	372	Death	Other		PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	1	1.9881833552	266	372	70	1	4	372	Year 1	67	186	3	in	lb			185.64	0	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		242	5	5			2	2	1		Baseline	1	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1169	-19	No	191	191	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	2	3.1385308309	177		74	1	2	177	Month 6	69	238	3	in	lb			167.96	1	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0								177	1	25.285714286	91	5	5			2	2	1	1	Baseline	-33	74	Male					Checked			Hispanic or Latino	-19	0	1
MMRF_1312	-6															1	2	1	Yes	1	1		3.8733501437	2696		70	1	30	2696	Month 90	69	226	1	in	lb			97.24	0	1	combined bortezomib/IMIDs-based	1	1	3	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	150	200	Stem cell, Autologous	1	1	Lenalidomide	341	739	398	2	2	1569	1	224.14285714	1441	3	1	1	2	2	1	1		Baseline	-6	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1796	-12	No		1808	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	2.7666416227	1808		73	1	20	1808	Year 5	62	125	1	in	lb			136.136	1	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0								1808	1	258.28571429	1471	3	3			2	1	1		Baseline	-12	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2186	-6	No		1798	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	1		1798		69	1	20	1798	Year 5	71	309	3	in	lb			141.44	1	1	combined bortezomib/IMIDs-based	3	1	2	0		0							0								1527	1	218.14285714	1438	3	3	2		2	1	1		Baseline	-6	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2545	-4	No	1681	1681	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1			1643		63	1	18	1643	Month 54	67	181		in	lb			114.92		2	Bortezomib-based	3	2	4	0	0	1	1	Bortezomib/Dexamethasone	1	1681	123	Stem cell, Autologous	1	1							1097	1	156.71428571	1013	5	1	3	2	2	1			Baseline	1	63	Male					Checked			Hispanic or Latino		0	1
MMRF_1239	-33	No		1398	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1			1001		64	1	12	1001	Year 3	65	186	2	in	lb			79.56	1	1	IMIDs-based	4	3	1	0		0							0									0			4	4			2		1		Baseline	-28	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1436	-27															1	2	1	Yes	1	1	0	1.4565870431	2537		64	1	28	2537	Year 7	67	143	1	in	lb			106.08	0	1	IMIDs-based	4	3	1	0		0							0									0		707	1	1			2	1	1		Baseline	-4	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2595	-13	No	1213	1213	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	7.0504143359	1185		60	1	13	1185	Month 39	67	184	2	in	lb			70.72	2	2	combined bortezomib/IMIDs-based	1	1	4	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	92	116	Stem cell, Autologous	1	1	Bortezomib	260	344	84	1	1	360	1	51.428571429	269	5	1	3	2	2	2		1	Baseline	1	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1273	-27	No	113	113	Death	Other		RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1			50	113	71	1	2	112	Month 6	71	167	3	in	lb			53.04	1	1	Bortezomib-based		2	1	0		0							0									0		64	5	5			2	2	1		Baseline	-15	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1109	-23	No	117	117	Death	Other		STROKE	Neurological	2	1	1	2	6		1	2	1	Yes	1	1			60		70	1	1	60	Month 3	70	207	2	in	lb	Stage II	2	79.56	1	1	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	-23	70	Male					Checked			Not Hispanic or Latino	-23	0	1
MMRF_1117	-3	No	1332	1332	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1			1263		68	1	14	1263	Month 42	65	232	1	in	lb			79.56	1	1	combined bortezomib/IMIDs-based	3	1	5	0		0							0								255	1	36.428571429	164	5	3	2	2	2	2		1	Baseline	-2	68	Male					Checked			Hispanic or Latino	-3	0	1
MMRF_1146	-12	No		1653	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			1492		67	1	17	1492	Month 51	72	274	3	in	lb			167.96	0	1	IMIDs-based	4	3	2	0	0	1	1	Lenalidomide/Dexamethasone	1	184	201	Stem cell, Autologous	1	1	Lenalidomide	319	1194	875	2	2	1166	1	166.57142857	1081	3	3	2		2	1	1		Baseline	-12	67	Male					Checked			Not Hispanic or Latino	-12	0	1
MMRF_1184	-5	No		1821	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		2.2533158198	1815		71	1	20	1815	Year 5	65	113	2	in	lb	Stage I	1	88.4	1	1	IMIDs-based	4	3	1	0	1	1	1	Lenalidomide/Dexamethasone	1	199	161	Stem cell, Autologous	1	1	Lenalidomide	295	1815	1520	2	2		0		1731	1	1			2	1	1		Baseline	-4	71	Female					Checked			Not Hispanic or Latino	-4	0	1
MMRF_1250	-39															1	2	1	Yes	1	1	0	1.9450671517	2745		59	1	30	2745	Month 90	71	159	1	in	lb			88.4	0	1	IMIDs-based	4	3	1	0		0							0									0		2596	1	1			2	1	1		Baseline	-13	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1261	-6	No	1110	1110	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1		3.7231389508	1077		57	1	12	1077	Year 3	66	125	2	in	lb	Stage II	2	106.08	1	1	combined bortezomib/IMIDs-based	2	1	4	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	232	246	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	351	615	264	1	1	638	1	91.142857143	553	5	1	1	2	2	1		1	Baseline	-6	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1260	-5	No	1100	1100	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		1.3095418683	1058		84	1	12	1052	Year 3	65	134	1	in	lb	Stage II	2	88.4	1	2	Bortezomib-based	2	2	1	1		0							0									0		1023	5	5			2	1			Baseline	-8	84	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1295	-12															1	1	1	Yes	1	1			2706		65	1	30	2706	Month 90	63	158	2	in	lb			141.44	0	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0								1355	1	193.57142857	1263	3	3			2	1	1		Baseline	-12	65	Male					Checked			Hispanic or Latino		0	1
MMRF_1344	1															1	2	2	Yes	1	1	0	4.4308277822	2556		66	1	28	2556	Year 7	63	171	1	in	lb			53.04	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	106	169	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	361	2556	2195	2	2		0		2472	1	1			2	1	1		Baseline	1	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1453	-10	No		815	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	2	2.3260693703	773		51	1	9	773	Month 27	73	224	2	in	lb			70.72	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	106	137	Stem cell, Autologous	1	1	Lenalidomide	236	773	537	2	2		0		699	1	1			2	1	1		Baseline	-10	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1538	-8															1	2	1	Yes	1	1	0	1.9054427797	2420		66	1	26	2420	Month 78	68	260	2	in	lb			97.24	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		2352	1	1			2	1	1		Baseline	-7	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1588	-76															1	2	1	Yes	1	1	0	1.4591157353	2367		67	1	26	2367	Month 78	74	225	1	in	lb			88.4	1	1	Bortezomib-based	2	2	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	161	205	Stem cell, Autologous	1	1								0		2284	1	1	4		2	1	1		Baseline	-76	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1596	-6	No	382	382	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	5.9334123509	347		67	1	4	347	Year 1	171	176	2	cm	lb			87.516	1	1	combined bortezomib/IMIDs-based	1	1	4	1		0							0								272	1	38.857142857	185	5	1	2	4	2	2	1	1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1740	0	No		1076	Patient is lost to follow-up					2	1	5				1	1	1	Yes	1	1	0		989		83	1	11	989	Month 33	62	157	2	in	lb			106.08	3	2	IMIDs-based	4	3	2	0		0							0								712	1	101.71428571	659	3	3	4		2	1	1	1	Baseline	0	83	Male					Checked			Hispanic or Latino		0	1
MMRF_1794	-13	No	1707	1707	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	0		1686		79	1	19	1686	Month 57	152	66	2	cm	kg			99.008	1	2	Bortezomib-based	2	2	3	1		0							0									0		1651	5	1	1	5	2	1			Baseline	1	79	Male					Checked			Hispanic or Latino		0	1
MMRF_1932	-6															1	2	1	Yes	1	1	0	10.039327008	2220		65	1	24	2220	Year 6	71	149	2	in	lb			132.6	2	2	IMIDs-based	4	3	1	0		0							0									0		2141	1	1			2	1	1		Baseline	-6	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1980	-27														Middle Eastern	6	2	1	Yes	1	1			2169		67	1	24	2169	Year 6	61	145	1	in	lb			88.4	0	1	IMIDs-based	4	3	2	0		0							0								635	1	90.714285714	552	3	3	1		2	1	1	1	Baseline	0	67	Male						Checked	Middle Eastern	Not Hispanic or Latino		0	1
MMRF_2173	-7	No	1986	1986	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0		1764	1090	75	1	22	1986	Month 66	48	130	2	in	lb			167.96	1	1	Bortezomib-based	2	2	2	1		0							0									0			5	4	5		2				Baseline	-7	75	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2220	-4															1	2	2	Yes	1	1	2	1.4704368843	2024		56	1	22	2024	Month 66	68	161	2	in	lb			75.14	0	1	Bortezomib-based	2	2	2	1		0							0									0		1940	1	1	4		2	1	1		Baseline	1	56	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2587	-14	No		1590	Other		PT HAS BEEN PUT ON HOSPICE CARE			2	1	7				1	2	2	Yes	1	1	0	3.6126530703	1442		72	1	16	1442	Year 4	62	138	1	in	lb			88.4	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	134	138	138	Stem cell, Autologous	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	139	1442	1303	2	2		0		1200	1	1			2	1	1		Baseline	-6	72	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1216	-10	No	1345	1345	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	2	2.1372140192	1256		71	1	14	1256	Month 42	158	152	2	cm	lb			53.04	0	1	Bortezomib-based	3	2	3	0		0							0								1030	1	147.14285714	981	5	1	3	5	2	1		1	Baseline	-2	71	Female					Checked			Not Hispanic or Latino	-10	0	1
MMRF_1228	-2	No	1366	1366	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1259		70	1	14	1259	Month 42	181	115	1	cm	kg			79.56	0	1	Bortezomib-based		2	2	0		0							0								910	1	130	837	5	3	5		2	1		1	Baseline	-2	70	Male					Checked			Not Hispanic or Latino	-1	0	1
MMRF_1296	-12	No		667	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		5.066805987	506		81	1	6	506	Month 18	165	59	1	cm	kg			55.692	0	2	IMIDs-based	4	3	1	0		0							0									0			4	4			2		1		Baseline	-3	81	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1364	-5	No		364	Patient is lost to follow-up					2	1	5				1	1	1	Yes	1	1	1	14.772122904	268		56	1	3	268	Month 9	179	100	1	cm	kg			114.92	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		95	1	1			2	2	1		Baseline	-5	56	Male					Checked			Hispanic or Latino		0	1
MMRF_1531	-12	No	520	520	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	2.6747607022	514		63	1	6	514	Month 18	73	84	3	in	kg			133.484	1	1	Bortezomib-based	2	2	1	1		0							0								475	1	67.857142857	405	5	5			2	1	1	1	Baseline	-12	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1659	1	No	1785	1785	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	4.1478514457	1604		50	1	18	1604	Month 54	182	81	3	cm	kg			132.6	1	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	0	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	507	1772	508	Stem cell, Autologous	1	1	Carfilzomib	1773	1773	0	1	1	715	1	102.14285714	618	5	1	5		2	1		1	Baseline	1	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1691	-29															1	2	1	Yes	1	1			2302		62	1	26	2302	Month 78	170	111	3	cm	kg			449.956	2	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	118	487	385	Stem cell, Autologous	1	1	Lenalidomide	488	599	111	1	1		0		2128	1	1			2	1	1		Baseline	-29	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1803	-13															1	2	1	Yes	1	1	2		2206		65	1	24	2206	Year 6	175	84	2	cm	kg			140.556	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	182	143	Stem cell, Autologous	1	1								0		2038	1	1			2	1	1		Baseline	-13	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1810	1	No		1827	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	2.6636975839	1826		61	1	20	1826	Year 5	177	88	1	cm	kg			106.08	1	1	combined bortezomib/IMIDs-based	4	1	3	0	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	161	994	162	Stem cell, Autologous	1	1	Bortezomib/Dexamethasone	995	999	4	1	1	804	1	114.85714286	547	3	3	1	3	2	1	1	1	Baseline	1	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1831	-3	No	1918	1918	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	4.1228169598	1507		69	1	17	1507	Month 51	173	99	1	cm	kg			83.096	0	1	Bortezomib-based		2	1	1		0							0									0		1812	5	5			2	1			Baseline	-3	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1917	-21	No		807	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0	1.5442868867	718		54	1	8	718	Year 2	186	128	1	cm	kg			96.356	0	1	combined IMIDs/carfilzomib-based	8	4	2	1		0							0								690	1	98.571428571	597	3	3	4		2	1	1	1	Baseline	-21	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2290	0	No	139	139	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	6.9799326771	99	139	79	1	2	139	Month 6	161	63	2	cm	kg			54.808	2	2	IMIDs-based	4	3	1	0		0							0									0		75	5	5			2	2	1		Baseline	9	79	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2461	-14	No	1102	1102	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	1.5038296768	1071		87	1	12	1071	Year 3	159	40	2	cm	kg			102.544	2	2	Bortezomib-based	3	2	2	0		0							0								499	1	71.285714286	442	5	3	5		2	1		1	Baseline	-14	87	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1254	-12	No	1730	1730	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1576		87	1	18	1576	Month 54	61	135	1	in	lb			114.92	1	2	Bortezomib-based	3	2	3	0		0							0								283	1	40.428571429	227	5	1	2	5	2	2		1	Baseline	-12	87	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1348	-13	No		423	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0	1.6126472133	274		68	1	3	274	Month 9	183	108	1	cm	kg			141.44	1	1	Bortezomib-based	3	2	1	0		0							0									0		92	1	1			2	2	1		Baseline	1	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1371	-10															1	2	1	Yes	1	1		2.3756056585	2548		61	1	28	2548	Year 7	191	99	1	cm	kg			79.56	1	1	combined bortezomib/IMIDs-based	3	1	2	0	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	264	264	292	Stem cell, Autologous	1	1	Lenalidomide	404	2290	1886	2	2	2280	1	325.71428571	2022	3	3	4		2	1	1		Baseline	-10	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1377	-12															1	2	1	Yes	1	1	0		2535		67	1	28	2535	Year 7	182	117	1	cm	kg	Stage I	1	132.6	1	1	Bortezomib-based	2	2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	143	207	Stem cell, Autologous	1	1							774	1	110.57142857	697	3	1	1		2	1	1	1	Baseline	-4	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1703	-12	No	1554	1554	Death	Other		PROSTATE CANCER	Other	2	1	1	2	10		1	2	1	Yes	1	1			1415		74	1	16	1415	Year 4	178	90	2	cm	kg			88.4	1	1	combined bortezomib/IMIDs-based	2	1	2	1		0							0								563	1	80.428571429	493	5	3	5		2	1		1	Baseline	-12	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2166	1	No		106	Other		INVESTIGATOR REMOVED PT. BECAUSE TREATMENT STOPPED AND WENT INTO HOSPICE			2	1	7				1	2	1	Yes	1	1			26		88	1	1	26	Month 3	69	170	2	in	lb			88.4	2	2	IMIDs-based	4	3	1	0		0							0												4	4			2		1		Baseline	14	88	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2324	-21															1	2	1	Yes	1	1	0		1864		66	1	20	1864	Year 5	71	215	2	in	lb			88.4	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	126	155	Stem cell, Autologous	1	1	Lenalidomide	275	1864	1589	2	2		0		1809	1	1			2	1	1		Baseline	-21	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2326	-19	No	1933	1933	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	1.4718864331	1820		72	1	20	1820	Year 5	72	202	1	in	lb			99.892	0	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	203	163	Stem cell, Autologous	1	1	Lenalidomide	281	1543	1262	2	2	1536	1	219.42857143	1480	5	3	5		2	1			Baseline	-25	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1090	-5	No	681	681	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	1		526	681	68	1	7	681	Month 21	170	74	3	cm	kg			154.7	0	1	combined bortezomib/IMIDs-based		1	2	1		0							0								435	1	62.142857143		5	4	5		2		1	1	Baseline	-5	68	Female			Checked					Not Hispanic or Latino	-5	0	1
MMRF_1122	-17	No	697	697	Death	Disease progression				2	1	1	1		Middle Eastern	6	2	1	Yes	1	1			694	697	52	1	9	697	Month 27	171	88	3	cm	kg			76.908	0	1	combined bortezomib/IMIDs-based	3	1	3	0		0	2	Lenalidomide	176	229	234	Stem cell, Autologous	1	0							143	1	20.428571429	16	5	3	4	5	2	2	1	1	Baseline	-17	52	Male						Checked	Middle Eastern	Not Hispanic or Latino	-17	0	1
MMRF_1386	-8															2	2	2	Yes	1	1	0	1.4864809836	2555		54	1	28	2555	Year 7	152	179	1	cm	lb			128.18	0	1	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		2471	1	1			2	1	1		Baseline	-8	54	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1403	-8															1	2	2	Yes	1	1	0	2.0607943517	2563		62	1	28	2563	Year 7	171	172	2	cm	lb			103.428	0	1	combined IMIDs/carfilzomib-based	7	4	3	0		0	2	Lenalidomide/Melphalan	940	944	945	Stem cell, Autologous	1	0	Lenalidomide	1045	1506	461	2		904	1	129.14285714	820	3	3	1	1	2	1	1	1	Baseline	-8	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1458	-26	No	1569	1864	Patient is lost to follow-up					2	1	5			Unknown	6	3	1	Yes	1	1		2.1829636754	1864	1569	79	1	20	1864	Year 5	170	170	3	cm	lb			122.876	1	2	combined IMIDs/carfilzomib-based	7	4	2	0		0							0								1339	1	191.28571429	1254	5	3	5		2	1			Baseline	-10	79	Male						Checked	Unknown	Other		0	1
MMRF_1462	-13														Unknown	6	2	1	Yes	1	1	1	1.7411723574	2544		59	1	28	2544	Year 7	176	262	1	cm	lb			73.372	1	1	combined IMIDs/carfilzomib-based	7	4	3	0		0	3	Carfilzomib/Pomalidomide/ACY-241/Dexamethasone	1130	2544	1130	Stem cell, Autologous	1	0							625	1	89.285714286	541	3	3	1	1	2	1	1	1	Baseline	1	59	Male						Checked	Unknown	Not Hispanic or Latino		0	1
MMRF_1493	-11	No		897	Patient is lost to follow-up					2	1	5			Unknown	6	3	1	Yes	1	1			1083		70	1	11	1083	Month 33	173	88	2	cm	kg			122.876	1	1	combined bortezomib/IMIDs/carfilzomib-based	7	5	1	0		0							0									0		999	1	1			2	1	1		Baseline	1	70	Male						Checked	Unknown	Other		0	1
MMRF_1608	-4															1	2	1	Yes	1	1	0		2374		61	1	26	2374	Month 78	168	90	2	cm	kg			91.052	1	1	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		2207	1	1			2	1	1		Baseline	-4	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1662	-1															1	2	1	Yes	1	1			2394		78	1	26	2394	Month 78	174	220	2	cm	lb			49.504		2	IMIDs-based		3	1	1		0							0									0		2297	1	1			2	1	1		Baseline	-1	78	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1689	1															1	2	1	Yes	1	1	1	4.8035511863	2381		90	1	26	2381	Month 78	170	86	3	cm	kg			176.8		2	combined bortezomib/IMIDs-based	2	1	2	1		0							0								1198	1	171.14285714	1112	3	3	1		2	1	1		Baseline	1	90	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1718	-8	No	682	682	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	1.8707468265	624	682	60	1	8	653	Year 2	177	92	1	cm	kg			124.644	1	1	combined IMIDs/carfilzomib-based	7	4	2	0		0	2	Bortezomib/Cyclophosphamide/Dexamethasone	418	449	470	Stem cell, Autologous	1	0							405	1	57.857142857	314	5	3	5		2	2	1	1	Baseline	15	60	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1733	-13															1	2	1	Yes	1	1	0	1.8307954445	1563		50	1	17	1563	Month 51	178	62	1	cm	kg			86.632	1	1	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		1472	1	1			2	1	1		Baseline	-13	50	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1775	-7															2	2	1	Yes	1	1	0	1.2324507808	2322		54	1	26	2322	Month 78	175	85	1	cm	kg			91.936	1	1	combined IMIDs/carfilzomib-based	7	4	1	0	0	1	1	Carfilzomib/Dexamethasone	1	168	175	Stem cell, Autologous	1	1	Lenalidomide/CLARITHROMYCIN/Dexamethasone	184	267	83	1	1		0		2238	1	1			2	1	1		Baseline	1	54	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1795	-11															1	2	2	Yes	1	1	1	1.5234381127	2167		75	1	24	2167	Year 6	158	69	3	cm	kg			182.104	1	1	Carfilzomib-based		9	3	0		0							0								1293	1	184.71428571	1209	3	3	4	1	2	1	1		Baseline	1	75	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1825	-6															1	2	1	Yes	1	1	2	1.388472965	2200		54	1	24	2200	Year 6	180	93	2	cm	kg			102.544	1	1	combined IMIDs/carfilzomib-based	8	4	3	1		0	3	Lenalidomide/Melphalan	1111	1115	1116	Stem cell, Autologous	1	0	Lenalidomide	1215	2200	985	2		821	1	117.28571429	737	3	3	1	1	2	1	1	1	Baseline	1	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1835	-17															1	2	1	Yes	1	1	0	2.0078960123	2187		66	1	24	2187	Year 6	173	77	2	cm	kg			75.14	1	1	combined IMIDs/carfilzomib-based	7	4	2	0		0							0								1969	1	281.28571429	1909	3	3	4		2	1	1		Baseline	-17	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1855	-6	No		826	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0	3.2260869946	826		62	1	9	826	Month 27	160	67	1	cm	kg			51.272	1	1	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		735	1	1			2	1	1		Baseline	-6	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1935	-8															1	2	1	Yes	1	1		2.2112695791	2191		46	1	24	2191	Year 6	187	102	1	cm	kg			91.052	0	1	combined IMIDs/carfilzomib-based	8	4	5	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	1	611	285	Stem cell, Autologous	1	1							600	1	85.714285714	510	3	3	3	3	2	1	1	1	Baseline	-8	46	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1985	-15															1	2	2	Yes	1	1	0	1.6191694469	2182		52	1	24	2182	Year 6	172	118	2	cm	kg			43.316	1	2	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		2091	1	1			2	1	1		Baseline	-15	52	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2072	-17															1	2	2	Yes	1	1		2.117476876	1493		73	1	16	1493	Year 4	154	55	1	cm	kg			61.88	1	1	combined IMIDs/carfilzomib-based	7	4	2	0		0							0								1096	1	156.57142857	1005	3	1	2		2	1	1		Baseline	-17	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2095	-18															1	2	2	Yes	1	1	0		1992		84	1	22	1992	Month 66	154	66	2	cm	kg			127.296	1	2	Bortezomib-based	9	2	3	1		0							0								463	1	66.142857143	373	3	3	3	2	2	1	1	1	Baseline	-18	84	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2159	-5															1	2	2	Yes	1	1	0		2088		59	1	22	2088	Month 66	165	91	1	cm	kg			73.372	1	1	combined IMIDs/carfilzomib-based	7	4	2	0	0	1	1	Lenalidomide/CLARITHROMYCIN/Dexamethasone	91	455	1151	Stem cell, Autologous	1	1							1079	1	154.14285714	904	3	3	1		2	1	1	1	Baseline	-5	59	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2237	-33														Declined	6	2	1	Yes	1	1	0		2003		45	1	22	2003	Month 66	175	83	1	cm	kg			96.356	2	2	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		1912	1	1			2	1	1		Baseline	-16	45	Male						Checked	Declined	Not Hispanic or Latino		0	1
MMRF_2236	-12	No		944	Patient is lost to follow-up					2	1	5			Declined	6	2	2	Yes	1	1	0	1.8971849499	827		58	1	9	827	Month 27	157	65	2	cm	kg			39.78	1	2	Carfilzomib-based	7	9	1	0		0							0									0		736	1	1			2	1	1		Baseline	-12	58	Female						Checked	Declined	Not Hispanic or Latino		0	1
MMRF_2244	-12														Declined	6	3	2	Yes	1	1	2		1776		50	1	19	1776	Month 57	175	112	2	cm	kg			76.908	1	1	combined IMIDs/carfilzomib-based	7	4	2	0		0							0								554	1	79.142857143	462	3	3	3		2	1	1	1	Baseline	-17	50	Female						Checked	Declined	Other		0	1
MMRF_2281	-17															1	2	1	Yes	1	1	0		1620		51	1	17	1620	Month 51	175	92	1	cm	kg			106.964	1	1	combined IMIDs/carfilzomib-based	7	4	5	0		0	5	Lenalidomide/Melphalan	1396	1400	1401	Stem cell, Autologous	1	0	Lenalidomide	1502	1605	103	1		1081	1	154.42857143	989	3	1	4	2	2	1	1	1	Baseline	-17	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2292	-20														Declined	6	3	2	Yes	1	1	0		1983		73	1	22	1983	Month 66	158	97	2	cm	kg			53.924	1	1	Bortezomib-based	2	2	2	1		0							0								906	1	129.42857143	815	3	1	1		2	1	1	1	Baseline	-20	73	Female						Checked	Declined	Other		0	1
MMRF_2325	-25														Unknown	6	3	1	Yes	1	1	0	1.5029729249	1969		44	1	22	1969	Month 66	175	84	1	cm	kg			106.964	1	1	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		1878	1	1			2	1	1		Baseline	-25	44	Male						Checked	Unknown	Other		0	1
MMRF_2363	-13															1	2	2	Yes	1	1	0	1.8338398056	1821		52	1	20	1821	Year 5	167	69	1	cm	kg			64.532	1	1	combined IMIDs/carfilzomib-based	7	4	3	0		0	2	Lenalidomide/Melphalan	381	385	386	Stem cell, Autologous	1	0	Ixazomib	619	829	210	1		818	1	116.85714286	728	3	1	1	1	2	1	1	1	Baseline	-13	52	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2394	-9														Unknown	6	3	1	Yes	1	1	0	4.8656885474	1826		66	1	20	1826	Year 5	185	71	1	cm	kg			77.792	2	2	combined IMIDs/carfilzomib-based	7	4	5	0		0	5	Daratumumab/Dexamethasone	1016	1023	1028	Stem cell, Autologous	1	0	Bortezomib	1148	1223	75	1		440	1	62.857142857	352	3	3	1	3	2	2	1	1	Baseline	-9	66	Male						Checked	Unknown	Other		0	1
MMRF_2399	-4														Unknown	6	2	1	Yes	1	1	0	1.3263028371	1821		53	1	20	1821	Year 5	170	85	1	cm	kg			101.66	1	1	combined IMIDs/carfilzomib-based	7	4	3	0		0	3	Lenalidomide/Melphalan	1322	1326	1327	Stem cell, Autologous	1	0	Lenalidomide	1435	1821	386	2			0		1730	1	1	1	1	2	1	1		Baseline	-7	53	Male						Checked	Unknown	Not Hispanic or Latino		0	1
MMRF_2453	-6														Declined	6	3	2	Yes	1	1	0	3.1906058613	1682		58	1	19	1682	Month 57	173	48	2	cm	kg			209.508	2	2	Bortezomib-based	2	2	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	301	312	Stem cell, Autologous	1	1								0		1410	1	1	1		2	1	1		Baseline	-6	58	Female						Checked	Declined	Other		0	1
MMRF_2503	-12															1	2	1	Yes	1	1	0		1800		67	1	20	1800	Year 5	180	105	1	cm	kg			83.096	1	1	combined IMIDs/carfilzomib-based	7	4	3	0		0	2	CC-122/CC-122 (PLEIOTROPIC PATHWAY MODIFIER ML-122)/Dexamethasone	1002	1506	1550	Stem cell, Autologous	1	0							911	1	130.14285714	820	3	1	3	1	2	1	1	1	Baseline	-12	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2522	-27														Declined	6	3	2	Yes	1	1	0	2.2056918628	1808		60	1	20	1808	Year 5	65	230	1	in	lb			62.764		2	combined IMIDs/carfilzomib-based	7	4	1	0		0							0									0		1717	1	1			2	1	1		Baseline	-27	60	Female						Checked	Declined	Other		0	1
MMRF_2524	-26														Declined	6	3	2	Yes	1	1	0	1.7593916138	1710		65	1	19	1710	Month 57	66	233	2	in	lb			65.416		2	Carfilzomib-based	7	9	1	0		0							0									0		1619	1	1			2	1	1		Baseline	-26	65	Female						Checked	Declined	Other		0	1
MMRF_2599	-5														Declined	6	3	2	Yes	1	1	0	1.7139882605	1816		71	1	20	1816	Year 5	63	54	2	in	kg			58.344		2	combined IMIDs/carfilzomib-based	7	4	2	0		0							0									0		1725	1	1	1		2	1	1		Baseline	-5	71	Female						Checked	Declined	Other		0	1
MMRF_1120	1	Yes		2957						1	2					2	2	1	Yes	1	1			2777		51	1	30	2777	Month 90	180	149	2	cm	kg			82.212	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	237	237	239	Stem cell, Autologous	1	1	Lenalidomide	473	1405	932	2	2		0		2658	1	1			2	1	1		Baseline	1	51	Male			Checked					Not Hispanic or Latino	1	0	1
MMRF_1140	1	Yes		2928						1	2					1	2	2	Yes	1	1			2926		62	1	32	2926	Year 8	153	84	1	cm	kg			56.576	1	1	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	330	331	Stem cell, Autologous	1	1	Bortezomib	451	1955	1504	2	2		0		2849	1	1	1		2	1	1		Baseline	1	62	Female					Checked			Not Hispanic or Latino	1	0	1
MMRF_1167	6	No	950	950	Death	Other		METASTATIC ESOPHAGEAL ADENOCARCINOMA	Secondary Malignancy	2	1	1	2	8		1	2	1	Yes	1	1	0	6.8498282984	919	950	74	1	11	948	Month 33	183	111	2	cm	kg			53.924	3	2	Bortezomib-based	3	2	2	0		0							0								652	1	93.142857143	463	5	1	5		2	1		1	Baseline	11	74	Male					Checked			Not Hispanic or Latino	11	0	1
MMRF_1336	-29	No		962	Noncompliance with study procedures					2	1	2				1	2	2	Yes	1	1			980		71	1	11	980	Month 33	162	60	2	cm	kg			62.764	1	1	combined bortezomib/IMIDs-based	9	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	276	360	408	Stem cell, Autologous	1	1	Bortezomib	616	933	317	1	1		0		706	1	1			2	1	1		Baseline	1	71	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1587	-10	No	629	629	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	3.879381484	564	629	74	1	7	620	Month 21	181	195	3	cm	lb			159.12	0	1	Bortezomib-based	2	2	2	1		0							0								204	1	29.142857143	120	5	3	5		2	2	1	1	Baseline	1	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1857	-12	No		1729	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1		1.489114648	1636		71	1	16	1443	Year 4	62	57	2	in	kg			70.72	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	124	219	250	Stem cell, Autologous	1	1	Lenalidomide	377	1443	1066	2	2		0		1449	1	1			2	1	1		Baseline	-5	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2297	-12															1	2	1	Yes	1	1	2	1.4507427182	1831		58	1	22	2009	Month 66	177	80	2	cm	kg			68.952	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Dexamethasone	199	210	276	Stem cell, Autologous	1	1	Bortezomib	406	1234	828	2	2	1831	1	261.57142857	1811	3	3			2	1	1		Baseline	1	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2302	-37															1	2	1	Yes	1	1		1.9840906884	1839		77	1	20	1839	Year 5	179	88		cm	kg			99.892	1	2	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		1756	1	1			2	1	1		Baseline	-2	77	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2352	-5															1	2	1	Yes	1	1	1	1.9321433563	1975		60	1	22	1975	Month 66	174	76	3	cm	kg			318.24	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	139	151	Stem cell, Autologous	1	1	Lenalidomide	307	1975	1668	2	2		0		1716	1	1			2	1	1		Baseline	-5	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2464	-33															1	2	2	Yes	1	1	0	1.3219322734	1843		62	1	20	1843	Year 5	170	102	2	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	56	121	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	210	244	34	1	1		0		1758	1	1			2	1	1		Baseline	-3	62	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2217	-3	No	1674	1674	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1		1633		60	1	18	1633	Month 54	177	85	3	cm	kg			150.28		2	Bortezomib-based	2	2	5	1		0							0								970	1	138.57142857	873	5	3	3	4	2	1		1	Baseline	4	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1629	-14															1	2	1	Yes	1	1	2		2337		61	1	26	2337	Month 78	173	109	2	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	189	206	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide	350	1707	1357	2	2	1721	1	245.85714286	1638	3	1	1		2	1	1		Baseline	-4	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1380	-16															2	2	1	Yes	1	1	2	1.5721310698	2508		63	1	28	2508	Year 7	67	190	2	in	lb			106.08	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1		0							0									0		2431	1	1			2	1	1		Baseline	-3	63	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1432	1	No	401	401	Death	Other		SECONDARY MALIGNANCY	Secondary Malignancy	2	1	1	2	8		1	2	1	Yes	1	1	2	9.2070189623	348	401	67	1	5	398	Month 15	72	261	3	in	lb			159.12	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								278	1	39.714285714	219	5	3	5		2	2	1	1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1460	-2	No		258	Inter-current illness that interferes with study assessments					2	1	4				2	2	1	Yes	1	1	1	2.1453175965	257		85	1	3	257	Month 9	71	175	3	in	lb			167.96	3	2	Bortezomib-based	3	2	1	0		0							0									0		165	1	1			2	2	1		Baseline	1	85	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1542	-19	No	1137	1137	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1	2.4255007275	1093	1137	72	1	13	1136	Month 39	71	175	3	in	lb			176.8	0	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								485	1	69.285714286	330	5	3	5		2	2		1	Baseline	-19	72	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1646	-5	No	23	23	Death	Other		ASPIRATION PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	1	Yes	1	1	1			23	82	1	1	23	Month 3	67	197	3	in	lb			397.8	3	2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	-5	82	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1647	-18	No	936	936	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1		910	936	80	1	11	935	Month 33	170	86	3	cm	kg			521.56	1	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		859	5	5			2	1			Baseline	-4	80	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1778	0	No	19	19	Death	Other		RENAL FAILURE		2	1	1	1			1	2	1	Yes	1	1	1	2.3751191879		19	82	1	1	19	Month 3	65	183	3	in	lb			601.12	4	2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	0	82	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2058	-24															2	2	1	Yes	1	1			1961		63	1	22	1961	Month 66	69	167		in	lb			70.72	1	1	IMIDs-based	4	3	1	0		0							0									0		1885	1	1			2	1	1		Baseline	-24	63	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2079	-29	No		157	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1	0	1.2983466925	157		62	1	2	157	Month 6	66	130	2	in	lb			88.4	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		93	1	1			2	2	1		Baseline	-29	62	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2143	-12	No	841	841	Death	Other		ADENOCARCINOMA, HEART AND LIVER FAILURE	Cardiovascular	2	1	1	2	1		2	2	1	Yes	1	1	0	1.5496524808	791	841	64	1	10	840	Month 30	70	211	2	in	lb			132.6	2	2	IMIDs-based	4	3	1	0		0							0									0		738	5	5			2	1			Baseline	-7	64	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2204	-9	No	616	616	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1		1.9021876276	492	616	82	1	7	611	Month 21	71	208		in	lb			185.64	2	2	IMIDs-based	4	3	2	0		0							0								93	1	13.285714286		5	2	5		1		1	1	Baseline	-9	82	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2362	1	Yes		1827	Patient no longer consents to participate in the study					1	2	3				2	2	1	Yes	1	1		2.9360539581	1767		65	1	20	1767	Year 5	68	172	2	in	lb			88.4	3	2	combined bortezomib/IMIDs/carfilzomib-based	3	5	1	0		0							0								1162	1	166	1064	3	3			2	1	1		Baseline	1	65	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2487	1															1	1	1	Yes	1	1		1.7059230894	1894		63	1	20	1894	Year 5	73	186	2	in	lb			70.72	2	2	Bortezomib-based	3	2	1	0	1	1	1	Bortezomib/Dexamethasone	1	226	260	Stem cell, Autologous	1	1	Bortezomib	435	897	462	2	2	1283	1	183.28571429	1191	3	3			2	1	1		Baseline	1	63	Male					Checked			Hispanic or Latino		0	1
MMRF_2581	-7	No	360	360	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	1.6700199759	283	360	72	1	4	359	Year 1	67	117	2	in	lb			79.56	3	2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	1	72	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1504	-7	No	2424	2424	Death	Other		INFLUENZA A&B, PNEUMONIA, MULTIPLE MYELOMA	Other	2	1	1	2	10		1	2	2	Yes	1	1		2.5815108816	2380		73	1	26	2380	Month 78	163	82	3	cm	kg			132.6	0	1	combined bortezomib/IMIDs-based	1	1	5	1		0							0								950	1	135.71428571	867	5	3	4	2	2	1		1	Baseline	-7	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2055	-33	No	1662	1662	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1	1	1.9447588477	1557	1295	84	1	18	1655	Month 54	150	66	3	cm	kg			176.8	2	2	IMIDs-based	4	3	2	0		0							0									0		1569	5	1	5		2	1			Baseline	-7	84	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2253	-13	No	744	744	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.755931687	716		61	1	8	716	Year 2	176	87	2	cm	kg			61.88	1	1	combined bortezomib/IMIDs-based	1	1	2	1	0	1	1	Melphalan/Dexamethasone	164	166	166	Stem cell, Autologous	1	1	Lenalidomide	260	495	235	1	1	716	1	102.28571429	653	5	1	5		2	1		1	Baseline	-16	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1349	-3	No	1150	1150	Death	Other		UNKNOWN-MEDICAL  EXAMINER CASE, AUTOPSY RESULTS PENDING	Unknown	2	1	1	2	9		2	2	1	Yes	1	1	2	1.7503954771	1078	1150	85	1	13	1149	Month 39	170	59	3	cm	kg			477.36	1	2	Bortezomib-based	3	2	1	0		0							0								772	1	110.28571429	720	5	5			2	1		1	Baseline	-2	85	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1332	-2	No		712	Patient is lost to follow-up					2	1	5				2	2	1	Yes	1	1		2.0356373416	515		32	1	7	1277	Month 21	68	179	1	in	lb			113.152	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	167	201	Stem cell, Autologous	1	1	Lenalidomide	310	1277	967	2	2		0		1204	1	1			2	1	1		Baseline	1	32	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1365	1	No		643	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	0		375		65	1	4	375	Year 1	64	58	2	in	kg			110.5	2	2	Bortezomib-based	2	2	1	1	0	1	1	Bortezomib/Cyclophosphamide	60	375	307	Stem cell, Autologous	1	1											4	4			2		1		Baseline	0	65	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1425	0	No	1260	1260	Death	Other		ACUTE CORONARY SYNDROME	Cardiovascular	2	1	1	2	1		2	2	1	Yes	1	1	1	1.375064539	1256		74	1	14	1256	Month 42	69	197	3	in	lb			834.496	2	2	Bortezomib-based	3	2	1	0		0							0									0		1167	5	5			2	1			Baseline	0	74	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1451	0	No	154	154	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	4.1112272382	91	154	65	1	2	152	Month 6	66	170	3	in	lb			309.4	1	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		64	5	5			2	2	1		Baseline	-5	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1501	-1	No	891	891	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	2	2.5147317342	873	891	65	1	11	891	Month 33	165	93	2	cm	kg			318.24	1	1	combined bortezomib/IMIDs-based	3	1	3	0		0							0								370	1	52.857142857	277	5	3	4	2	2	2		1	Baseline	-2	65	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1525	-85															2	2	2	Yes	1	1	0		2407		63	1	28	2407	Year 7	65	175	1	in	lb			114.92	0	1	combined bortezomib/IMIDs-based	3	1	4	0		0							0								979	1	139.85714286	890	3	3	2	1	2	1	1	1	Baseline	-99	63	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1519	0	No	647	647	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	3.2274434594	627	647	88	1	8	647	Year 2	193	114	3	cm	kg			124.644	1	2	combined bortezomib/IMIDs-based	3	1	2	0		0							0								279	1	39.857142857	106	5	1	5		2	2	1	1	Baseline	0	88	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1627	0	No	1574	1574	Death	Other		HEART FAILURE	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	2	2.2303553352	1526	1574	82	1	18	1574	Month 54	65	136	3	in	lb			167.96	2	2	combined bortezomib/IMIDs-based	3	1	4	0		0							0								581	1	83	485	5	3	3	2	2	1		1	Baseline	-1	82	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1633	-1	No		420	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1	1	5.2278154981	247		54	1	3	247	Month 9	60	244	3	in	lb			161.772	3	2	Bortezomib-based	3	2	1	0		0							0									0		150	1	1			2	2	1		Baseline	-2	54	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1639	1	No	704	704	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	1		650	704	67	1	8	701	Year 2	64	186	3	in	lb			139.672	3	2	combined bortezomib/IMIDs-based	3	1	2	0		0							0								531	1	75.857142857	448	5	1	5		2	1	1	1	Baseline	1	67	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1645	-1															2	2	1	Yes	1	1	1	3.9747018033	2364		36	1	26	2364	Month 78	68	173	3	in	lb			1986.348	2	2	combined bortezomib/IMIDs-based	2	1	1	1	0	1	1	Lenalidomide/Dexamethasone	180	439	440	Stem cell, Autologous	1	1	Lenalidomide						370	1	52.857142857	280	3	3			2	2	1	1	Baseline	1	36	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1651	-5	No	642	642	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	1.4508899317	635		54	1	7	607	Month 21	73	222	3	in	lb			100.776	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0								606	1	86.571428571	536	5	5			2	1	1	1	Baseline	1	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1650	-10	No		997	Other		HOSPICE			2	1	7				2	2	2	Yes	1	1	1		997		82	1	11	997	Month 33	62	139	3	in	lb			267.852	1	2	combined bortezomib/IMIDs-based	3	1	2	0		0							0								458	1	65.428571429	279	3	3	2		2	2	1	1	Baseline	-6	82	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1672	-27															1	2	2	Yes	1	1	1	1.3627019197	2322		57	1	26	2310	Month 78	62	146	3	in	lb			433.16	0	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		2252	1	1			2	1	1		Baseline	-30	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1693	1															2	2	1	Yes	1	1			2378		62	1	26	2364	Month 78	66	191	1	in	lb			70.72	1	1	combined bortezomib/IMIDs-based	3	1	2	0	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	145	166	257	Stem cell, Autologous	1	1	Lenalidomide	532	2364	1832	2	2	2175	1	310.71428571	2093	3	3	4		2	1	1		Baseline	1	62	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1780	-1	No	849	849	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1	15.629534901	806	849	65	1	10	849	Month 30	187	118	3	cm	kg			110.5	1	1	combined bortezomib/IMIDs-based	3	1	3	0		0							0								552	1	78.857142857	476	5	1	2	5	2	1		1	Baseline	-4	65	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1897	0	No	237	237	Death	Other		CARDIOPULMONAYR ARREST, RENAL FAILUE, MULTPLE MYELOMA		2	1	1	1			1	2	1	Yes	1	1		5.1596292441	69		57	1	1	69	Month 3	191	105	3	cm	kg			419.9	3	2	Bortezomib-based	10	2	1	0		0							0												5	5			2		1		Baseline	0	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1922	-9															1	2	1	Yes	1	1	2	6.6207875363	2176		58	1	24	2176	Year 6	185	104	3	cm	kg			95.472	1	1	IMIDs-based	11	3	3	0		0	2	Bortezomib	1	169	236	Stem cell, Autologous	1	0	Daratumumab/Dexamethasone							0			1	4	1	1	2		1		Baseline	-13	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1945	-2	No		213	Patient is lost to follow-up					2	1	5				2	2	2	Yes	1	1			59		44	1	1	59	Month 3	163	109	3	cm	kg			107.848	3	2	Bortezomib-based	3	2	1	0		0							0												4	4			2		1		Baseline	-2	44	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1994	-3	No		272	Other		PT ADMITTED TO HOSPICE.			2	1	7				1	2	2	Yes	1	1	1		249		89	1	3	272	Month 9	149	54	3	cm	kg			61.88	1	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0								174	1	24.857142857		2	2			2		1	1	Baseline	-3	89	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2160	-13	No	79	79	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1				79	68	1	1	79	Month 3	172	89	3	cm	lb			103.428	1	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0												5	5			2		1		Baseline	-8	68	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2478	-6															2	2	1	Yes	1	1		1.5891441512	1854		52	1	20	1854	Year 5	69	168		in	lb			256.36	1	1	Bortezomib-based	2	2	4	1		0							0								209	1	29.857142857	120	3	1	3	4	2	2	1	1	Baseline	13	52	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2505	0	No	881	881	Death	Other		ACUTE ENCEPHALOPATHY - PATEINT HAD RECENLTY PROGRESSED WITH MM	Secondary Malignancy	2	1	1	2	8		2	2	1	Yes	1	1	2	2.3624876163	787	881	68	1	10	880	Month 30	69	88	2	in	kg			134.368		2	combined bortezomib/IMIDs-based	4	1	2	0		0							0								703	1	100.42857143	600	5	3	5		2	1		1	Baseline	-6	68	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2504	-1	No		1157	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1			1157		32	1	13	1157	Month 39	65	60	2	in	kg			93.704	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	119	185	201	Stem cell, Autologous	1	1								0		1084	1	1			2	1	1		Baseline	13	32	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2523	-10	No	666	666	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1	1	1.8326847415	584	666	55	1	8	665	Year 2	59	119	3	in	kg			238.68	1	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0								584	1	83.428571429	519	5	5			2	1	1	1	Baseline	-23	55	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2589	-3	No	911	911	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1			794	911	61	1	10	879	Month 30	70	186	1	in	lb			60.996		2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	327	376	Stem cell, Autologous	1	1	Lenalidomide	519	712	193	1	1	794	1	113.42857143	643	5	1	5		2	1		1	Baseline	-3	61	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1607	-13															2	2	1	Yes	1	1	0		2229		57	1	24	2229	Year 6	71	169	1	in	lb			159.12	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	2229	203	Stem cell, Autologous	1	1								0		2131	1	1			2	1	1		Baseline	1	57	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1605	-16															2	2	1	Yes	1	1	0	1.6308368402	2184		47	1	24	2184	Year 6	68	263	2	in	lb			104.312	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	522	252	Stem cell, Autologous	1	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	523	525	2	1	1		0		2138	1	1			2	1	1		Baseline	-9	47	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1939	-12	No	328	328	Death	Other		UNKNOWN PHONE CALL FROM FAMILY MEMBER	Unknown	2	1	1	2	9		2	2	1	Yes	1	1			262	328	68	1	4	328	Year 1	72	235	3	in	lb			117.572	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		256	5	5			2	2	1		Baseline	-9	68	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2035	1	No		142	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	1	3.9917188006	86		73	1	1	86	Month 3	73	180	3	in	lb			423.436	2	2	Bortezomib-based	3	2	1	0		0							0									0		1	1	1			2	2	1		Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2493	-6															1	2	1	Yes	1	1			1613		68	1	18	1653	Month 54	71	266	3	in	lb			131.716	1	1	combined bortezomib/IMIDs-based	4	1	1	0		0							0									0		1549	1	1			2	1	1		Baseline	-6	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1470	-2	No		1081	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1		2.4882077227	964		70	1	11	964	Month 33	58	113	2	in	lb			68.952	3	2	IMIDs-based	4	3	1	0		0							0								964	1	137.71428571	618	3	3			2	1	1	1	Baseline	-2	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1820	-19															1	2	2	Yes	1	1	0		2207		49	1	24	2147	Year 6	66	144	2	in	lb			141.44	0	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	1	1	1	1	1	Carfilzomib	164	179	193	Stem cell, Autologous	1	1								0		2123	1	1			2	1	1		Baseline	-20	49	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2115	-10	No	21	21	Death	Other		SELF INFLICTED	Other	2	1	1	2	10		1	2	1	Yes	1	1	0	2.0345869541			66	1	0	-10	Baseline	73	209	2	in	lb			97.24	2	2	Bortezomib-based	2	2	1	1		0							0												5	5			2		1		Baseline	-10	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2269	-47															1	2	2	Yes	1	1	0	2.1589996308	1970		68	1	22	1970	Month 66	65	254	2	in	lb			53.04	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0								1355	1	193.57142857	1313	3	3			2	1	1		Baseline	-19	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2026	-34	No	1521	1521	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	0	1.6221083154	1409	1521	61	1	15	1409	Month 45	190	119	1	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	2	1	2	1		0							0								917	1	131	306	5	3	5		2	2		1	Baseline	-34	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2436	-1															1	2	1	Yes	1	1		3.3684472436	1777		60	1	20	1777	Year 5	167	82		cm	kg			317.356	0	1	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		1678	1	1			2	1	1		Baseline	1	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1486	-20	No	459	459	Death	Other		CARDIAC ARREST	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	1		429	459	56	1	6	457	Month 18	170	103	3	cm	kg			295.256	0	1	Bortezomib-based	3	2	1	0		0							0									0		200	5	5			2	2	1		Baseline	-23	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1671	-17															1	2	1	Yes	1	1	0	2.3047363349	2360		68	1	26	2360	Month 78	167	75	1	cm	kg			99.892	1	1	Bortezomib-based	2	2	5	1		0							0								71	1	10.142857143		3	2	3	2	1		1	1	Baseline	-31	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1720	-20	No	64	64	Death	Other		CO-MORBIDITY - CONGESTIVE HEART FAILURE	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	1	3.4664723425			83	1	0	1	Baseline	165	82	3	cm	kg			236.912	2	2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	1	83	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1912	-9	No	389	389	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			362		58	1	4	353	Year 1	175	98	3	cm	kg			192.712	0	1	Bortezomib-based	2	2	2	1		0							0								204	1	29.142857143	113	5	3	5		2	2	1	1	Baseline	-10	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1505	-2	No		280	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	2		162		62	1	2	162	Month 6	185	106	3	cm	kg			106.08	1	1	combined bortezomib/IMIDs-based		1	1	0		0							0								162	1	23.142857143	78	3	3			2	2	1	1	Baseline	-2	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1782	-15	No		1100	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	0	1.9534408607	1009		63	1	11	1009	Month 33	161	79	1	cm	kg			61.88	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								562	1	80.285714286	450	3	3	1		2	1	1	1	Baseline	-26	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1944	0	No	96	96	Death	Disease progression				2	1	1	1		Unknown	6	2	2	Yes	1	1		1.8370535081			66	1	0	1	Baseline	150	45	3	cm	kg			265.2	2	2	Bortezomib-based	2	2	1	1		0							0												5	5			2		1		Baseline	1	66	Female						Checked	Unknown	Not Hispanic or Latino		0	1
MMRF_2203	-4	No		172	Patient is lost to follow-up					2	1	5				4	2	1	Yes	1	1	1		144		58	1	2	144	Month 6	65	70	1	in	kg			141.44	1	1	Bortezomib-based	2	2	1	1		0							0									0		58	1	1			2	2	1		Baseline	-4	58	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1533	-7	No	763	763	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	2		685		65	1	8	685	Year 2	76	224	3	in	lb			243.1	0	1	Bortezomib-based		2	2	0	1	1	1	Bortezomib/METHYLPREDNISOLONE	1	685	189	Stem cell, Autologous	1	1							511	1	73	442	5	3	5		2	1		1	Baseline	-7	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1580	-3	No	123	123	Death	Other		RESPIRATORY FAILURE SECONDARY TO INFLUENZA PNEUMONIA	Respiratory	2	1	1	2	7		1	1	1	Yes	1	1	0	3.9675317607	81		64	1	1	81	Month 3	71	181	2	in	lb			911.404	1	1	Bortezomib-based		2	1	0		0							0									0		43	5	5			2	2	1		Baseline	-3	64	Male					Checked			Hispanic or Latino		0	1
MMRF_2113	-68	No	465	465	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	1	Yes	1	1	1	1.5538129362	151		71	1	2	151	Month 6	70	268	3	in	lb			151.164	2	2	combined bortezomib/IMIDs-based		1	1	0		0							0									0		375	5	5			2	1	1		Baseline	-24	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1499	-14	No		1806	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	2	5.6177149682	1778		68	1	20	1778	Year 5	163	73	2	cm	kg			78	1	1	IMIDs-based		3	3	1		0							0								1232	1	176	1121	3	3	2	1	2	1	1		Baseline	0	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1512	-1															4	2	2	Yes	1	1	0	1.3996227591	2359		61	1	26	2358	Month 78	156	49	2	cm	kg			105	1	1	combined bortezomib/IMIDs-based	2	1	3	1	1	1	1	Bortezomib	126	162	160	Stem cell, Autologous	1	1	Lenalidomide	344	943	599	2	2	1364	1	194.85714286	1189	3	3	1	1	2	1	1		Baseline	-1	61	Female		Checked						Not Hispanic or Latino		0	1
MMRF_1577	-4															1	3	1	Yes	1	1	0	2.1538979698	2362		42	1	26	2362	Month 78	175	110	2	cm	kg			86	1	1	combined bortezomib/IMIDs-based	2	1	3	1	0	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	86	233	254	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	340	539	199	1	1	1039	1	148.42857143	961	3	3	1	1	2	1	1	1	Baseline	-4	42	Male					Checked			Other		0	1
MMRF_1589	-14															1	2	1	Yes	1	1	0	3.0205317737	2374		51	1	26	2374	Month 78	178	112	1	cm	kg			77		2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Cyclophosphamide/Dexamethasone	162	196	197	Stem cell, Autologous	1	1	Lenalidomide	273	1211	938	2	2		0		2307	1	1			2	1	1		Baseline	-14	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1715	-6	No		287	Patient no longer consents to participate in the study					2	1	3				1	1	2	Yes	1	1	0	4.3740186739	278		56	1	3	249	Month 9	172	63	2	cm	kg			71	0	1	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	126	159	Stem cell, Autologous	1	1								0		197	1	1			2	2	1		Baseline	-6	56	Female					Checked			Hispanic or Latino		0	1
MMRF_1867	-14															1	2	2	Yes	1	1	0	1.784791755	2198		58	1	24	2198	Year 6	157	86	1	cm	kg			61	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib	121	124	132	Stem cell, Autologous	1	1	Lenalidomide	233	2198	1965	2	2		0		2102	1	1			2	1	1		Baseline	-7	58	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1873	-9	No	130	130	Death	Other		ATHEROSCLEROTIC HEART DISEASE	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	0		93	130	90	1	2	127	Month 6	157	59	1	cm	kg			49	2	2	Bortezomib-based	2	2	1	1		0							0									0			5	5			2		1		Baseline	-9	90	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1910	23	No	538	538	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		1.8692709312	487		61	1	5	478	Month 15	174	91	2	cm	kg			66	1	1	Bortezomib-based		2	5	0		0	2	Lenalidomide	123	332	254	Stem cell, Autologous	1	0	Bortezomib/Lenalidomide/Dexamethasone	333	415	82	1		127	1	18.142857143		5	4	3	2	2		1	1	Baseline	23	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1927	-1	No	1659	1659	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	3.3558315024	1525	1344	67	1	19	1658	Month 57	184	84	3	cm	kg			119	0	1	combined bortezomib/IMIDs-based	2	1	4	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	274	300	Stem cell, Autologous	1	1	Lenalidomide	389	788	399	2	2	1065	1	152.14285714	899	5	3	4	1	2	1		1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2265	-13														Honduras	6	1	2	Yes	1	1	0	2.0902986362	1988		67	1	22	1988	Month 66	157	76	1	cm	kg			61	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib	153	158	159	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	260	316	56	1	1		0		1912	1	1			2	1	1		Baseline	-13	67	Female						Checked	Honduras	Hispanic or Latino		0	1
MMRF_2563	-6															1	2	1	Yes	1	1	2		1834		62	1	20	1834	Year 5	183	79	3	cm	kg			129	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	237	175	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	238	299	61	1	1		0		1635	1	1			2	1	1		Baseline	1	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1597	1	No		1619	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	1	3.7898474347	1428		53	1	16	1428	Year 4	169	88	3	cm	kg			132	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	BUSULPHAN/Melphalan	147	150	152	Stem cell, Autologous	1	1	Lenalidomide	251	1428	1177	2	2		0		1323	1	1			2	1	1		Baseline	1	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1610	-5															1	2	1	Yes	1	1	0		2368		52	1	26	2368	Month 78	184	101	1	cm	kg			70	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	BUSULFAN/BUSULPHAN/Melphalan	150	153	155	Stem cell, Autologous	1	1	Lenalidomide	260	2368	2108	2	2		0		2267	1	1			2	1	1		Baseline	-5	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1614	-4	No		1186	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	2	4.5663629375	1094		60	1	12	1064	Year 3	161	80	2	cm	kg	Stage II	2	106	3	2	IMIDs-based	4	3	1	0		0							0								1094	1	156.28571429	1011	3	3			2	1	1		Baseline	-4	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1638	-16	No	808	808	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			683	808	65	1	9	808	Month 27	167	98	1	cm	kg			100	1	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	135	185	Stem cell, Autologous	1	1	Lenalidomide	319	683	364	1	1	514	1	73.428571429	378	5	3	5		2	1		1	Baseline	-16	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1655	-7															1	2	2	Yes	1	1	1		2362		63	1	26	2362	Month 78	170	60	3	cm	kg			95	2	2	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	162	226	Stem cell, Autologous	1	1	Lenalidomide	318	1851	1533	2	2	1851	1	264.42857143	1740	3	3	4		2	1	1		Baseline	-7	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1856	-8															1	2	1	Yes	1	1	0	1.429470986	2159		54	1	24	2107	Year 6	174	87	2	cm	kg			129	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	138	188	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	253	335	82	1	1		0		2012	1	1			2	1	1		Baseline	-7	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2170	0	No	1522	1522	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1		1501		55	1	17	1501	Month 51	154	50	3	cm	kg			113	3	2	combined bortezomib/IMIDs-based	2	1	2	1		0							0								1283	1	183.28571429	1200	5	3	5		2	1			Baseline	0	55	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2279	-5															1	2	1	Yes	1	1	0	1.9117868189	2004		65	1	22	2004	Month 66	162	76	1	cm	kg			61	2	2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	147	147	Stem cell, Autologous	1	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	148	154	6	1	1		0		1919	1	1			2	1	1		Baseline	-5	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2288	-26	No	577	577	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1		416		59	1	5	416	Month 15	172	80	3	cm	kg			92	2	2	Bortezomib-based	2	2	1	1		0							0									0		519	5	5			2	1	1		Baseline	-26	59	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1676	0															1	2	2	Yes	1	1	0		2380		51	1	26	2380	Month 78	166	72	1	cm	kg			82	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	BUSULFAN/Melphalan	176	179	181	Stem cell, Autologous	1	1	Lenalidomide	271	2380	2109	2	2		0		2346	1	1			2	1	1		Baseline	-2	51	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1725	-13															1	2	1	Yes	1	1	0		2164		68	1	24	2164	Year 6	172	75	2	cm	kg			104	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	196	196	197	Stem cell, Autologous	1	1	Lenalidomide	271	1871	1600	2	2		0		2283	1	1			2	1	1		Baseline	-13	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1771	0	No	574	574	Death	Disease progression				2	1	1	1			4	2	1	Yes	1	1	1	13.708561206	497		58	1	6	497	Month 18	170	72	3	cm	kg			149	3	2	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Cyclophosphamide/Melphalan/Dexamethasone	189	203	204	Stem cell, Autologous	1	1	Lenalidomide	310	455	145	1	1	475	1	67.857142857	392	5	3	5		2	1	1	1	Baseline	0	58	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1777	-6															1	2	2	Yes	1	1	0	1.40891534	2241		67	1	24	2241	Year 6	165	70	1	cm	kg			71	2	2	Bortezomib-based	2	2	1	1		0							0									0		1925	1	1			2	1	1		Baseline	-6	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1785	-5															4	2	1	Yes	1	1	2	2.0349078583	2011		63	1	19	2088	Month 57	156	76	2	cm	kg			58	3	2	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	217	259	Stem cell, Autologous	1	1	Lenalidomide	461	687	226	1	1	800	1	114.28571429	624	3	1	1		2	1	1	1	Baseline	-5	63	Male		Checked						Not Hispanic or Latino		0	1
MMRF_1792	0	No	1576	1576	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	2.8815010303	1437		47	1	16	1437	Year 4	156	80	2	cm	kg			64	1	1	combined bortezomib/IMIDs-based	2	1	5	1	1	1	1	BUSULFAN/Melphalan	203	206	208	Stem cell, Autologous	1	1	Lenalidomide	301	1131	830	2	2	1115	1	159.28571429	1037	5	3	2	2	2	1			Baseline	0	47	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1805	-48															2	2	2	Yes	1	1	2	2.3023000826	2143		48	1	24	2143	Year 6	163	65	2	cm	kg			33	4	2	combined bortezomib/IMIDs-based		1	2	0	0	1	1	Cyclophosphamide/Dexamethasone	281	313	315	Stem cell, Autologous	1	1	Lenalidomide	415	1631	1216	2	2	1583	1	226.14285714	1499	3	3	4		2	1	1		Baseline	-52	48	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1846	-11															1	2	1	Yes	1	1	0	1.9676304143	2156		58	1	24	2156	Year 6	174	83	1	cm	kg			82	1	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Dexamethasone	169	186	191	Stem cell, Autologous	1	1	Lenalidomide	317	2247	1930	2	2	2156	1	308	2073	3	3	4		2	1	1		Baseline	-11	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1845	-13															4	2	2	Yes	1	1	2	2.0547396923	2185		46	1	24	2185	Year 6	153	56	3	cm	kg			70	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Lenalidomide/Dexamethasone	145	198	201	Stem cell, Autologous	1	1							945	1	135	861	3	3	1		2	1	1	1	Baseline	-13	46	Female		Checked						Not Hispanic or Latino		0	1
MMRF_1928	-42															1	2	1	Yes	1	1	0	2.3634064381	2147		53	1	24	2147	Year 6	179	86	1	cm	kg			93	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	169	171	Stem cell, Autologous	1	1	Lenalidomide	276	1140	864	2	2	762	1	108.85714286	625	3	3	1		2	1	1	1	Baseline	-42	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1960	0	No	575	575	Death	Other		CONGESTIVE HEART FAILURE SECONDARY TO AMYLOIDOSIS	Cardiovascular	2	1	1	2	1		4	2	1	Yes	1	1	1		525		72	1	6	525	Month 18	164	54	3	cm	kg			358	1	1	combined bortezomib/IMIDs-based	9	1	1	1		0							0									0		401	5	5			2	1	1		Baseline	0	72	Male		Checked						Not Hispanic or Latino		0	1
MMRF_2174	1	No	425	425	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		12.751692326	376		85	1	4	376	Year 1	180	79		cm	kg			778	3	2	Bortezomib-based		2	2	0		0							0								110	1	15.714285714		5	2	5		1		1	1	Baseline	1	85	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2251	-19	No	104	104	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	2	9.7856366915	50		47	1	1	50	Month 3	172	58	3	cm	kg			126	1	1	Bortezomib-based	2	2	1	1		0							0									0		41	5	5			2	2	1		Baseline	-20	47	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2428	-7															1	2	1	Yes	1	1	0		1807		54	1	20	1807	Year 5	186	92	1	cm	kg			83	1	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1	0	1	1	Carfilzomib/Lenalidomide/Dexamethasone	176	224	263	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	351	715	364	1	1		0		1716	1	1			2	1	1		Baseline	-7	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1555	-27	No	469	469	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	2		344		83	1	4	344	Year 1	152	50	3	cm	kg			66.3	1	2	combined bortezomib/IMIDs-based	1	1	3	1		0							0								239	1	34.142857143		5	4	2	5	2		1	1	Baseline	-27	83	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1564	-12	No	1510	1510	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		1493		86	1	17	1493	Month 51	179	90	2	cm	kg			98.124	1	2	IMIDs-based	4	3	2	0		0							0								1206	1	172.28571429	1135	5	3	5		2	1			Baseline	-12	86	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1569	-20															1	2	1	Yes	1	1			2359		70	1	26	2359	Month 78	185	86	1	cm	kg			118.456	0	1	IMIDs-based	4	3	4	0		0							0								945	1	135	860	3	3	2	4	2	1	1	1	Baseline	-20	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1574	0	No	1832	1832	Death	Other		RELAPSED AML	Other	2	1	1	2	10		1	2	1	Yes	1	1	0	1.9863053956	1786	1832	65	1	20	1832	Year 5	178	114	1	cm	kg			91.052	0	1	IMIDs-based	4	3	1	0	1	1	1	Lenalidomide/Dexamethasone	1	221	248	Stem cell, Autologous	1	1	Lenalidomide	569	1577	1008	2	2		0		1612	5	5			2	1			Baseline	-6	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1593	-3															1	2	1	Yes	1	1	2	1.77495748	2388		68	1	26	2388	Month 78	188	102	2	cm	kg			333.268	1	1	Bortezomib-based	3	2	2	0		0	2	Carfilzomib/Lenalidomide/Dexamethasone	133	189	218	Stem cell, Autologous	1	0	Lenalidomide	312	2388	2076	2			0			1	4	1		2		1		Baseline	-3	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1618	-16															1	2	2	Yes	1	1	0	1.846095654	2394		55	1	28	2394	Year 7	163	80	1	cm	kg			65.416	0	1	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	86	119	Stem cell, Autologous	1	1	Lenalidomide	338	1479	1141	2	2	1491	1	213	1406	3	1	3	4	2	1	1		Baseline	-16	55	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1717	-16	No	2086	2086	Death	Other		ADVANCED HEART FAILURE AND MULTI-ORGAN FAILURE	Other	2	1	1	2	10		1	2	1	Yes	1	1			1917	1334	64	1	24	2084	Year 6	185	101	2	cm	kg			94.588	1	1	IMIDs-based	4	3	2	0	1	1	1	Lenalidomide/Dexamethasone	1	104	162	Stem cell, Autologous	1	1	Lenalidomide	334	1464	1130	2	2	1474	1	210.57142857	1386	5	3	5		2	1			Baseline	-16	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1726	-2	No	813	813	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.1785741681	789		74	1	8	783	Year 2	70	200	2	in	lb			81.328	3	2	combined bortezomib/IMIDs-based	3	1	3	0		0							0								664	1	94.857142857		5	4	4	5	2			1	Baseline	-2	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1763	1															1	2	1	Yes	1	1	0		2213		53	1	24	2213	Year 6	170	171	1	cm	lb			73.372	1	1	combined bortezomib/IMIDs-based	4	1	3	0	0	1	1	Lenalidomide/Dexamethasone	132	133	133	Stem cell, Autologous	1	1	Bortezomib	194	764	570	2	2	827	1	118.14285714	729	3	1	1	1	2	1	1	1	Baseline	1	53	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1847	-12															1	2	1	Yes	1	1	1	2.8579730763	2234		52	1	26	2234	Month 78	175	76	1	cm	kg			101.66		2	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	672	161	Stem cell, Autologous	1	1	Ixazomib/Lenalidomide/Dexamethasone	692	2234	1542	2	2		0		2107	1	1			2	1	1		Baseline	-12	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1888	-58															1	2	2	Yes	1	1	0	2.6924264318	2179		64	1	24	2179	Year 6	152	73	2	cm	kg	Stage II	2	60.112	0	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	29	85	143	Stem cell, Autologous	1	1	Lenalidomide	388	2179	1791	2	2		0		2014	1	1			2	1	1		Baseline	-58	64	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1915	1															1	2	2	Yes	1	1	1	2.3614273202	2242		60	1	26	2242	Month 78	169	73	1	cm	kg			81.328	1	1	combined bortezomib/IMIDs-based	3	1	1	0	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	25	82	113	Stem cell, Autologous	1	1	Lenalidomide	358	850	492	2	2		0		2161	1	1			2	1	1		Baseline	1	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2041	1															1	2	2	Yes	1	1	0	3.775084414	2137		52	1	24	2137	Year 6	156	49	2	cm	kg			82.212	0	1	combined bortezomib/IMIDs-based	2	1	1	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	29	108	Stem cell, Autologous	1	1	Lenalidomide	199	2137	1938	2	2	1547	1	221	1440	3	3			2	1	1		Baseline	-39	52	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2064	-5															1	2	2	Yes	1	1			2108		57	1	22	2108	Month 66	170	179	1	cm	lb			71.604	1	1	Bortezomib-based	3	2	2	0	1	1	1	Bortezomib/Dexamethasone	1	102	118	Stem cell, Autologous	1	1							1067	1	152.42857143	976	3	3	4		2	1	1	1	Baseline	1	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2409	-6															1	2	1	Yes	1	1	0	2.4161390187	1872		66	1	20	1872	Year 5	170	102	1	cm	kg			87.516	0	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Bortezomib/Dexamethasone	1	135	178	Stem cell, Autologous	1	1	Lenalidomide	345	1872	1527	2	2		0		1767	1	1			2	1	1		Baseline	1	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2585	-4															1	2	1	Yes	1	1			1794		69	1	18	1794	Month 54	69	86	1	in	kg			70.72	1	1	IMIDs-based	4	3	1	0		0							0								262	1	37.428571429	1	1	1			2	2	1	1	Baseline	11	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1750	-22															1	1	2	Yes	1	1	1	1.3979328847	2267		69	1	26	2267	Month 78	173	81	1	cm	kg			54.808	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	79	128	Stem cell, Autologous	1	1	Lenalidomide	212	2267	2055	2	2		0		2120	1	1			2	1	1		Baseline	-22	69	Female					Checked			Hispanic or Latino		0	1
MMRF_2019	-11															1	2	2	Yes	1	1		1.3263465877	2151		69	1	24	2151	Year 6	154	57	3	cm	kg			182.104	1	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Bortezomib/Dexamethasone	1	140	142	Stem cell, Autologous	1	1	Lenalidomide	251	303	52	1	1		0		1970	1	1			2	1	1		Baseline	-11	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2377	-15														Filipino	6	2	1	Yes	1	1	0	1.5404027811	1832		62	1	20	1832	Year 5	170	68	2	cm	kg			83.98	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1638	1	1			2	1	1		Baseline	4	62	Male						Checked	Filipino	Not Hispanic or Latino		0	1
MMRF_2380	-3	No		729	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1	1	2.4736827557	729		69	1	8	729	Year 2	183	79	3	cm	kg			236.028	1	1	Bortezomib-based	3	2	2	0		0	2	Bortezomib/Lenalidomide/Dexamethasone	547	631	661	Stem cell, Autologous	1	0							578	1	82.571428571	265	3	1	1		2	2	1	1	Baseline	4	69	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2402	-25	No	1368	1368	Death	Other		PNEUMONIA/UNSPECIFIED INFECTION	Other	2	1	1	2	10		1	2	1	Yes	1	1			1270		70	1	14	1270	Month 42	175	90	2	cm	kg			114.036	0	1	IMIDs-based	4	3	2	0		0							0								1072	1	153.14285714	991	5	1	5		2	1		1	Baseline	1	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1930	-18															1	2	1	Yes	1	1	0		1981		57	1	22	1981	Month 66	69	86	1	in	kg			94.588	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	59	115	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	224	273	49	1	1		0		1905	1	1			2	1	1		Baseline	-18	57	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2167	0	No	839	839	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1		816		70	1	9	816	Month 27	178	113	3	cm	kg			270.504	2	2	Bortezomib-based	3	2	5	0		0	2	Carfilzomib/Lenalidomide/Dexamethasone	201	307	336	Stem cell, Autologous	1	0							194	1	27.714285714	101	5	3	1	4	2	2		1	Baseline	0	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1456	-12	No		92	Patient no longer consents to participate in the study					2	1	3			Costa Rican	6	1	1	Yes	1	1			92		59	1	1	92	Month 3	65	148	1	in	lb			61.88	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0												4	4			2		1		Baseline	-12	59	Male						Checked	Costa Rican	Hispanic or Latino		0	1
MMRF_1535	-21	No		1085	Other		STUDY CLOSURE AT SITE			2	1	7				2	2	1	Yes	1	1	0		1071		65	1	12	1010	Year 3	72	199	1	in	lb			114.92	2	2	IMIDs-based	4	3	1	0		0							0									0		986	1	1			2	1	1		Baseline	-23	65	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2112	-50	No	201	201	Death	Other		BRAIN METS POSSIBLY FROM NEW UNKNOWN PRIMARY	Secondary Malignancy	2	1	1	2	8		1	2	1	Yes	1	1	0		110	201	51	1	3	190	Month 9	65	160	2	in	lb			53.04	3	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		179	5	5			2	2	1		Baseline	-57	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2151	-5	No	13	13	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	2.5718049511		13	56	1	1	13	Month 3	66	175	3	in	lb			176.8	2	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	-5	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2379	-20	No	90	90	Death	Other		INFECTIOUS PROCESS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	2	1.9110898861	63		79	1	1	63	Month 3	70	183	3	in	lb			167.96	1	2	IMIDs-based	11	3	1	0		0							0									0		28	5	5			2	2	1		Baseline	-20	79	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1882	-27	No	1054	1054	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	1.4232747053	1052		67	1	12	1052	Year 3	72	248	3	in	lb			503.88	1	1	Bortezomib-based	10	2	1	0		0							0								1052	1	150.28571429		5	5			2			1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2015	12	No	533	533	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	2	3.5007685019	197	533	65	1	3	476	Month 9	74	203	2	in	lb			97.24	1	1	Bortezomib-based	2	2	1	1	1	1	1	Cyclophosphamide/Dexamethasone	139	533	258	Stem cell, Autologous	1	1							478	1	68.285714286		5	5			2		1	1	Baseline	8	65	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2187	-5	No		99	Patient is lost to follow-up					2	1	5			Declines To Answer	6	3	1	Yes	1	1	1				53	1	-1	-5	Screening	74	224	3	in	lb			140.556	3	2	combined bortezomib/IMIDs-based	1	1	1	1		0							0												4	4			2		1		Baseline	-6	53	Male						Checked	Declines To Answer	Other		0	1
MMRF_2386	-1															2	2	1	Yes	1	1	0		1811		64	1	20	1811	Year 5	183	87	2	cm	kg			86.632	1	1	Bortezomib-based	2	2	4	1		0							0								454	1	64.857142857		2	4	4	2	2		1	1	Baseline	-1	64	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2078	1	No	77	77	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1					78	1	0	1	Baseline	68	140	3	in	lb			109.616		2	Bortezomib-based	10	2	1	0		0							0												5	5			2		1		Baseline	1	78	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1644	-5	No		199	Other		PATIENT IS IMMOBILE AND BEING MOVED TO HOSPICE			2	1	7				2	2	2	Yes	1	1	2	7.0818378691	66		84	1	1	66	Month 3	70	64	3	in	kg			88.4	3	2	Bortezomib-based	10	2	1	0		0							0									0		1	1	1			2	2	1		Baseline	-20	84	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2118	-29	No		1923	Patient is lost to follow-up					2	1	5				2	2	1	Yes	1	1	2	3.5927877301	1160		63	1	13	1160	Month 39	173	178	2	cm	lb			88.4	1	1	Bortezomib-based	3	2	3	0		0							0								625	1	89.285714286	438	3	1	3	4	2	1	1	1	Baseline	1	63	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2138	-9															2	2	1	Yes	1	1	0		1817		81	1	20	1817	Year 5	157	67	1	cm	kg	Stage I	1	98.124	1	2	combined bortezomib/carfilzomib-based	3	9	2	0		0							0								455	1	65		1	2	1		2		1	1	Baseline	-9	81	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1706	-7															1	2	1	Yes	1	1	0		2181		66	1	24	2181	Year 6	185	103	1	cm	kg			87	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	BUSULFAN/Melphalan	160	163	165	Stem cell, Autologous	1	1	Lenalidomide	265	455	190	1	1		0		2098	1	1			2	1	1		Baseline	0	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1881	-26	No	1758	1758	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	2.0550552978	1976	1340	66	1	18	1976	Month 54	172	86	1	cm	kg			78	0	1	combined bortezomib/IMIDs-based	2	1	1	1	0	1	1	BUSULFAN/Melphalan	249	252	254	Stem cell, Autologous	1	1	Lenalidomide	358	751	393	2	2		0		1679	5	5			2	1			Baseline	-32	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1972	-5	No	2197	2197	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.0970655154	2171		82	1	24	2172	Year 6	180	80	2	cm	kg			106	0	2	Bortezomib-based	2	2	3	1		0							0								814	1	116.28571429	720	5	3	1	5	2	1		1	Baseline	-5	82	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2007	-6															2	2	1	Yes	1	1	0		2191		66	1	24	2191	Year 6	176	94	2	cm	kg			102	0	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	101	154	Stem cell, Autologous	1	1	Lenalidomide	436	1005	569	2	2	1270	1	181.42857143	1184	3	3	1		2	1	1		Baseline	-6	66	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1829	0	No	979	979	Death	Disease progression				2	1	1	1			2	2	2	Yes	1	1			917	979	61	1	11	974	Month 33	62	236	3	in	lb			821.236	2	2	combined bortezomib/IMIDs-based	10	1	2	0		0							0								917	1	131	841	5	3	5		2	1		1	Baseline	0	61	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1977	-5															2	2	1	Yes	1	1	1	3.0788126148	2171		45	1	24	2171	Year 6	67	149	3	in	lb			309.4	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	2171	365	Stem cell, Autologous	1	1								0		2080	1	1			2	1	1		Baseline	1	45	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2012	-4	No	1619	1556	Other	Disease progression	DISEASE PROGRESSION, D/T T4BN0M0 SQUAMOUS CELL CARCINOMA OF THE LEFT PARANA			2	1	7	1			2	2	2	Yes	1	1	0	2.2928183698	1549		62	1	17	1549	Month 51	63	101	2	in	lb			70.72	1	1	IMIDs-based	4	3	1	0		0							0									0		1444	5	5			2	1			Baseline	-4	62	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2106	-28	No	344	344	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	4.3713403475	257	344	54	1	4	344	Year 1	66	125	1	in	lb			61.88	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								265	1	37.857142857	107	5	3	5		2	2	1	1	Baseline	-10	54	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2125	-17	No		1483	Patient is lost to follow-up					2	1	5				2	2	1	Yes	1	1	1	2.961346341	1483		54	1	17	1483	Month 51	56	125	3	in	lb			141.44	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								323	1	46.142857143	165	3	3	2		2	2	1	1	Baseline	-29	54	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2256	0	No	309	309	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			283	309	73	1	4	299	Year 1	60	229	3	in	lb			274.04	2	2	Bortezomib-based	3	2	1	0		0							0								283	1	40.428571429		5	5			2		1	1	Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2259	-9	No	123	123	Death	Other		CAR ACCIDENT	Other	2	1	1	2	10		2	2	2	Yes	1	1			102		50	1	1	102	Month 3	62	219	3	in	lb			188.292	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0												5	5			2		1		Baseline	1	50	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2525	-6	No		745	Other		PATIENT MOVED			2	1	7				2	2	2	Yes	1	1	0	1.964064318	715		51	1	8	715	Year 2	64	127	2	in	lb			61.88	2	2	IMIDs-based	4	3	1	0		0							0									0		358	1	1			2	2	1		Baseline	0	51	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1753	-19	No	101	101	Death	Other		CARDIOPULMONARY ARREST	Cardiovascular	2	1	1	2	1		2	2	1	Yes	1	1	0			101	64	1	1	81	Month 3	171	72	1	cm	kg			105.196	0	1	Bortezomib-based	2	2	1	1		0							0									0			5	5			2		1		Baseline	-5	64	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1786	-10															2	2	2	Yes	1	1	0	1.6399472906	2172		48	1	24	2172	Year 6	68	74	1	in	kg			63.648	0	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	120	138	Stem cell, Autologous	1	1	Lenalidomide	207	1290	1083	2	2	1416	1	202.28571429	1317	3	3	1		2	1	1		Baseline	-3	48	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1793	-20															2	2	1	Yes	1	1	0	1.3132991914	2129		63	1	24	2129	Year 6	62	128	1	in	lb			108.732	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	105	129	Stem cell, Autologous	1	1	Lenalidomide	196	2129	1933	2	2		0		2046	1	1			2	1	1		Baseline	-20	63	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1816	-2															1	2	2	Yes	1	1	1		2103		66	1	24	2103	Year 6	161	111	1	cm	lb			88.4	1	1	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	100	133	Stem cell, Autologous	1	1	Carfilzomib/Pomalidomide/Dexamethasone	232	2103	1871	2	2		0		2003	1	1			2	1	1		Baseline	-2	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1842	-25	No	1590	1590	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	2.6869377213	1530	1590	56	1	18	1590	Month 54	180	88	1	cm	kg			129.064		2	combined bortezomib/IMIDs-based	1	1	4	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	123	159	Stem cell, Autologous	1	1	Lenalidomide	227	689	462	2	2	731	1	104.42857143	668	5	3	2	3	2	1		1	Baseline	-4	56	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1858	-2	No	1278	1278	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	1		1175	1596	62	1	14	1278	Month 42	65	133	3	in	lb			172.38	2	2	combined bortezomib/IMIDs-based	2	1	3	1		0							0								742	1	106	667	5	3	3	5	2	1		1	Baseline	-2	62	Male			Checked					Not Hispanic or Latino		0	1
MMRF_1886	-3															1	2	1	Yes	1	1	0	3.4793968994	2003		66	1	22	2003	Month 66	174	89	2	cm	kg			185.64	2	2	Bortezomib-based	2	2	2	1		0							0								1493	1	213.28571429	1413	3	3	1		2	1	1		Baseline	-3	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2074	-25															1	2	2	Yes	1	1	0	2.5168791339	1967		61	1	22	1967	Month 66	160	75	2	cm	kg			63.648	1	1	combined bortezomib/IMIDs-based		1	2	1	1	1	1	Thalidomide	117	127	171	Stem cell, Autologous	1	1	Bortezomib	302	1198	896	2	2	1163	1	166.14285714	1086	3	3	1		2	1	1		Baseline	-25	61	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2093	-11															1	2	2	Yes	1	1	2	1.3192618098	1979		51	1	22	1979	Month 66	68	253	2	in	lb			80.444	1	1	combined bortezomib/IMIDs-based	2	1	3	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	127	179	Stem cell, Autologous	1	1	Lenalidomide	253	531	278	1	1	751	1	107.28571429	673	3	3	3	3	2	1	1	1	Baseline	-11	51	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2266	1	No	519	519	Death	Other		ACUTE RESPIRATORY FAILURE	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1	0	1.9984303821	412	519	73	1	6	519	Month 18	177	79	2	cm	kg			123.76	3	2	Bortezomib-based	2	2	1	1		0							0									0		431	5	5			2	1	1		Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2306	-22															2	2	1	Yes	1	1	0	1.7073610646	2022		40	1	22	2022	Month 66	170	135	2	cm	kg			94.588	1	1	Bortezomib-based	2	2	3	1		0	2	Carfilzomib/Cyclophosphamide/Dexamethasone	266	371	427	Stem cell, Autologous	1	0	Carfilzomib/Dexamethasone	502	961	459	2		259	1	37	197	3	3	1	1	2	2	1	1	Baseline	-22	40	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2486	-2															2	2	2	Yes	1	1	0		1673		34	1	20	1840	Year 5	180	136	1	cm	kg			48.62	2	2	combined bortezomib/IMIDs/carfilzomib-based	2	5	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	176	219	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	288	552	264	1	1		0		1777	1	1			2	1	1		Baseline	6	34	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2497	-28															1	2	2	Yes	1	1	0	2.0548965887	1779		70	1	20	1779	Year 5	168	50	1	cm	kg			53.924	0	1	IMIDs-based	4	3	1	0		0							0									0		1541	1	1			2	1	1		Baseline	-28	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2501	0															2	2	2	Yes	1	1	0	2.8263412982	1795		55	1	20	1795	Year 5	168	102	2	cm	kg			56.576	1	1	combined bortezomib/IMIDs-based	2	1	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	113	172	Stem cell, Autologous	1	1	Lenalidomide	276	984	708	2	2	982	1	140.28571429	898	3	3	1		2	1	1	1	Baseline	-6	55	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2557	-10	No	325	325	Death	Other		ACUTE KIDNEY INJURY	Other	2	1	1	2	10		1	2	1	Yes	1	1	1	2.0474137256	257	325	83	1	4	325	Year 1	169	81	3	cm	kg			181.22	1	2	Bortezomib-based	3	2	2	0		0							0								131	1	18.714285714		5	2	5		2		1	1	Baseline	-10	83	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2087	1	No	283	283	Death	Disease progression				2	1	1	1			2	2	1	Yes	1	1	0	1.6368765946	190	283	74	1	3	261	Month 9	65	140	2	in	lb			96.356	2	2	combined bortezomib/IMIDs-based	4	1	2	0		0							0								190	1	27.142857143	88	5	3	5		2	2	1	1	Baseline	18	74	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2141	-32															1	2	1	Yes	1	1	0	1.7789409434	2003		61	1	22	2003	Month 66	68	108	2	in	lb			76.908	1	1	Bortezomib-based	3	2	2	0	0	1	1	Bortezomib/Dexamethasone	1	175	270	Stem cell, Autologous	1	1							1143	1	163.28571429	1056	3	3	1		2	1	1		Baseline	1	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2149	-13	No	454	454	Death	Other		UNKNOWN	Unknown	2	1	1	2	9	Unknown	6	1	1	Yes	1	1	0	3.5106201941	351	454	63	1	5	450	Month 15	63	157	2	in	lb			105.196	1	1	Bortezomib-based	3	2	1	0		0							0									0		369	5	5			2	1	1		Baseline	23	63	Male						Checked	Unknown	Hispanic or Latino		0	1
MMRF_2153	-11	No		604	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	1.589400575	535		78	1	6	535	Month 18	68	106	2	in	lb			85.748	1	2	Bortezomib-based	3	2	2	0		0							0									0		176	1	1	1		2	2	1		Baseline	1	78	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2191	-8															2	2	1	Yes	1	1	0		2010		59	1	22	2010	Month 66	73	259	2	in	lb			87.516	1	1	Bortezomib-based	3	2	5	0		0	2	Carfilzomib/Lenalidomide	568	694	731	Stem cell, Autologous	1	0							567	1	81	491	3	3	1	2	2	1	1	1	Baseline	1	59	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2228	-17	No	527	527	Death	Other		PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	1	Yes	1	1	0	1.7500449725	420	527	61	1	6	527	Month 18	75	326	2	in	lb			112.268	1	1	Bortezomib-based	3	2	1	0		0							0									0		248	5	5			2	2	1		Baseline	1	61	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2301	-31	No	1298	1298	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	3.5276702868	1248		62	1		1286	Unscheduled 2	71	215	2	in	lb			121.992	1	1	Bortezomib-based	3	2	2	0		0							0								1003	1	143.28571429	1024	5	3	5		2	1		1	Baseline	-113	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1766	-3															1	2	1	Yes	1	1	0	3.4875413738	2186		60	1	24	2186	Year 6	181	103	1	cm	kg			97.24	1	1	Bortezomib-based	2	2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	155	218	Stem cell, Autologous	1	1	Bortezomib	339	989	650	2	2	1002	1	143.14285714	925	3	3	1		2	1	1	1	Baseline	-3	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1824	-20	No		1801	Patient no longer consents to participate in the study					2	1	3				2	2	2	Yes	1	1	0	2.1463892005	1997		68	1	22	1997	Month 66	173	92	2	cm	kg			79.56	1	1	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	163	221	Stem cell, Autologous	1	1	Lenalidomide	325	1997	1672	2	2		0		1941	1	1			2	1	1		Baseline	-20	68	Female			Checked					Not Hispanic or Latino		0	1
MMRF_1879	-13	No	323	323	Death	Other		PATIENT DIED OF SEVERE BURNS OVER MOST OF HIS BODY.	Other	2	1	1	2	10		2	2	1	Yes	1	1	1	2.2621631475	249	323	69	1	4	322	Year 1	183	73	1	cm	kg			106.08	1	1	Bortezomib-based	2	2	1	1		0							0									0		239	5	5			2	2	1		Baseline	-13	69	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2006	-10	No		855	Other		TREATED BY PHYSICIAN AT UNC HEALTHCARE			2	1	7				1	2	1	Yes	1	1	2	1.7634285658	1064		61	1	11	1064	Month 33	188	114	2	cm	kg			79.56	2	2	Bortezomib-based	2	2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	102	128	Stem cell, Autologous	1	1	Bortezomib	232	1064	832	2	2		0		973	1	1			2	1	1		Baseline	-10	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2047	-19															1	2	1	Yes	1	1	0	1.6362697594	2039		67	1	22	2039	Month 66	175	101	1	cm	kg			97.24	1	1	combined bortezomib/carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	162	186	Stem cell, Autologous	1	1	Bortezomib	288	2039	1751	2	2		0		1962	1	1			2	1	1		Baseline	-7	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2116	-21															1	2	1	Yes	1	1	0	1.3117747147	1996		56	1	22	1996	Month 66	186	108	1	cm	kg			114.92	1	1	combined bortezomib/IMIDs-based	2	1	1	1		0							0									0		1898	1	1			2	1	1		Baseline	-4	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2201	-13	No	423	423	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	4.7726348926	344	423	75	1	5	422	Month 15	182	145	2	cm	lb			106.08	1	1	Bortezomib-based	2	2	1	1		0							0								253	1	36.142857143	213	5	5			2	2	1	1	Baseline	-7	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2232	-18															2	2	2	Yes	1	1	0	3.2063622769	1988		56	1	22	2018	Month 66	175	84	1	cm	kg			61.88	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Cyclophosphamide/Melphalan	80	99	100	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	176	207	31	1	1		0		1962	1	1			2	1	1		Baseline	-18	56	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2425	-11	No	819	819	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		793		54	1	9	793	Month 27	185	86	2	cm	kg			79.56	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	225	233	Stem cell, Autologous	1	1	Lenalidomide	344	812	468	2	2		0		742	5	5			2	1			Baseline	-11	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2440	-7															1	2	1	Yes	1	1	0	2.8198733058	1842		47	1	20	1842	Year 5	185	86	2	cm	kg			88.4	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	84	115	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	210	253	43	1	1		0		1756	1	1			2	1	1		Baseline	-7	47	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2485	-7															1	2	2	Yes	1	1	1	2.3950154464	1359		60	1	15	1359	Month 45	151	74	3	cm	kg			194.48	1	1	Bortezomib-based	2	2	1	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	238	292	Stem cell, Autologous	1	1	Bortezomib	434	1359	925	2	2		0		1304	1	1			2	1	1		Baseline	0	60	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2566	-11															1	3	1	Yes	1	1	0		1780		57	1	20	1780	Year 5	183	93	1	cm	kg			70.72	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1709	1	1			2	1	1		Baseline	-11	57	Male					Checked			Other		0	1
MMRF_2590	-25															1	2	2	Yes	1	1	1	1.417146991	1815		72	1	20	1815	Year 5	157	85	3	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1717	1	1			2	1	1		Baseline	-13	72	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2622	-7															1	2	1	Yes	1	1	0	3.1803419646	1743		59	1	19	1711	Month 57	185	85	2	cm	kg			114.92	0	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		1652	1	1			2	1	1		Baseline	-7	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2147	-62	No		658	Other		PATIENT CONSENTED TO ANOTHER STUDY, MEETING EXCLUSION FOR THIS STUDY.			2	1	7				1	2	1	Yes	1	1			554		65	1	7	554	Month 21	178	101	2	cm	kg			88.4	0	1	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								617	1	88.142857143	503	3	3			2	1	1	1	Baseline	-62	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2419	-10															1	2	1	Yes	1	1	1	2.3918569342	1738		55	1	19	1738	Month 57	184	98	3	cm	kg			114.92	1	1	combined bortezomib/IMIDs-based	2	1	2	1		0							0									0			1	4	1		2		1		Baseline	-10	55	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2438	-51	No	1272	1272	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1	0	5.8261419471	1201		51	1	14	1201	Month 42	159	86	1	cm	kg			61.88	1	1	Bortezomib-based		2	4	0	0	1	1	Bortezomib/Cyclophosphamide	1	106	152	Stem cell, Autologous	1	1	Bortezomib	288	457	169	1	1	494	1	70.571428571	442	5	1	2	1	2	1		1	Baseline	-51	51	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2517	-22	No		1806	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	0		1672		56	1	19	1672	Month 57	174	95	1	cm	kg			79.56	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	120	171	Stem cell, Autologous	1	1	Lenalidomide	260	673	413	2	2		0		1532	1	1			2	1	1		Baseline	-19	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2573	-12															1	2	1	Yes	1	1		1.7671490293	1837		72	1	20	1828	Year 5	170	88	2	cm	kg			141.44	0	1	combined daratumumab/IMIDs/carfilzomib-based	8	8	1	1		0							0									0		1491	1	1			2	1	1		Baseline	-9	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2597	-6														N/A	6	1	2	Yes	1	1	0	2.6743594708	1721		64	1	19	1721	Month 57	171	76	1	cm	kg			70.72		2	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	106	149	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	261	288	27	1	1		0		1388	1	1			2	1	1		Baseline	-6	64	Female						Checked	N/A	Hispanic or Latino		0	1
MMRF_2608	-1														Not Available	6	1	1	Yes	1	1	1	2.6006300282	1807		67	1	20	1807	Year 5	176	102	1	cm	kg			265.2		2	Bortezomib-based	2	2	2	1		0							0									0		1683	1	1	1		2	1	1		Baseline	0	67	Male						Checked	Not Available	Hispanic or Latino		0	1
MMRF_2223	-13															1	2	2	Yes	1	1	0		1854		82	1	20	1805	Year 5	151	55	1	cm	kg			79.56	0	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0								1119	1	159.85714286	972	3	3			2	1	1		Baseline	-13	82	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2568	-9	No	1658	1658	Death	Other		CARDIAC ARREST	Cardiovascular	2	1	1	2	1		1	2	1	Yes	1	1	1	9.6234884151	1649	1071	69	1	18	1658	Month 54	174	70	1	cm	kg			70.72	2	2	IMIDs-based	4	3	2	0	1	1	1	Lenalidomide/Dexamethasone	170	757	171	Stem cell, Autologous	1	1							1472	1	210.28571429	1387	5	3	5		2	1			Baseline	-9	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1833	-38															1	3	1	Yes	1	1	0	2.5386265615	2145		60	1	24	2145	Year 6	72	206	1	in	lb			88.4	0	1	combined bortezomib/IMIDs-based	1	1	3	1		0							0								260	1	37.142857143	151	3	1	3	4	2	2	1	1	Baseline	1	60	Male					Checked			Other		0	1
MMRF_2196	-49	No	1416	1416	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1			1319	1416	68	1	16	1381	Year 4	62	95	1	in	kg			167.96		2	combined bortezomib/IMIDs-based	2	1	3	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	134	199	Stem cell, Autologous	1	1	Lenalidomide	406	1050	644	2	2	1207	1	172.42857143	1085	5	1	2	5	2	1			Baseline	-45	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2054	-11															1	2	1	Yes	1	1	0	2.1583874655	1920		63	1	22	1884	Month 66	69	183	2	in	lb			88.4	0	1	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	289	576	289	Stem cell, Autologous	1	1							709	1	101.28571429		1	4	1		2		1	1	Baseline	-4	63	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2062	0	No		636	Patient no longer consents to participate in the study					2	1	3				2	2	1	Yes	1	1	1	7.1308013365	636		62	1	7	636	Month 21	183	99	3	cm	kg			294.372	1	1	Bortezomib-based	3	2	1	0		0							0									0		489	1	1			2	1	1		Baseline	0	62	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2171	-20															2	2	1	Yes	1	1			1981		64	1	22	1981	Month 66	68	204	1	in	lb			123.76	0	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	120	170	Stem cell, Autologous	1	1	Lenalidomide	287	1981	1694	2	2		0		1950	1	1			2	1	1		Baseline	-28	64	Male			Checked					Not Hispanic or Latino		0	1
MMRF_2181	0	No		626	Patient no longer consents to participate in the study					2	1	3				1	2	2	Yes	1	1	1		485		80	1	6	485	Month 18	68	180	3	in	lb			310.284	2	2	combined bortezomib/IMIDs-based	3	1	1	0		0							0									0		171	1	1			2	2	1		Baseline	-3	80	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2222	0															1	2	2	Yes	1	1	0		1993		46	1	22	1993	Month 66	67	255	1	in	lb			65.416	3	2	combined bortezomib/IMIDs-based	2	1	2	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	106	154	Stem cell, Autologous	1	1	Lenalidomide	258	1666	1408	2	2	1587	1	226.71428571	1531	3	3	1		2	1	1		Baseline	0	46	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2286	-48	No	1069	1069	Death	Other		SEPSIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		2	2	2	Yes	1	1	0		956	1069	67	1	12	1026	Year 3	66	199	2	in	lb			97.24	1	1	combined bortezomib/IMIDs-based	2	1	1	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	110	343	Stem cell, Autologous	1	1	Lenalidomide	473	1069	596	2	2		0		1013	5	5			2	1			Baseline	-48	67	Female			Checked					Not Hispanic or Latino		0	1
MMRF_2507	0	No		384	Patient no longer consents to participate in the study					2	1	3				1	2	1	Yes	1	1	1	1.9845137252	324		68	1	4	324	Year 1	173	62	3	cm	kg			131.716		2	combined bortezomib/IMIDs-based		1	1	0		0							0									0			4	4			2		1		Baseline	-4	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2126	-20	No	566	566	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0	1.7504012362	521	566	70	1	7	551	Month 21	63	232	2	in	lb	Stage II	2	88.4	1	1	combined bortezomib/IMIDs-based	1	1	2	1		0							0								347	1	49.571428571	193	5	1	5		2	2	1	1	Baseline	-32	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2339	1															1	2	2	Yes	1	1	0	4.7573447619	1992		53	1	22	1991	Month 66	65	138	1	in	lb			60.996	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	162	214	Stem cell, Autologous	1	1								0		1894	1	1			2	1	1		Baseline	1	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2114	-3	No		1467	Other		PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION & IN ANOTHER STUDY			2	1	7			Unknown	2	2	2	Yes	1	1			1433		53	1	16	1433	Year 4	67	124	1	in	kg			132.6	1	1	combined bortezomib/IMIDs/carfilzomib-based	1	5	3	1	1	1	1	Lenalidomide	219	224	236	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	351	392	41	1	1	883	1	126.14285714	694	3	3	2	4	2	1	1	1	Baseline	-6	53	Female			Checked			Checked	Unknown	Not Hispanic or Latino		0	1
MMRF_2150	-6															1	2	2	Yes	1	1		1.8864756534	1945		71	1	22	1964	Month 66	66	165		in	lb			70.72	0	1	combined bortezomib/IMIDs-based	3	1	3	0		0							0								1077	1	153.85714286	887	3	3	4	2	2	1	1	1	Baseline	-6	71	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1642	-12	No	72	72	Death	Other		SEPTIC SHOCK.	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1				65	1	-1	-12	Screening	161	74	3	cm	kg			150.28	0	1	combined bortezomib/IMIDs-based		1	1	0		0							0												5	5			2		1		Baseline	-18	65	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1661	-46	No		548	Patient is lost to follow-up					2	1	5				3	1	2	Yes	1	1			548		53	1	6	548	Month 18	163	63	2	cm	kg			70.72	0	1	Bortezomib-based		2	1	1	1	1	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	86	250	176	Stem cell, Autologous	1	1								0		352	1	1			2	2	1		Baseline	-30	53	Female	Checked							Hispanic or Latino		0	1
MMRF_1682	0	No	620	620	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	0	3.7073356936	567	620	72	1	7	616	Month 21	155	71	2	cm	kg			88.4	1	1	Bortezomib-based	9	2	4	1		0							0								295	1	42.142857143	211	5	3	4	2	2	2	1	1	Baseline	0	72	Male					Checked			Hispanic or Latino		0	1
MMRF_1705	-49															1	2	1	Yes	1	1	0	1.7788673566	2186		68	1	26	2186	Month 78	155	56	1	cm	kg			79.56	1	1	Bortezomib-based	9	2	1	1		0							0									0		2083	1	1			2	1	1		Baseline	-119	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1862	-13															1	2	2	Yes	1	1	1	1.9209461135	2174		53	1	24	2174	Year 6	164	76	3	cm	kg			152.048	0	1	combined bortezomib/IMIDs-based		1	2	0	1	1	1	Bortezomib/Lenalidomide	1	198	288	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	728	1059	331	1	1	1999	1	285.57142857	1628	3	1	1		2	1	1		Baseline	-13	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1969	0	No	945	945	Death	Other		HYPOVOLEMIC SHOCK	Hematologic	2	1	1	2	4		1	2	1	Yes	1	1			909		54	1	10	909	Month 30	162	62	3	cm	kg			468.52	1	1	combined bortezomib/IMIDs-based	3	1	1	0	1	1	1	Bortezomib/Dexamethasone	1	279	330	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	538	600	62	1	1		0		346	5	5			2	2			Baseline	2	54	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2024	1															1	2	2	Yes	1	1	1		2167		58	1	24	2167	Year 6	162	49	3	cm	kg			258.128	1	1	combined bortezomib/IMIDs-based	3	1	3	0	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	88	420	248	Stem cell, Autologous	1	1	Lenalidomide	452	732	280	1	1		0		1996	1	1	4	1	2	1	1		Baseline	1	58	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2039	1	No	475	475	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	6.2670996246	386	475	70	1	5	474	Month 15	170	70	3	cm	kg			380.12	1	1	combined bortezomib/IMIDs-based	3	1	2	0		0							0								296	1	42.285714286	209	5	3	5		2	2	1	1	Baseline	1	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2515	-13															1	2	2	Yes	1	1	1	1.7793707381	1751		87	1	19	1751	Month 57	144	49	1	cm	kg			66.3	2	2	Bortezomib-based	9	2	1	1		0							0									0		624	1	1			2	1	1		Baseline	-13	87	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2543	-83	No	1400	1400	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.6339360415	1302		68	1	15	1302	Month 45	184	72	2	cm	kg			87.516		2	Bortezomib-based	2	2	3	1		0							0								800	1	114.28571429	638	5	1	2	5	2	1		1	Baseline	-83	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2586	-19	No	707	707	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			535		68	1	6	535	Month 18	167	76	1	cm	kg			74.256	1	1	Bortezomib-based	9	2	1	1		0							0									0			5	5			2		1		Baseline	-2	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1908	-4	No	2077	2077	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	3.4501416135	2005	1247	68	1	24	2077	Year 6	151	58	1	cm	kg			44.2	2	2	combined bortezomib/IMIDs-based		1	2	1	0	1	1	Bortezomib/Thalidomide/Dexamethasone	1	179	190	Stem cell, Autologous	1	1	Thalidomide	387	718	331	1	1	978	1	139.71428571	883	5	3	5		2	1		1	Baseline	-4	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2013	-6															1	2	1	Yes	1	1	1		2087		61	1	24	2087	Year 6	164	62	1	cm	kg			69.836	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	226	2087	227	Stem cell, Autologous	1	1								0		2031	1	1			2	1	1		Baseline	-6	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2185	-5	No	1023	1023	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	0		981	1023	67	1	12	1023	Year 3	160	82	2	cm	kg			91.052		2	combined bortezomib/IMIDs-based		1	2	1	0	1	1	Bortezomib/Thalidomide/Dexamethasone	1	183	221	Stem cell, Autologous	1	1	Lenalidomide	533	718	185	1	1	746	1	106.57142857	575	5	3	4	4	2	1		1	Baseline	1	67	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1790	-6	No	983	983	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	1	4.7316663695	930	983	76	1	11	983	Month 33	146	66	3	cm	kg			81.328	1	2	Bortezomib-based	9	2	5	1		0							0								268	1	38.285714286	83	5	3	2	2	2	2		1	Baseline	1	76	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2225	-2	No	782	782	Death	Disease progression				2	1	1	1			1	2	2	Yes	1	1	0	8.0904321812	716	782	53	1	9	782	Month 27	157	65	2	cm	kg			115.804	1	1	combined bortezomib/IMIDs-based		1	4	1	1	1	1	Bortezomib/Dexamethasone/Doxorubicin	1	168	183	Stem cell, Autologous	1	1	Bortezomib/Dexamethasone	239	270	31	1	1	549	1	78.428571429	290	5	3	4	2	2	2		1	Baseline	1	53	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2307	-1	No		125	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	0	3.5740110494	94		66	1	1	94	Month 3	161	70	1	cm	kg			118.456	0	1	Bortezomib-based		2	1	1		0							0									0			4	4			2		1		Baseline	-1	66	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2465	1															1	2	2	Yes	1	1	2	3.114689272	1814		67	1	20	1814	Year 5	154	58	2	cm	kg			80.444	4	2	Bortezomib-based		2	2	1	0	1	1	Bortezomib/Dexamethasone/Doxorubicin	1	145	180	Stem cell, Autologous	1	1							1642	1	234.57142857	1564	3	3	1		2	1	1		Baseline	1	67	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2556	-10															1	2	1	Yes	1	1			1814		52	1	20	1814	Year 5	169	75	1	cm	kg			71.604	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	190	211	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	310	358	48	1	1	1814	1	259.14285714	1758	3	3			2	1	1		Baseline	-10	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2567	-19	No	1718	1718	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.9592250319	1637		62	1	18	1637	Month 54	181	97	2	cm	kg			90.168	0	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	189	214	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	295	352	57	1	1		0		1662	5	5			2	1			Baseline	-6	62	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1727	-14		2256	2256	Death	Disease progression						1	1			1	2	1	Yes	1	1	1		2190		71	1	24	2190	Year 6	166	66	3	cm	kg			52.156	2	2	Carfilzomib-based		9	4	0		0							0								610	1	87.142857143	528	5	3	1	2	2	1		1	Baseline	-13	71	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1916	-27	No	1688	1688	Death	Disease progression				2	1	1	1			1	1	2	Yes	1	1	0	3.529578167	1598	1346	75	1	19	1688	Month 57	146	61	2	cm	kg			91.936	1	1	Bortezomib-based		2	2	0		0							0								1252	1	178.85714286		5	2	5		2				Baseline	-27	75	Female					Checked			Hispanic or Latino		0	1
MMRF_1971	-23	No		1403	Other		PATIENT DERIVED TO THE PALLIATIVE CARE UNIT			2	1	7				1	1	2	Yes	1	1	0	3.3115667404	1316		65	1	15	1316	Month 45	150	59	1	cm	kg			72.488	1	1	Bortezomib-based		2	3	1		0							0								722	1	103.14285714	660	3	3	3	4	2	1	1	1	Baseline	-23	65	Female					Checked			Hispanic or Latino		0	1
MMRF_2017	-14	No	421	421	Death	Other		PANCOLITIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	1	1	Yes	1	1	1		349	421	82	1	5	421	Month 15	158	64	3	cm	kg			137.02	1	2	Bortezomib-based		2	3	1		0							0								167	1	23.857142857	85	5	3	2	5	2	2	1	1	Baseline	-14	82	Male					Checked			Hispanic or Latino		0	1
MMRF_2068	1	No	654	654	Death	Other		RESPIRATORY INFECTION	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	1	1.8923792339	623		82	1	7	623	Month 21	150	63	3	cm	kg			71.604	1	2	Bortezomib-based		2	1	1		0							0									0		564	5	5			2	1	1		Baseline	1	82	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2089	-8	No	449	449	Death	Other		INFECTION	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	2	Yes	1	1	1		351	449	66	1	5	449	Month 15	152	62	3	cm	kg			71.604	1	1	Bortezomib-based	9	2	2	1		0							0								259	1	37	175	5	3	5		2	2	1	1	Baseline	-8	66	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2102	-17	No	1486	1486	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1		1424		76	1	16	1424	Year 4	170	75	3	cm	kg			148.512	1	2	Bortezomib-based	9	2	4	1		0							0								631	1	90.142857143	547	5	3	3	1	2	1		1	Baseline	-17	76	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2142	-61	No		318	Other		PATIENT INCLUDED IN MILLENIUM TRIAL			2	1	7				1	2	1	Yes	1	1			318		75	1	4	318	Year 1	158	75	1	cm	kg			62.764	2	2	Bortezomib-based	9	2	1	1		0							0									0		276	1	1			2	2	1		Baseline	-61	75	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2335	-6	No	264	264	Death	Other		RESPIRATORY INFECTION	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1	2.5694296261	162	264	64	1	3	264	Month 9	170	80	3	cm	kg			95.472	1	1	combined bortezomib/IMIDs-based	1	1	1	1		0							0									0		180	5	5			2	2	1		Baseline	-6	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2468	-20															1	1	1	Yes	1	1	1	2.0287727747	1834		60	1	20	1834	Year 5	170	75	3	cm	kg			137.02	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	189	222	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	351	404	53	1	1		0		1737	1	1			2	1	1		Baseline	-19	60	Male					Checked			Hispanic or Latino		0	1
MMRF_1654	0	No	81	81	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	0	2.42558067	64	81	86	1	1	64	Month 3	156	70	2	cm	kg			155.584		2	Bortezomib-based	3	2	1	0		0							0												5	5			2		1		Baseline	0	86	Male					Checked			Hispanic or Latino		0	1
MMRF_1678	-6	No	231	231	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1		1.9122383795	183	231	80	1	3	230	Month 9	165	75		cm	kg			87.516	3	2	IMIDs-based		3	1	1		0							0									0		49	5	5			2	2	1		Baseline	-8	80	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1738	0	No	689	689	Death	Other		SEPTIC SHOCK	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	1	2	Yes	1	1	2	4.5731389348	623		78	1	7	623	Month 21	165	65	3	cm	kg			808.86	0	2	Bortezomib-based	3	2	3	0		0							0								93	1	13.285714286	28	5	1	3	5	1	2	1	1	Baseline	0	78	Female					Checked			Hispanic or Latino		0	1
MMRF_2224	-3															1	2	1	Yes	1	1	1	2.1952041043	1995		56	1	22	1995	Month 66	184	79	3	cm	kg			112.268	0	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	401	242	Stem cell, Autologous	1	1	Lenalidomide/Dexamethasone	477	1222	745	2	2		0		1921	1	1			2	1	1		Baseline	-3	56	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2368	-16	No		133	Inter-current illness that interferes with study assessments					2	1	4				1	2	2	Yes	1	1	1	2.8722481796	133		82	1	2	133	Month 6	149	54	3	cm	kg			93.704	1	2	Bortezomib-based	9	2	1	1		0							0									0		17	1	1			2	2	1		Baseline	-17	82	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2050	-5	No		206	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	1		164		78	1	2	164	Month 6	155	72	3	cm	kg			99.008	1	2	Bortezomib-based	9	2	1	1		0							0									0		70	1	1			2	2	1		Baseline	-5	78	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2197	-2	No		51	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1			82		82	1	1	82	Month 3	173	70		cm	kg			129.948		2	Bortezomib-based	9	2	1	1		0							0												4	4			2		1		Baseline	-5	82	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2200	0	No	449	449	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	1	4.0481699797	441		58	1	5	441	Month 15	174	84	3	cm	kg			423.436	2	2	Bortezomib-based		2	2	1		0	2	Thalidomide/Cyclophosphamide/Dexamethasone	147	208	211	Stem cell, Autologous	1	0							140	1	20	50	5	3	5		2	2	1	1	Baseline	1	58	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2273	-3	No	1360	1360	Death	Other		INTRACRANIAL HEMORRHAGE	Hematologic	2	1	1	2	4		1	2	2	Yes	1	1		2.8123108385	1248	1360	69	1	15	1360	Month 45	165	60		cm	kg			72.488	1	1	Bortezomib-based	2	2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	266	253	Stem cell, Autologous	1	1							1066	1	152.28571429	981	5	3	5		2	1		1	Baseline	-3	69	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2336	-41															1	2	2	Yes	1	1	1	2.4410246289	1802		63	1	20	1802	Year 5	154	87	1	cm	kg			53.04	0	1	combined bortezomib/IMIDs-based		1	2	1	0	1	1	Bortezomib/Thalidomide/Dexamethasone	1	132	164	Stem cell, Autologous	1	1							689	1	98.428571429	603	3	1	1		2	1	1	1	Baseline	-18	63	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2365	-21	No		260	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	1	3.0570394432	165		77	1	2	165	Month 6	141	56	3	cm	kg			70.72	1	2	Bortezomib-based	9	2	1	1		0							0									0		1	1	1			2	2	1		Baseline	-15	77	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2519	-18															1	1	1	Yes	1	1	0	2.0138050738	1830		67	1	20	1830	Year 5	183	103	1	cm	kg			83.096	1	1	combined bortezomib/IMIDs-based		1	1	1	1	1	1	Bortezomib/Thalidomide/Dexamethasone	1	876	186	Stem cell, Autologous	1	1							1811	1	258.71428571	1725	3	3			2	1	1		Baseline	-17	67	Male					Checked			Hispanic or Latino		0	1
MMRF_2578	-5	No	761	761	Death	Other		MULTIFACTORIAL COGNITIVE IMPAIRMENT	Neurological	2	1	1	2	6		1	2	1	Yes	1	1			716		74	1	8	716	Year 2	166	68	1	cm	kg			63.648		2	combined bortezomib/IMIDs-based	9	1	1	1		0							0									0		585	5	5			2	1			Baseline	-5	74	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2602	1	No		75	Patient is lost to follow-up					2	1	5				1	2	1	Yes	1	1	2	1.9812742913			51	1	0	1	Baseline	173	96	3	cm	kg			707.2		2	Bortezomib-based	3	2	1	0		0							0												4	4			2		1		Baseline	1	51	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2606	-4															1	2	2	Yes	1	1	2	2.2198502123	1823		70	1	20	1823	Year 5	148	59	2	cm	kg			53.04	1	1	Bortezomib-based	2	2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	211	221	Stem cell, Autologous	1	1							549	1	78.428571429	470	3	3	3		2	1	1	1	Baseline	-2	70	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1923	-12															1	1	2	Yes	1	1		1.9474227023	2124		52	1	24	2124	Year 6	169	70	1	cm	kg			61.88	0	1	combined bortezomib/IMIDs-based		1	1	0	1	1	1	Bortezomib/Daratumumab/Thalidomide/Dexamethasone	1	162	173	Stem cell, Autologous	1	1								0		1963	1	1			2	1	1		Baseline	-12	52	Female					Checked			Hispanic or Latino		0	1
MMRF_1716	-3	No	77	77	Death	Disease progression				2	1	1	1			1	1	2	Yes	1	1	0	1.942305429		139	84	1	1	77	Month 3	158	69	2	cm	kg			137.02	4	2	Bortezomib-based	9	2	1	1		0							0												5	5			2		1		Baseline	-3	84	Female					Checked			Hispanic or Latino		0	1
MMRF_1931	-94															1	1	2	Yes	1	1	1	1.6359036653	2206		72	1	24	2206	Year 6	155	53	3	cm	kg			57.46	3	2	Bortezomib-based	9	2	3	1		0							0								520	1	74.285714286	338	3	3	3	1	2	2	1	1	Baseline	-5	72	Female					Checked			Hispanic or Latino		0	1
MMRF_2194	1	No	1094	1094	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	2	4.572773139	990	1094	75	1	12	1094	Year 3	163	80	2	cm	kg			74.256	2	2	Bortezomib-based	9	2	5	1		0							0								443	1	63.285714286	260	5	3	2	4	2	2		1	Baseline	1	75	Male					Checked			Hispanic or Latino		0	1
MMRF_2245	-1	No		64	Patient is lost to follow-up					2	1	5				1	1	2	Yes	1	1	0	4.5197967723	91		77	1	1	91	Month 3	160	80	2	cm	kg			45.968	4	2	Bortezomib-based	9	2	1	1		0							0												4	4			2		1		Baseline	-1	77	Female					Checked			Hispanic or Latino		0	1
MMRF_2257	-8															1	1	1	Yes	1	1	0	2.6124972408	1969		67	1	22	1969	Month 66	173	85	2	cm	kg			118.456	1	1	Bortezomib-based	3	2	2	0		0							0								1154	1	164.85714286	1067	3	1	1		2	1	1		Baseline	-8	67	Male					Checked			Hispanic or Latino		0	1
MMRF_2526	-20															1	1	2	Yes	1	1	2	1.8170356621	1774		69	1	20	1774	Year 5	162	65	2	cm	kg			62.764	1	1	Bortezomib-based	9	2	1	1		0							0									0		1697	1	1			2	1	1		Baseline	-20	69	Female					Checked			Hispanic or Latino		0	1
MMRF_1913	-14	No	1459	1459	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1405	1459	79	1	17	1426	Month 51	170	71	3	cm	kg			167.96	1	2	Bortezomib-based	9	2	4	1		0							0								452	1	64.571428571	386	5	3	2	3	2	1		1	Baseline	-14	79	Male					Checked			Not Hispanic or Latino		0	1
MMRF_1978	-6															1	2	2	Yes	1	1	0	1.6707850426	2165		73	1	24	2165	Year 6	168	77	2	cm	kg			112.268	1	1	Bortezomib-based	9	2	2	1		0							0								604	1	86.285714286	521	3	3	1		2	1	1	1	Baseline	0	73	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1989	-1															1	2	1	Yes	1	1			2197		49	1	24	2197	Year 6	188	85	1	cm	kg			85.748	1	1	combined bortezomib/IMIDs-based	1	1	1	1	0	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	200	235	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	333	1205	872	2	2		0		2074	1	1			2	1	1		Baseline	1	49	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2049	-76															1	2	1	Yes	1	1			2009		60	1	22	2009	Month 66	163	67	1	cm	kg			103.428		2	combined bortezomib/IMIDs-based	1	1	2	1		0							0								634	1	90.571428571	526	3	3	1		2	1	1	1	Baseline	1	60	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2384	-14															1	2	2	Yes	1	1	0	2.3253181172	1808		57	1	20	1808	Year 5	156	50	2	cm	kg			54.808	1	1	combined bortezomib/IMIDs-based	1	1	1	1	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	1	1808	231	Stem cell, Autologous	1	1								0		1717	1	1			2	1	1		Baseline	1	57	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2385	-2	No	1451	1451	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1			1368	1286	60	1	16	1451	Year 4	174	94	3	cm	kg			195.364	2	2	Bortezomib-based		2	3	1	0	1	1	Bortezomib/Cyclophosphamide/METHYLPREDNISOLONE	1	77	139	Stem cell, Autologous	1	1							619	1	88.428571429	524	5	1	1	5	2	1		1	Baseline	1	59	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2413	-2	No	1442	1442	Death	Disease progression				2	1	1	1			1	2	1	Yes	1	1	2	1.9156651	1365	1272	61	1	16	1442	Year 4	183	98	3	cm	kg			85.748	2	2	Bortezomib-based	9	2	2	1		0							0								847	1	121	774	5	3	5		2	1		1	Baseline	-9	61	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2580	-15															1	2	2	Yes	1	1	0	2.1656450686	1834		80	1	20	1834	Year 5	151	59	1	cm	kg			55.692	1	2	Bortezomib-based	9	2	1	1		0							0								677	1	96.714285714	596	3	3			2	1	1	1	Baseline	-23	80	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1861	-55	No	1309	1309	Death	Other		ACUTE ISCHEMIC ICTUS	Neurological	2	1	1	2	6		1	2	2	Yes	1	1	0	1.8484029043	1269		71	1	14	1269	Month 42	145	54	1	cm	kg			53.04		2	Bortezomib-based	9	2	2	1		0							0								801	1	114.42857143	700	5	3	5		2	1		1	Baseline	-4	71	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1933	-6	No		977	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1			977		77	1	11	977	Month 33	175	80	2	cm	kg			35.36	3	2	Bortezomib-based	9	2	2	1		0							0								831	1	118.71428571	737	3	3	4		2	1	1	1	Baseline	1	77	Female					Checked			Not Hispanic or Latino		0	1
MMRF_1995	0	No	1489	1489	Death	Other		ACUTE DIVERTICULITIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1		1435		72	1	16	1435	Year 4	169	81	3	cm	kg			167.96	1	1	Bortezomib-based	3	2	5	0		0							0								453	1	64.714285714	389	5	3	3	4	2	1		1	Baseline	0	72	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2008	-77	No	1381	1381	Death	Other		UNKNWOM	Unknown	2	1	1	2	9		1	2	1	Yes	1	1			1339		70	1	15	1339	Month 45	173	95	3	cm	kg			141.44	0	1	combined bortezomib/IMIDs-based	3	1	4	0		0							0								891	1	127.28571429	802	5	3	2	4	2	1		1	Baseline	1	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2011	-25	No	1972	1972	Death	Other		SEPSIS OF ORIGIN CUTANEOUS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1			1796		73	1	20	1796	Year 5	164	110	3	cm	kg			185.64	1	1	Bortezomib-based		2	4	0		0							0								281	1	40.142857143		5	2	3	3	2			1	Baseline	1	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2085	-24	No	512	512	Death	Other		UNKNOWN	Unknown	2	1	1	2	9		1	2	2	Yes	1	1			435		74	1	5	435	Month 15	163	100		cm	kg			123.76	1	1	Bortezomib-based	9	2	2	1		0							0								346	1	49.428571429		5	4	3	5	2		1	1	Baseline	-17	74	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2229	-61	No	1369	1369	Death	Other		DIVERTICULITIS WITH COLOVESICAL FISTULA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1	1		1291	1369	70	1	16	1369	Year 4	165	75	1	cm	kg			81.328	0	1	Bortezomib-based		2	2	1		0							0								1031	1	147.28571429	1003	5	3	5		2	1		1	Baseline	-61	70	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2328	0	No	976	976	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	2	3.4367256196	897		66	1	10	897	Month 30	177	74	3	cm	kg			221	1	1	combined bortezomib/IMIDs-based	2	1	4	1		0							0								687	1	98.142857143	596	5	3	2	2	2	1		1	Baseline	0	66	Male					Checked			Hispanic or Latino		0	1
MMRF_2401	-3	No	389	389	Death	Other		SEVERE RESPIRATORY INSUFFICIENCY	Respiratory	2	1	1	2	7		1	2	1	Yes	1	1	2	7.1781881588	365	389	64	1	5	389	Month 15	169	67	3	cm	kg			331.5		2	combined bortezomib/IMIDs-based		1	3	1		0	3	CLARITHROMYCIN/ETOPOSIDE (VP16)/Melphalan/Dexamethasone/Doxorubicin	251	272	274	Stem cell, Autologous	1	0	Bortezomib/Lenalidomide/Dexamethasone	305	364	59	1		81	1	11.571428571		5	2	2	5	1		1	1	Baseline	-3	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2427	-61	No	638	638	Death	Other		PNEUMONIA	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	2	1	Yes	1	1		3.4189192234	610	638	64	1	8	638	Year 2	157	68	2	cm	kg			59.228	0	1	combined bortezomib/IMIDs-based		1	2	1		0							0								460	1	65.714285714	90	5	1	5		2	2	1	1	Baseline	1	64	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2435	-4	No	741	741	Death	Other		STOP CARDIORESPIRATORY	Unknown	2	1	1	2	9		1	2	2	Yes	1	1			688	741	76	1	8	740	Year 2	149	71	3	cm	kg			146.744	1	2	Bortezomib-based	9	2	1	1		0							0									0		671	5	5			2	1			Baseline	-8	76	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2488	0															1	2	1	Yes	1	1	1	3.3935474129	1843		52	1	20	1843	Year 5	180	88	3	cm	kg			106.08	2	2	combined bortezomib/IMIDs-based	1	1	2	1	1	1	1	BUSULFAN/Melphalan	243	246	248	Stem cell, Autologous	1	1	Bortezomib/Lenalidomide/Dexamethasone	346	402	56	1	1	1521	1	217.28571429	1427	3	3	1		2	1	1		Baseline	1	52	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2490	-1	No	349	349	Death	Other		STROKE	Neurological	2	1	1	2	6		1	2	2	Yes	1	1	1	17.32912179	266		81	1	3	266	Month 9	166	80	3	cm	kg			144.976	2	2	Bortezomib-based	3	2	2	0		0							0								91	1	13		5	4	5		1		1	1	Baseline	-1	81	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2518	-52	No		1117	Patient is lost to follow-up					2	1	5				1	2	2	Yes	1	1	2	1.6594227201	1117		84	1	13	1117	Month 39	155	83	3	cm	kg			60.996	1	2	Bortezomib-based		2	1	0		0							0									0		1068	1	1			2	1	1		Baseline	-41	84	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2293	1															1	1	1	Yes	1	1	0	2.2546696809	1981		69	1	20	1981	Year 5	168	78	1	cm	kg			102.544	0	1	combined bortezomib/IMIDs-based		1	1	1	1	1	1	Bortezomib/Thalidomide/Dexamethasone	1	1981	298	Stem cell, Autologous	1	1								0		1897	1	1			2	1	1		Baseline	1	69	Male					Checked			Hispanic or Latino		0	1
MMRF_2300	0	No	66	66	Death	Other		PNEUMONIAE. RENAL INSUFFICIENCY	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	1	1	Yes	1	1	1	9.0308894106		66	80	1	1	66	Month 3	165	87	3	cm	kg			185.64	2	2	Bortezomib-based		2	1	0		0							0									0			5	5			2		1		Baseline	-1	80	Male					Checked			Hispanic or Latino		0	1
MMRF_2313	-12	No	1933	1933	Death	Disease progression				2	1	1	1			1	1	1	Yes	1	1	0	3.6119154283	1855	1008	53	1	24	1933	Year 6	190	130	2	cm	kg			98.124	0	1	combined bortezomib/IMIDs-based		1	4	1	1	1	1	Bortezomib/Thalidomide/Dexamethasone	1	358	268	Stem cell, Autologous	1	1							731	1	104.42857143	647	5	3	1	1	2	1		1	Baseline	-12	53	Male					Checked			Hispanic or Latino		0	1
MMRF_2314	1	No	96	96	Death	Other		PSEUDOMONAS AERUGINOSA NEUMONIA BECAUSE OF PREVIOUS CHRONIC PNEUMOPATHY	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	1	1	Yes	1	1	0	9.5764957205		96	59	1	1	96	Month 3	183	79	2	cm	kg			75.14	3	2	combined bortezomib/IMIDs-based		1	1	1		0							0												5	5			2		1		Baseline	1	59	Male					Checked			Hispanic or Latino		0	1
MMRF_2327	-1	No	1507	1507	Death	Other		PNEUMONIAE	Other	2	1	1	2	10		1	1	1	Yes	1	1	0		1469	1235	73	1	17	1507	Month 51	170	82	1	cm	kg			93.704	1	1	combined bortezomib/IMIDs-based	9	1	1	1		0							0								1140	1	162.85714286	696	5	5			2	1			Baseline	1	73	Male					Checked			Hispanic or Latino		0	1
MMRF_2364	-7	No	156	156	Death	Other		PARAPARESIA SECONDARY TO VERTEBRAE FRACTURE AND SPONDILODISCYTIS-SEPSIS	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5		1	1	1	Yes	1	1	1	2.7891883014	90		51	1	1	90	Month 3	164	102	3	cm	kg			94.588	0	1	combined bortezomib/IMIDs-based		1	1	1		0							0									0		67	5	5			2	2	1		Baseline	-8	51	Male					Checked			Hispanic or Latino		0	1
MMRF_2452	1															1	1	1	Yes	1	1	0		1835		64	1	20	1835	Year 5	167	73	1	cm	kg			88.4	2	2	combined bortezomib/IMIDs-based		1	1	1	1	1	1	Bortezomib/Thalidomide/Dexamethasone	1	1835	193	Stem cell, Autologous	1	1								0		1570	1	1			2	1	1		Baseline	1	64	Male					Checked			Hispanic or Latino		0	1
MMRF_2535	3	No	565	565	Death	Disease progression				2	1	1	1			1	1	2	Yes	1	1	1	4.4811123081	533		46	1	6	533	Month 18	163	54	3	cm	kg			297.024	3	2	combined bortezomib/IMIDs-based		1	2	1	0	1	1	Bortezomib/Thalidomide/Dexamethasone	1	200	213	Stem cell, Autologous	1	1							354	1	50.571428571	256	5	1	5		2	2	1	1	Baseline	3	46	Female					Checked			Hispanic or Latino		0	1
MMRF_2572	-1	No	1176	1176	Death	Other		HEPATIC CIRRHOSIS	Hematologic	2	1	1	2	4		1	1	1	Yes	1	1	0	1.567728471	1082	1176	75	1	13	1176	Month 39	162	71	2	cm	kg			88.4	3	2	Bortezomib-based	9	2	3	1		0							0								630	1	90	546	5	3	2	5	2	1		1	Baseline	-1	75	Male					Checked			Hispanic or Latino		0	1
MMRF_2601	-2															1	1	2	Yes	1	1	0	2.2912234309	1821		70	1	20	1821	Year 5	152	100	2	cm	kg			70.72	0	1	Bortezomib-based	9	2	2	1		0							0								554	1	79.142857143	385	3	3	1		2	1	1	1	Baseline	1	70	Female					Checked			Hispanic or Latino		0	1
MMRF_2613	-5	No	621	621	Death	Disease progression				2	1	1	1			1	1	2	Yes	1	1	0	2.9754601925	534	621	70	1	7	621	Month 21	152	83	2	cm	kg			66.3	1	1	Bortezomib-based	9	2	3	1		0							0								344	1	49.142857143	176	5	1	3	5	2	2	1	1	Baseline	-5	70	Female					Checked			Hispanic or Latino		0	1
MMRF_2016	-3															1	2	1	Yes	1	1	1	1.6790813202	1982		76	1	22	1982	Month 66	175	84	3	cm	kg			113	3	2	combined bortezomib/IMIDs-based	9	1	1	1		0							0								1975	1	282.14285714	1905	3	3			2	1	1		Baseline	-7	76	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2268	-19															1	2	1	Yes	1	1	0		1824		73	1	20	1824	Year 5	167	70	2	cm	kg			75	1	1	Bortezomib-based	9	2	2	1		0							0								718	1	102.57142857	640	3	3	1		2	1	1	1	Baseline	-10	73	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2305	-6															1	2	1	Yes	1	1	1	2.9356126543	888		68	1	10	881	Month 30	165	95	3	cm	kg			75	2	2	Bortezomib-based		2	2	1	1	1	1	Bortezomib/Cyclophosphamide/Prednisone	1	131	243	Stem cell, Autologous	1	1							833	1	119	745	3	3	4		2	1	1	1	Baseline	-5	68	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2421	-6															1	2	2	Yes	1	1			1625		68	1	18	1632	Month 54	154	55	2	cm	kg			63	1	1	Bortezomib-based	2	2	1	1	0	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	1	98	194	Stem cell, Autologous	1	1								0		1535	1	1			2	1	1		Baseline	-6	68	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2444	-3	No	76	76	Death	Other		CARDIAC ARRITHMIA	Cardiovascular	2	1	1	2	1		1	2	2	Yes	1	1	2	1.8194236307		76	81	1	1	74	Month 3	160	52	3	cm	kg			92	0	2	Bortezomib-based	9	2	1	1		0							0									0		3	5	5			2	2	1		Baseline	-2	81	Female					Checked			Not Hispanic or Latino		0	1
MMRF_2558	-11	No		1087	Patient no longer consents to participate in the study					2	1	3				1	1	2	Yes	1	1			998		73	1	11	998	Month 33	166	65	2	cm	kg			78	2	2	Bortezomib-based	9	2	1	1		0							0								998	1	142.57142857	918	3	3			2	1	1	1	Baseline	-5	73	Female					Checked			Hispanic or Latino		0	1
MMRF_2195	-6	No	1742	1742	Death	Other		FEBRILE SYNDROME	Other	2	1	1	2	10		1	2	1	Yes	1	1	0		1608	1183	69	1	19	1742	Month 57	165	75	2	cm	kg			78.676	1	1	Bortezomib-based	9	2	3	1		0							0								725	1	103.57142857	601	5	3	3	5	2	1		1	Baseline	-6	69	Male					Checked			Not Hispanic or Latino		0	1
MMRF_2317	-26	No		610	Patient no longer consents to participate in the study					2	1	3				1	1	1	Yes	1	1	1	1.7181532625	610		75	1	7	610	Month 21	155	78	1	cm	kg			68.068		2	Bortezomib-based	9	2	2	1		0							0								610	1	87.142857143	503	3	1	2		2	1	1	1	Baseline	1	75	Male					Checked			Hispanic or Latino		0	1
MMRF_2426	-3																	2	Yes	1	1					63	1	7	617	Month 21	162	66	1	cm	kg			65.41600084		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	125	125	173	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	262	443	181	1	1		0		561	1	1			2	1	1																1
MMRF_2583	-11																	2	Yes	1	1					60	1	6	495	Month 18	156	48	2	cm	kg			55.691999576		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	116	116	159	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	267	414	147	1	1		0		467	1	1			2	1	1																1
MMRF_2584	-4																	2	Yes	1	1					57	1	6	505	Month 18	155	48	2	cm	kg			52.155997684		2	combined IMIDs/carfilzomib-based		4	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	118	159	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	267	421	154	1	1		0		477	1	1			2	1	1																1
MMRF_2604	-12																	1	Yes	1	1					62	1	7	604	Month 21	165	87	3	cm	kg			95.472003792		2	combined IMIDs/carfilzomib-based		4	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	133	205	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	311	436	125	1	1		0		474	1	1			2	1	1																1
MMRF_2609	0																	1	Yes	1	1					65	1	7	604	Month 21	175	79	2	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		576	1	1			2	1	1																1
MMRF_2624	-2																	1	Yes	1	1					58	1	7	587	Month 21	167	55	1	cm	kg			97.240002104		2	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	114	163	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	274	404	130	1	1		0		531	1	1			2	1	1																1
MMRF_2626	-13	No		292	Other					2	1	7						1	Yes	1	1					62	1	3	218	Month 9	170	69	3	cm	kg			91.051997472		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		190	1	1			2	2	1																1
MMRF_2628	-15	No		337	Other		Pre-consolidation BOM showed a cellularity of 15%. In june 2016 worsening o			2	1	7						1	Yes	1	1					65	1	4	336	Year 1	175	92	2	cm	kg			123.7599979		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	114	114	159	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	253	280	27	1	1		0		309	1	1			2	2	1																1
MMRF_2630	-6																	1	Yes	1	1					58	1	6	569	Month 18	176	75	1	cm	kg			65.41600084		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	139	139	199	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	296	429	133	1	1		0		541	1	1			2	1	1																1
MMRF_2631	-6																	1	Yes	1	1					63	1	7	617	Month 21	178	84	2	cm	kg			91.935996632		2	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	121	159	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	274	392	118	1	1		0		290	1	1			2	2	1																1
MMRF_2634	-18																	1	Yes	1	1					59	1	5	456	Month 15	172	77	2	cm	kg			114.91999578		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	117	117	172	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	263	382	119	1	1		0		428	1	1			2	1	1																1
MMRF_2635	-20																	1	Yes	1	1					63	1	7	581	Month 21	178	67	2	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	123	123	165	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	275	385	110	1	1		0		552	1	1			2	1	1																1
MMRF_2636	-9																	1	Yes	1	1					57	1	5	447	Month 15	184	82	3	cm	kg			112.26799831		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	113	162	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	259	371	112	1	1		0		419	1	1			2	1	1																1
MMRF_2637	-14																	2	Yes	1	1					55	1	5	406	Month 15	165	69	2	cm	kg			72.487999364		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	144	144	188	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	281	393	112	1	1		0		378	1	1			2	1	1																1
MMRF_2638	-14																	1	Yes	1	1					53	1	5	435	Month 15	169	59	2	cm	kg			72.487999364		2	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	120	166	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	260	385	125	1	1		0		379	1	1			2	1	1																1
MMRF_2639	-1																	1	Yes	1	1					48	1	6	553	Month 18	180	85	1	cm	kg			57.459997896		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								553	1	79	497	3	3			2	1	1	1															1
MMRF_2640	-13																	1	Yes	1	1					45	1	7	561	Month 21	180	70	1	cm	kg			71.604000212		2	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	157	203	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	302	420	118	1	1		0		504	1	1			2	1	1																1
MMRF_2641	-12																	1	Yes	1	1					53	1	3	232	Month 9	173	63	1	cm	kg			77.791999576		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		204	1	1			2	2	1																1
MMRF_2642	-15																	2	Yes	1	1					59	1	7	567	Month 21	155	48	2	cm	kg			67.18399916		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		538	1	1			2	1	1																1
MMRF_2643	-12																	1	Yes	1	1					56	1	4	337	Year 1	175	87	2	cm	kg			114.91999578		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	117	158	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	253	365	112	1	1		0			4	4			2		1																1
MMRF_2647	-3																	1	Yes	1	1					57	1	4	309	Year 1	172	74	1	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	138	138	200	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	309	421	112	1	1					4	4			2		1																1
MMRF_2644	-5																	1	Yes	1	1					48	1	6	520	Month 18	170	85	1	cm	kg			117.57200379		2	combined IMIDs/carfilzomib-based		4	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	130	164	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	260	383	123	1	1		0		492	1	1			2	1	1																1
MMRF_2646	-7	No		190	Other					2	1	7						1	Yes	1	1					56	1	2	154	Month 6	80	170	2	cm	kg			150.28000422		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		84	1	1			2	2	1																1
MMRF_2648	-9																	2	Yes	1	1					64	1	6	540	Month 18	70	152	1	cm	kg			53.040002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		512	1	1			2	1	1																1
MMRF_2650	-8																	2	Yes	1	1					59	1	6	481	Month 18	163	71	3	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	149	149	190	Stem cell, Autologous	1	1								0		453	1	1			2	1	1																1
MMRF_2651	-4																	1	Yes	1	1					61	1	6	512	Month 18	163	88	2	cm	kg			99.891999576		2	combined IMIDs/carfilzomib-based		4	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	123	170	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	267	413	146	1	1		0		484	1	1			2	1	1																1
MMRF_2652	-3																	2	Yes	1	1					65	1	6	528	Month 18	165	75	3	cm	kg			53.040002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		500	1	1			2	1	1																1
MMRF_2653	-13																	1	Yes	1	1					52	1	6	484	Month 18	176	86	1	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		456	1	1			2	1	1																1
MMRF_2654	-5																	2	Yes	1	1					60	1	2	175	Month 6			1	cm	kg			70.720001052		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	116	177	Stem cell, Autologous	1	1								0		64	1	1			2	2	1																1
MMRF_2655	-15																	1	Yes	1	1					64	1	6	528	Month 18	166	76	2	cm	kg			123.7599979		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	150	185	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	300	447	147	1	1		0		500	1	1			2	1	1																1
MMRF_2659	-12	No	135	28	Death	Other	SAE G2 related, GastrointestinaI G2 related	FEVER, PANCYTOPENIA (PATIENT DEAD AT HOME)	Other	2	1	1	2	10				1	Yes	1	1					62	1	0	1	Baseline	173	53	2	cm	kg			88.4		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												5	5			2		1																1
MMRF_2660	-25																	1	Yes	1	1					38	1	5	373	Month 15	180	95	1	cm	kg			68.951997472		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	163	373	165	Stem cell, Autologous	1	1								0		346	1	1			2	2	1																1
MMRF_2664	-11	No		340	Other		SAE G3 not related, Pneumonia			2	1	7						1	Yes	1	1					64	1	4	305	Year 1	170	83	1	cm	kg			71.604000212		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	138	138	185	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	276	305	29	1	1	305	1	43.571428571	276	3	3			2	2	1	1															1
MMRF_2665	-13																	1	Yes	1	1					62	1	6	486	Month 18	184	84	2	cm	kg			89.28399916		2	combined IMIDs/carfilzomib-based		4	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	115	170	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	223	343	120	1	1		0		375	1	1			2	1	1																1
MMRF_2667	-6																	2	Yes	1	1					52	1	5	447	Month 15			1	cm	kg			61.879998948		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	122	122	163	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	247	366	119	1	1		0		391	1	1			2	1	1																1
MMRF_2666	-12	No		277	Other		THROMBOCYTOPENIA G3 related, NO PLTS RECOVERY IN TIME FOR CONSOLIDATION			2	1	7						1	Yes	1	1					62	1	2	156	Month 6	179	82	1	cm	kg			88.4		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	117	158	Stem cell, Autologous	1	1								0		128	1	1			2	2	1																1
MMRF_2669	-8																	1	Yes	1	1					48	1	3	230	Month 9	175	84	2	cm	kg			54.808000424		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		1	1	1			2	2	1																1
MMRF_2670	-21																	2	Yes	1	1					63	1	4	330	Year 1	90	159	2	cm	kg			65.41600084		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		302	1	1			2	2	1																1
MMRF_2671	-4	No		450	Other					2	1	7						2	Yes	1	1					43	1	4	339	Year 1	159	55	2	cm	kg			85.748002528		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	160	160	199	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	310	436	126	1	1		0		157	1	1			2	2	1																1
MMRF_2675	-19	No		95	Other		SAE G3 related, Atrial Fibrillation			2	1	7						2	Yes	1	1					60	1	1	92	Month 3	150	98	2	cm	kg			67.18399916		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		68	1	1			2	2	1																1
MMRF_2676	-19																	2	Yes	1	1					47	1	6	464	Month 18	168	64	2	cm	kg			68.067998312		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	131	180	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	269	451	182	1	1		0		436	1	1			2	1	1																1
MMRF_2677	-13																	1	Yes	1	1					58	1	6	475	Month 18	178	83	3	cm	kg			114.91999578		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		442	1	1			2	1	1																1
MMRF_2678	-20																	2	Yes	1	1					63	1	4	318	Year 1	160	55	1	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	117	154	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	262	381	119	1	1		0		289	1	1			2	2	1																1
MMRF_2679	-12																	1	Yes	1	1					47	1	5	452	Month 15	190	105	2	cm	kg			182.98799409		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	116	116	151	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	246	372	126	1	1		0		423	1	1			2	1	1																1
MMRF_2680	-27																	2	Yes	1	1					64	1	4	324	Year 1	160	62	1	cm	kg			44.2		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		281	1	1			2	2	1																1
MMRF_2681	-1																	1	Yes	1	1					45	1	5	392	Month 15	182	95	3	cm	kg			173.26400337		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	121	161	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	253	377	124	1	1		0			4	4			2		1																1
MMRF_2682	-5																	1	Yes	1	1					60	1	6	455	Month 18	175	69	1	cm	kg			63.648002528		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	139	139	197	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	295	427	132	1	1		0		395	1	1			2	1	1																1
MMRF_2683	-8																	2	Yes	1	1					45	1	5	414	Month 15	155	78	1	cm	kg			61.879998948		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	130	130	224	Stem cell, Autologous	1	1								0		387	1	1			2	1	1																1
MMRF_2685	-12																	1	Yes	1	1					63	1	3	268	Month 9	176	87	2	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		65	1	1			2	2	1																1
MMRF_2688	-11																	2	Yes	1	1					53	1	2	155	Month 6	160	64	1	cm	kg			53.040002104		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	123	158	Stem cell, Autologous	1	1								0		128	1	1			2	2	1																1
MMRF_2690	-5																	1	Yes	1	1					51	1	5	467	Month 15	175	67	2	cm	kg			89.28399916		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		439	1	1			2	1	1																1
MMRF_2689	-12																	1	Yes	1	1					62	1	5	431	Month 15	185	85	2	cm	kg			71.604000212		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		395	1	1			2	1	1																1
MMRF_2691	-7	No		369	Other					2	1	7						1	Yes	1	1					39	1	5	417	Month 15	170	61	1	cm	kg			88.4		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	113	113	154	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	251	417	166	1	1		0		333	1	1			2	2	1																1
MMRF_2692	-10	No	318	169	Death	Other	SAE G4 (SPM - Metastatic melanoma), Death after discontinuation	SPM	Other	2	1	1	2	10				2	Yes	1	1					43	1	2	155	Month 6	165	66	2	cm	kg			78.675998736		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0			5	5			2		1																1
MMRF_2694	-16																	1	Yes	1	1					60	1	5	438	Month 15	168	74	2	cm	kg			87.51600084		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	125	173	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	263	410	147	1	1		0		409	1	1			2	1	1																1
MMRF_2695	-19																	2	Yes	1	1					56	1	5	380	Month 15	159	54	3	cm	kg			104.31199536		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	145	192	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	268	450	182	1	1		0		327	1	1			2	2	1																1
MMRF_2696	-13																	2	Yes	1	1					49	1	4	302	Year 1	160	55	1	cm	kg			39.779998948		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	111	164	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	274	386	112	1	1		0		274	1	1			2	2	1																1
MMRF_2697	-10																	1	Yes	1	1					53	1	2	99	Month 6	187	77	1	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		64	1	1			2	2	1																1
MMRF_2698	-15																	1	Yes	1	1					50	1	3	196	Month 9	170	80	3	cm	kg			211.27600927		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		113	1	1			2	2	1																1
MMRF_2702	-20																	1	Yes	1	1					61	1	5	413	Month 15	180	70	1	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		385	1	1			2	1	1																1
MMRF_2699	-14																	2	Yes	1	1					64	1	5	426	Month 15	168	65	1	cm	kg			64.532001688		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		97	1	1			2	2	1																1
MMRF_2700	-22																	1	Yes	1	1					63	1	5	428	Month 15		75	2	cm	kg			82.212000636		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		401	1	1			2	1	1																1
MMRF_2701	-72																	2	Yes	1	1					62	1	3	195	Month 9	162	60	2	cm	kg			102.54399705		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	153	153	198	Stem cell, Autologous	1	1								0		167	1	1			2	2	1																1
MMRF_2703	-24																	2	Yes	1	1					59	1	3	206	Month 9	175	75	2	cm	kg			77.791999576		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		177	1	1			2	2	1																1
MMRF_2704	-7																	1	Yes	1	1					58	1	4	352	Year 1	170	72	1	cm	kg			80.444002316		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		323	1	1			2	2	1																1
MMRF_2705	-12																	2	Yes	1	1					65	1	3	194	Month 9	165	63	2	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	124	124	197	Stem cell, Autologous	1	1								0		130	1	1			2	2	1																1
MMRF_2706	-7	No		296	Other		SAE G4 related, Respiratory failure G4			2	1	7						2	Yes	1	1					64	1	2	156	Month 6	162	71	2	cm	kg			50.387999364		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	116	157	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2707	-15	No		13	Patient is lost to follow-up		SAE G4 related, maculoapular lesions with diffuse purpura			2	1	5						1	Yes	1	1					61	1	0	1	Baseline	160	58	2	cm	kg			89.28399916		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2708	-5	No		181	Other					2	1	7						2	Yes	1	1					48	1	2	148	Month 6	88	160	2	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1		0							0									0		92	1	1			2	2	1																1
MMRF_2709	-2																	2	Yes	1	1					47	1	2	166	Month 6	151	66	3	cm	kg			52.155997684		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	120	120	169	Stem cell, Autologous	1	1								0		139	1	1			2	2	1																1
MMRF_2716	-14																	2	Yes	1	1					38	1	4	343	Year 1	166	58	1	cm	kg			56.575998736		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	118	163	Stem cell, Autologous	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	260	287	27	1	1		0		316	1	1			2	2	1																1
MMRF_2711	-20																	2	Yes	1	1					60	1	4	357	Year 1	168	57	3	cm	kg			55.691999576		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	137	137	202	Stem cell, Autologous	1	1								0		29	1	1			2	2	1																1
MMRF_2715	-9																	1	Yes	1	1					44	1	5	392	Month 15	178	90	3	cm	kg			88.4		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	124	161	Stem cell, Autologous	1	1								0		365	1	1			2	2	1																1
MMRF_2717	-6																	1	Yes	1	1					44	1	4	353	Year 1	186	73	1	cm	kg			88.4		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		322	1	1			2	2	1																1
MMRF_2714	-6																	1	Yes	1	1					62	1	5	365	Month 15	182	73	1	cm	kg			75.140002104		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	139	139	179	Stem cell, Autologous	1	1	Carfilzomib/Lenalidomide/Dexamethasone	274	365	91	1	1		0		338	1	1			2	2	1																1
MMRF_2718	-8																	1	Yes	1	1					56	1	2	148	Month 6	188	126	1	cm	kg			93.703994944		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		120	1	1			2	2	1																1
MMRF_2719	-20																	1	Yes	1	1					58	1	5	401	Month 15	176	78	1	cm	kg			87.51600084		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	152	152	233	Stem cell, Autologous	1	1								0		373	1	1			2	1	1																1
MMRF_2720	-4	No	291	124	Death	Disease Progression	SAE PD			2	1	1	1					2	Yes	1	1					62	1	2	115	Month 6			1	cm	kg			64.532001688		2	Carfilzomib-based		9	1	1		0							0												5	5			2		1																1
MMRF_2721	-6																	2	Yes	1	1					41	1	2	143	Month 6	160	59	1	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1		0							0									0		87	1	1			2	2	1																1
MMRF_2727	-13																	1	Yes	1	1					48	1	2	166	Month 6	170	66	2	cm	kg					2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		138	1	1			2	2	1																1
MMRF_2722	-4	No	292	169	Death	Disease Progression				2	1	1	1					1	Yes	1	1					60	1	2	130	Month 6	175	112	2	cm	kg			65.41600084		2	Carfilzomib-based		9	1	1		0							0									0		264	5	5			2	2	1																1
MMRF_2723	-7																	1	Yes	1	1					52	1	4	377	Year 1	183	80	2	cm	kg			72.487999364		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	125	160	Stem cell, Autologous	1	1								0		349	1	1			2	2	1																1
MMRF_2728	-8																	1	Yes	1	1					59	1	2	154	Month 6	172	60	1	cm	kg			40.664000734		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2729	-22																	2	Yes	1	1					65	1	5	427	Month 15	160	79	1	cm	kg			65.41600084		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	115	115	156	Stem cell, Autologous	1	1								0		399	1	1			2	1	1																1
MMRF_2730	-17	No		66	Other		SAE not related, Sepsis			2	1	7						1	Yes	1	1					57	1	1	30	Month 3	170	70	3	cm	kg			101.6599979		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		1	1	1			2	2	1																1
MMRF_2731	-13																	1	Yes	1	1					62	1	4	372	Year 1	175	95	1	cm	kg			81.328001476		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	120	166	Stem cell, Autologous	1	1								0		343	1	1			2	2	1																1
MMRF_2732	-27																	1	Yes	1	1					56	1	5	350	Month 15	175	84	1	cm	kg			107.84800253		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	131	131	186	Stem cell, Autologous	1	1								0		322	1	1			2	2	1																1
MMRF_2733	-4																	1	Yes	1	1					46	1	5	393	Month 15	175	73	3	cm	kg			100.77599874		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	160	160	225	Stem cell, Autologous	1	1								0		372	1	1			2	1	1																1
MMRF_2734	-14																	1	Yes	1	1					56	1	5	384	Month 15	175	80	1	cm	kg			70.720001052		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	113	156	Stem cell, Autologous	1	1								0		328	1	1			2	2	1																1
MMRF_2736	-9																	1	Yes	1	1					59	1	5	374	Month 15	0	70	1	cm	kg			95.472003792		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	120	151	Stem cell, Autologous	1	1								0		345	1	1			2	2	1																1
MMRF_2737	-24																	2	Yes	1	1					44	1	2	160	Month 6	160	50	2	cm	kg			45.967998312		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	116	162	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2738	-6																	1	Yes	1	1					43	1	5	367	Month 15	187	80	1	cm	kg			68.067998312		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		311	1	1			2	2	1																1
MMRF_2739	-6	No	54	54	Death	Disease Progression	SAE G5 PD, Acute renal failure not related due to PD			2	1	1	1					1	Yes	1	1					43	1	1	1	Month 3	180	86	1	cm	kg			173.26400337		2	Carfilzomib-based		9	1	1		0							0												5	5			2		1																1
MMRF_2742	-9	No		392	Other					2	1	7						1	Yes	1	1					65	1	3	218	Month 9	173	87	1	cm	kg			97.240002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		190	1	1			2	2	1																1
MMRF_2740	-22																	2	Yes	1	1					59	1	5	398	Month 15	165	68	1	cm	kg			60.995999788		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		370	1	1			2	1	1																1
MMRF_2743	-5																	2	Yes	1	1					42	1	4	351	Year 1	160	54	1	cm	kg			61.879998948		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	122	122	166	Stem cell, Autologous	1	1								0		323	1	1			2	2	1																1
MMRF_2745	-8																	2	Yes	1	1					64	1	4	343	Year 1	164	85	2	cm	kg			106.08000422		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2746	-8	No		323	Other					2	1	7						2	Yes	1	1					40	1	2	171	Month 6	151	53	1	cm	kg			34.475998736		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	136	173	Stem cell, Autologous	1	1								0		80	1	1			2	2	1																1
MMRF_2749	-13																	2	Yes	1	1					48	1	4	339	Year 1	160	56	2	cm	kg			88.4		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		1	1	1			2	2	1																1
MMRF_2750	-13																	2	Yes	1	1					39	1	4	330	Year 1	172	60	1	cm	kg			63.648002528		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		302	1	1			2	2	1																1
MMRF_2751	-14																	2	Yes	1	1					53	1	2	128	Month 6			1	cm	kg			44.2		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		100	1	1			2	2	1																1
MMRF_2752	-6																	1	Yes	1	1					56	1	4	351	Year 1	176	69	2	cm	kg			114.03599663		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		323	1	1			2	2	1																1
MMRF_2754	0	No	8	8	Death	Other	SAE G5 not related, not related to treatment but to MM. Infection.	Adverse event (Heart failure)	Other	2	1	1	2	10				2	Yes	1	1					65	1	0	1	Baseline	158	60	3	cm	kg			53.040002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												5	5			2		1																1
MMRF_2753	-13																	1	Yes	1	1					65	1	4	330	Year 1			1	cm	kg			70.720001052		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	136	176	Stem cell, Autologous	1	1								0		302	1	1			2	2	1																1
MMRF_2755	-14	No		378	Other					2	1	7						1	Yes	1	1					62	1	2	152	Month 6	170	75	1	cm	kg			123.7599979		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	117	154	Stem cell, Autologous	1	1								0		62	1	1			2	2	1																1
MMRF_2756	-14																	1	Yes	1	1					62	1	4	344	Year 1			2	cm	kg			53.040002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		288	1	1			2	2	1																1
MMRF_2757	-17																	2	Yes	1	1					63	1	4	359	Year 1	173	73	1	cm	kg			47.736001901		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		331	1	1			2	2	1																1
MMRF_2758	-13																	1	Yes	1	1					43	1	4	351	Year 1			1	cm	kg			86.632001688		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	135	198	Stem cell, Autologous	1	1								0		316	1	1			2	2	1																1
MMRF_2760	-24																	2	Yes	1	1					53	1	2	161	Month 6	162	84	1	cm	kg			85.748002528		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	117	163	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2761	-13	No		9	Other		SAE related, acute miocardial infarction			2	1	7						1	Yes	1	1					62	1	0	1	Baseline	175	70	3	cm	kg			101.6599979		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2762	-8																	1	Yes	1	1					53	1	4	323	Year 1	175	75	1	cm	kg			70.720001052		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		295	1	1			2	2	1																1
MMRF_2763	-5																	1	Yes	1	1					64	1	4	337	Year 1	176	76	2	cm	kg			64.532001688		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	127	127	162	Stem cell, Autologous	1	1								0		305	1	1			2	2	1																1
MMRF_2764	-12																	1	Yes	1	1					56	1	4	315	Year 1	180	90	1	cm	kg			109.61600084		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	130	130	217	Stem cell, Autologous	1	1								0		224	1	1			2	2	1																1
MMRF_2765	-13	No		337	Other		G3 related, LVEF < 40%			2	1	7						2	Yes	1	1					60	1	2	156	Month 6			3	cm	kg			79.559997896		2	Carfilzomib-based		9	1	1		0							0									0		120	1	1			2	2	1																1
MMRF_2767	-4																	1	Yes	1	1					65	1	2	179	Month 6	187	100	2	cm	kg			139.67200379		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	143	143	182	Stem cell, Autologous	1	1								0		123	1	1			2	2	1																1
MMRF_2768	-26																	2	Yes	1	1					65	1	3	196	Month 9	163	67	1	cm	kg			84.863998099		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		168	1	1			2	2	1																1
MMRF_2769	-7																	1	Yes	1	1					39	1	4	330	Year 1	167	68	2	cm	kg			72.487999364		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	122	122	158	Stem cell, Autologous	1	1								0		302	1	1			2	2	1																1
MMRF_2770	-19																	1	Yes	1	1					52	1	2	160	Month 6	179	75	3	cm	kg			64.532001688		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	123	160	Stem cell, Autologous	1	1								0		132	1	1			2	2	1																1
MMRF_2772	-7																	2	Yes	1	1					51	1	2	186	Month 6		65	1	cm	kg			63.648002528		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		130	1	1			2	2	1																1
MMRF_2774	-29																	2	Yes	1	1					65	1	3	174	Month 9	160	65	1	cm	kg			84.863998099		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	122	194	Stem cell, Autologous	1	1								0		146	1	1			2	2	1																1
MMRF_2775	-12																	2	Yes	1	1					59	1	3	198	Month 9	160	52	1	cm	kg			61.879998948		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	132	132	200	Stem cell, Autologous	1	1								0		170	1	1			2	2	1																1
MMRF_2776	-12																	2	Yes	1	1					51	1	4	316	Year 1	167	68	1	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	133	205	Stem cell, Autologous	1	1								0		288	1	1			2	2	1																1
MMRF_2778	-12																	2	Yes	1	1					56	1	4	282	Year 1	165	69	2	cm	kg			52.155997684		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	113	113	152	Stem cell, Autologous	1	1								0		254	1	1			2	2	1																1
MMRF_2779	-6																	2	Yes	1	1					60	1	2	133	Month 6	170	54	1	cm	kg			56.575998736		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0			4	4			2		1																1
MMRF_2781	-5	No	208	62	Death	Disease Progression	Non responsive to therapy			2	1	1	1					2	Yes	1	1					65	1	1	57	Month 3	165	63	2	cm	kg			103.42799621		2	Carfilzomib-based		9	1	1		0							0												5	5			2		1																1
MMRF_2782	-7																	1	Yes	1	1					52	1	3	213	Month 9	165	75	3	cm	kg			106.08000422		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	127	215	Stem cell, Autologous	1	1								0		180	1	1			2	2	1																1
MMRF_2787	-9																	1	Yes	1	1					53	1	2	169	Month 6	175	80	2	cm	kg			61.879998948		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2788	-48																	1	Yes	1	1					53	1	3	198	Month 9	179	82	2	cm	kg			79.559997896		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	138	200	Stem cell, Autologous	1	1								0		169	1	1			2	2	1																1
MMRF_2789	-12																	1	Yes	1	1					43	1	2	117	Month 6	187	90	1	cm	kg			78.675998736		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0												4	4			2		1																1
MMRF_2792	-14																	1	Yes	1	1					60	1	2	134	Month 6	176	92	1	cm	kg			84.863998099		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		75	1	1			2	2	1																1
MMRF_2793	-5																	2	Yes	1	1					59	1	2	179	Month 6	148	52	3	cm	kg			175.91600084		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	137	181	Stem cell, Autologous	1	1								0		151	1	1			2	2	1																1
MMRF_2794	-19																	2	Yes	1	1					56	1	2	157	Month 6	167	64	3	cm	kg			71.604000212		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		127	1	1			2	2	1																1
MMRF_2795	-12																	2	Yes	1	1					58	1	4	288	Year 1	160	71	3	cm	kg			59.228001476		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	119	119	164	Stem cell, Autologous	1	1								0		260	1	1			2	2	1																1
MMRF_2801	-3																	1	Yes	1	1					60	1	3	203	Month 9			3	cm	kg			63.648002528		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	127	127	204	Stem cell, Autologous	1	1							183	1	26.142857143	128	3	3			2	2	1	1															1
MMRF_2796	-6																	2	Yes	1	1					54	1	2	159	Month 6	159	73	2	cm	kg			57.459997896		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	121	121	161	Stem cell, Autologous	1	1								0		75	1	1			2	2	1																1
MMRF_2799	-6																	1	Yes	1	1					54	1	2	128	Month 6	170	70	1	cm	kg			60.995999788		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	128	182	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2805	-23																	1	Yes	1	1					50	1	3	163	Month 9	185	95	1	cm	kg			67.18399916		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	118	118	165	Stem cell, Autologous	1	1								0		135	1	1			2	2	1																1
MMRF_2807	-10																	2	Yes	1	1					55	1	4	288	Year 1	177	87	1	cm	kg			67.18399916		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	124	197	Stem cell, Autologous	1	1								0		259	1	1			2	2	1																1
MMRF_2808	-6	No		183	Other		Mobilization failure			2	1	7						1	Yes	1	1					62	1	2	180	Month 6	175	80	1	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		95	1	1			2	2	1																1
MMRF_2809	-12																	1	Yes	1	1					59	1	3	223	Month 9	172	83	1	cm	kg			88.4		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	127	127	225	Stem cell, Autologous	1	1								0		209	1	1			2	2	1																1
MMRF_2810	-36																	1	Yes	1	1					59	1	3	175	Month 9	168	70	1	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	130	177	Stem cell, Autologous	1	1								0		147	1	1			2	2	1																1
MMRF_2813	-4																	1	Yes	1	1					54	1	2	167	Month 6	90	185	2	cm	kg			62.763998099		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		138	1	1			2	2	1																1
MMRF_2814	-7																	1	Yes	1	1					56	1	4	298	Year 1	166	70	2	cm	kg			183.87199326		2	combined IMIDs/carfilzomib-based	8	4	1	1	1	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	128	128	201	Stem cell, Autologous	1	1								0		270	1	1			2	2	1																1
MMRF_2815	-6																	1	Yes	1	1					65	1	4	310	Year 1			2	cm	kg					2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		282	1	1			2	2	1																1
MMRF_2816	-11																	1	Yes	1	1					60	1	4	318	Year 1	171	82	1	cm	kg			61.879998948		2	Carfilzomib-based		9	1	1	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	130	171	Stem cell, Autologous	1	1								0		256	1	1			2	2	1																1
MMRF_2817	-18																	2	Yes	1	1					56	1	2	158	Month 6	160	59	3	cm	kg			83.095999788		2	Carfilzomib-based		9	1	1		0							0									0		101	1	1			2	2	1																1
MMRF_2818	-11																	1	Yes	1	1					50	1	3	239	Month 9	179	79	1	cm	kg			100.77599874		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		211	1	1			2	2	1																1
MMRF_2819	-12																	1	Yes	1	1					56	1	3	245	Month 9	170	110	2	cm	kg			79.559997896		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	127	127	247	Stem cell, Autologous	1	1								0		217	1	1			2	2	1																1
MMRF_2820	-7																	2	Yes	1	1					50	1	2	175	Month 6			2	cm	kg			70.720001052		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	129	177	Stem cell, Autologous	1	1								0		147	1	1			2	2	1																1
MMRF_2821	-5																	1	Yes	1	1					55	1	2	173	Month 6	175	74	2	cm	kg			68.951997472		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		145	1	1			2	2	1																1
MMRF_2822	-6																	1	Yes	1	1					58	1	2	173	Month 6	172	106	1	cm	kg			80.444002316		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	123	123	175	Stem cell, Autologous	1	1								0		23	1	1			2	2	1																1
MMRF_2823	-24																	1	Yes	1	1					52	1	3	223	Month 9	170	70	3	cm	kg			107.84800253		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	183	225	Stem cell, Autologous	1	1								0		196	1	1			2	2	1																1
MMRF_2826	-14																	1	Yes	1	1					63	1	2	119	Month 6	89	175	1	cm	kg			76.908000424		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		92	1	1			2	2	1																1
MMRF_2827	-8																	1	Yes	1	1					62	1	2	189	Month 6	178	76	2	cm	kg			122.87599874		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	133	133	191	Stem cell, Autologous	1	1								0		162	1	1			2	2	1																1
MMRF_2828	-10																	2	Yes	1	1					55	1	2	169	Month 6	155	80	1	cm	kg			53.040002104		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0			4	4			2		1																1
MMRF_2829	-5																	1	Yes	1	1					57	1	3	210	Month 9	167	56	1	cm	kg			101.6599979		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		183	1	1			2	2	1																1
MMRF_2830	-4																	2	Yes	1	1					48	1	2	143	Month 6	160	60	1	cm	kg			67.18399916		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0									0		115	1	1			2	2	1																1
MMRF_2831	-66																	1	Yes	1	1					65	1	3	203	Month 9	182	65	1	cm	kg			73.371998524		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	166	166	205	Stem cell, Autologous	1	1								0		175	1	1			2	2	1																1
MMRF_2832	-7																	2	Yes	1	1					61	1	2	173	Month 6	170	73	2	cm	kg			47.736001901		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	124	175	Stem cell, Autologous	1	1								0		145	1	1			2	2	1																1
MMRF_2833	-11	No		157	Other		SAE G3 not related, Pneumonia			2	1	7						2	Yes	1	1					52	1	3	203	Month 9	160	100	2	cm	kg			54.808000424		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								203	1	29	174	3	3			2	2	1	1															1
MMRF_2834	-15																	2	Yes	1	1					60	1	2	126	Month 6			1	cm	kg			146.74399705		2	Carfilzomib-based		9	1	1		0							0									0		98	1	1			2	2	1																1
MMRF_2835	-5																	1	Yes	1	1					56	1	2	167	Month 6	178	91	2	cm	kg			103.42799621		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	136	136	170	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2836	-24																	1	Yes	1	1					57	1	2	161	Month 6	170	66	2	cm	kg			76.908000424		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	126	126	166	Stem cell, Autologous	1	1								0		22	1	1			2	2	1																1
MMRF_2838	1	No		237	Other					2	1	7						1	Yes	1	1					63	1	3	225	Month 9	182	78	2	cm	kg			121.99199958		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								225	1	32.142857143	202	3	3			2	2	1	1															1
MMRF_2839	-12	No		44	Other		SAE G4 PD			2	1	7						1	Yes	1	1					60	1	1	1	Month 3	182	79	1	cm	kg					2	Carfilzomib-based		9	1	1		0							0												4	4			2		1																1
MMRF_2840	1	No	25	25	Death	Other	SAE G5 not related, Pneumonia	Pneumonia	Infections (Sepsis, Pneumonia, etc)	2	1	1	2	5				1	Yes	1	1					59	1	0	1	Baseline	175	72	2	cm	kg			324.42800674		2	Carfilzomib-based		9	1	1		0							0												5	5			2		1																1
MMRF_2843	-14	No		203	Other					2	1	7						2	Yes	1	1					45	1	3	203	Month 9	160	60	3	cm	kg			162.65600295		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								57	1	8.1428571429	1	3	3			1	2	1	1															1
MMRF_2846	-30																	2	Yes	1	1					61	1	3	199	Month 9	160	70	3	cm	kg			58.344002316		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	121	203	Stem cell, Autologous	1	1											4	4			2		1																1
MMRF_2847	-4																	1	Yes	1	1					57	1	2	163	Month 6	180	73	3	cm	kg			76.908000424		2	combined IMIDs/carfilzomib-based	8	4	1	1		0							0								58	1	8.2857142857	1	3	3			1	2	1	1															1
MMRF_2848	-6																	2	Yes	1	1					45	1	3	198	Month 9		67	2	cm	kg			190.06000843		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	154	154	200	Stem cell, Autologous	1	1								0		170	1	1			2	2	1																1
MMRF_2851	-25																	2	Yes	1	1					62	1	3	189	Month 9	160	90	1	cm	kg			81.328001476		2	Carfilzomib-based		9	1	1	0	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	1	122	191	Stem cell, Autologous	1	1								0		104	1	1			2	2	1																1
MMRF_2853	-47																	1	Yes	1	1					64	1	3	170	Month 9	174	74	1	cm	kg			69.836001901		2	combined IMIDs/carfilzomib-based	8	4	1	1	0	1	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	129	129	173	Stem cell, Autologous	1	1								0		142	1	1			2	2	1																1
